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ABSTRACT
Growing evidence suggests that dietary n-3 very long chain polyunsaturated 
fatty acids (eicosapentaenoic acid; EPA and docosahexaenoic acid; DHA) 
reduce the risk of coronary heart disease and stroke, a-linolenic acid (a-LNA) 
is the natural precursor of EPA and DHA and is an abundant and accessible 
source of dietary n-3 PUFA that can be further elongated and unsaturated in 
vivo.
The overall aim of the project is to examine the conversion of a-LNA to its 
long chain metabolite, most importantly DHA. This aim was accomplished by 
a combination of a human dietary intervention study to assess accumulation 
of EPA and DHA from dietary a-LNA, and 13C-tracer studies of a-LNA & 
linoleic acid (LA) conversion to their long-chain metabolites.
The dietary intervention trial was a 12-week parallel design in men expressing 
an atherogenic lipoprotein phenotype, a common source of lipid-mediated 
coronary heart disease risk. Diets were enriched with 18 g of a-LNA as 
flaxseed oil (n=21), with a high LA oil (n=17), or with fish-oil (6g/d n=19) as a 
positive control group. Thus the intention was to provide an increased intake 
of a-LNA with a low ratio of n-6 to n-3 PUFA (1:1 or less), minimizing 
competition between a-LNA and the abundant LA and, in theory, increasing 
the conversion of a-LNA to LC n-3 PUFA.
The results from the dietary intervention indicate that, dietary a-LNA as 
flaxseed oil can increase n-3 membrane fatty acid contents, through a 3-fold 
increase in a-LNA (p <0.001)) and 2.5 fold increase in EPA (p<0.001) at 
week-12, decreasing in n-6:n-3 ratio (p =0.001), but not changing DHA level. 
In contrast the fish oil diet increased both EPA and DHA. Dietary a-LNA had 
7% of the efficacy of preformed EPA from fish oil to increase membrane EPA 
levels.
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Subjects on the 13C tracer study were a sub-group of the intervention study, 
studied after 12-weeks on the high a-LNA (n=6) or high n-6 (n=5) diets. 
Subjects were given an oral mixture of 400 mg each of uniformly 13C labelled 
a-LNA and LA in a milk shake after an overnight fast. 13C enrichment was 
measured in fatty acids isolated from plasma at 1,2,3,7,10 and 14 days after 
the dose.
Of the dose appearing in the plasma 35-45% was converted to EPA with no 
dietary effects. Some conversion to DHA did occur especially in the high n-6 
group (3.9% of dose) compared with the flaxseed-oil group (mean value 0.8% 
of the dose; p < 0.05). In the single subject studied on the fish-oil diet there 
was a much lower conversion rate compared to the flaxseed-oil diet. The 
variability between subjects for percent conversion to DHA ranged from zero 
to 6.2% of the dose appearing in plasma.
Taken together these results clearly establish the effectiveness of dietary a- 
LNA as a method of increasing the concentration of EPA, but not DHA, in 
membrane phospholipids, with up to 7% of the efficacy of preformed EPA. 
The increase in the EPA: AA ratio (eicosapentanoic: arachidonic acid) in 
membrane phospholipids with dietary a-LNA is likely to reduce the overall 
inflammatory environment with beneficial effects for long-term health.
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CHAPTER 1 INTRODUCTION
The health of the individual and the population in general is the result of 
interactions between genetics and a number of environmental factors. 
Nutrition is an environmental factor of major importance. Whereas our genetic 
profile has not changed over the past 40,000 years, major changes have 
taken place in the food supply and in energy expenditure/physical activity. 
Today, industrialized societies are characterized by (1) a decrease in energy 
expenditure; (2) an increase in high fat foods especially saturated fat, co6 fatty 
acids and trans fatty acids, and a decrease in co3 fatty acids intake; (3) a 
decrease in complex carbohydrates and fiber; (4) a decrease in fruits and 
vegetables; (5) a decrease in protein, antioxidants and calcium intake. 
Furthermore, the ratio of to6: w3 fatty acids is 15-20:1, whereas during late 
Paleolithic period, it was 2-1:1 (Simopoulos, 2001). Of these changes, there 
has been a particular concern about those relating to dietary fat and this is the 
subject of this research. The following section will summarise current 
knowledge about fatty acid metabolism, their biological role, and most 
importantly, the definition of ‘essentiality’.
1.1 Lipid nomenclature
Lipids are generally characterised by their lack of solubility in water and are 
categorised in terms of their structures such as sterols, glycerides, and 
phospho- or glycolipids. Some of the common lipids that will be discussed are 
depicted in (Fig. 1.1). Triglycerides or triacylglycerols, have a glycerol 
backbone to which three fatty acids are esterified. Most of natural oils are 
mainly composed of this lipid class. Mono- or diglycerides are closely related 
to this structure but contain only one or two fatty acids, respectively. An 
example of a phospholipid, phosphatidylethanolamine (PE), is also presented 
as these polar lipids constitute one of the structural elements of all biological 
organisms. In other phospholipid classes, the ethanolamine base is replaced
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by, for example, choline (PC), serine (PS), glycerol (PG), or inositol (PI). Fig.
1.2 shows an example of the composition of phosphatidylcholine.
Sterols are another ubiquitous lipid class that often constitutes a significant 
proportion of cellular dry weight. Cholesterol ester is depicted in (Fig. 1.1) as it 
is a form of sterol that contains a long chain fatty acid. When the R group is a 
proton, this structure becomes that of cholesterol.
Fig. 1.1 Structure of some commonly occurring complex lipids. 
The R groups represent long-chain fatty acyl moieties. (Salem, 1989).
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Fig. 1.2 Phosphatidylcholine composition.
a. Glycerol backbone covalently linked to:
b. Two long, non-polar fatty acid hydrocarbon chains.
c. Variable phosphate-containing polar group (http://www.dumn.edu).
The R groups on these lipids are usually 12-24 carbons in length and contain 
0-6 double bonds. Fatty acids can be subdivided into several families in 
accordance with the positions of their double bonds. Nonessential fatty acids,
17
i.e., those that can be biosynthesized by eukaryotes, include saturates and 10- 
7 or co-9 fatty acids (Fig. 1.3). The co-9 designation indicates that the first 
double bond is located 9 carbon atoms away from the methyl end of the 
molecule (between the 9th and 10th carbons from the methyl carbon, 
inclusive). The symbol (n) is often used in place of to, so n-9 (n minus 9) has 
the same meaning as co-9. However, the delta (A) notation often seen in the 
literature involves a numbering system that starts with the carboxyl rather than 
the methyl carbon. Another abbreviated notation that is very commonly used 
for fatty acids is X:Y, where X represents the number of carbons in the chain 
and Y, the number of double bonds. Putting this together with the co notation 
then, 18:1 co9 (omega-9) indicates a fatty acid of 18 carbons with one double 
bond that is located 9 carbons from the methyl end. The trivial name for this 
fatty acid is oleic acid and the systematic name is 9-cis-octadecenoic acid. 
Similarly, the co-6 fatty acid linoleate (18:2 co-6) is properly termed all cis-9,12- 
octadecadienoic acid. The naturally occurring polyunsaturated fatty acids 
(PUFA) usually contain all cis, methylene interrupted double bond systems; 
they are generally not conjugated (Salem, 1989). (Fig. 1.4) shows the two 
ways of defining the position of a double bond.
o
/ V W V W \ A , U Palmi,lcAcid 116:01
OH
o
w w = w w ' v u oleic Aoid <18:1w9)OH
Omega-6 Fatty Acids:
/ V V ==V ==V \ A / V C\ Linoleic A d d  I18-.2W6)
o 
OH
O
II
P. Arachidonic Acid (20:4w6)
/ V v / = V = V = V = V v \ JH
Fig. 1.3 Structure of some common fatty acids. (Salem, 1989).
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Fig. 1.4 The two ways of defining the position of a double bond:
a. By counting from the functional group.
b. By counting from the end opposite (w) the functional group. (Benyon et al., 1998).
The structures of the four commonly occurring w-3 fatty acids are presented in 
(Fig. 1.5). The shorthand notation and abbreviation is designated for each 
fatty acid. They are all highly unsaturated fatty acids, i.e., they contain three or 
more double bonds and, together with their tu-9 and to-6 counterparts, are 
therefore often referred to as HUFAs. The first double bond in each of these 
fatty acids is located between the third and fourth carbon from the methyl end 
(inclusive); thus the name "to-3 fatty acid” (Salem, 1989).
v = v = v = v v w OH
Unolenic Acid {18:3w3)
0n
/Y  Eicosapentaenoic Acid (20:5w3), EPA
OH
0
II
P Docosapentaenoic Acid (22:5w3), DPA
OH
0llp Docosahexaenoic Acid (22:6w3), DHA
OH
Fig. 1.5 Structures of the principal n-3 fatty acids. Their shorthand notations 
and abbreviations are also indicated. (Salem, 1989).
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1.2 Saturation
Fatty acids are distinguished by the number of hydrogen atoms they carry, 
saturated fatty acids have no double bonds; they carry the maximum 
complement of hydrogen atoms the structure will allow, the more double 
bonds a fatty acid has the more unsaturated it is. Fatty acids with one double 
bond are called monounsaturated, those with two or more double bonds are 
polyunsaturated, as shown in (Fig.1.6) which summaries the nomenclature 
and the structure of the most common fatty acids.
Saturated fatty acids have rigid straight structure which compacts more readily 
than bent or kinked unsaturated fatty acids (see Fig. 1.7).The most common 
saturated fatty acids in foods are lauric, myristic, palmitic, and stearic acids 
with 12, 14, 16 and 18 carbons, respectively. In animal fats such as butter, 
beef fat, and poultry fat, palmitic acid is the most abundant saturated fatty acid. 
As its name suggests, it is also the main fatty acid in palm oil. Stearic acid is 
the second most common saturated fatty acid in animal fats, but is much less 
abundant in poultry fats than beef and lamb. The shorter-chain saturates, 
lauric and myrisric, prevail in coconut and palm kernel oils. These oils and 
butter also have fair amounts of short-chain saturated fatty acids (Nettleton, 
1995). Table 1.1 shows some common fatty acids found in foods.
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Saturated
16 14 12 10 8 6 4 2
W W V X A A cooh
■J
Palmitic acid 
Hexadecanoic acid
Monounsaturated
a / v w A A A A cooh
18 16 14 12 10 9 1
Oleic acid (n-9 family)
cis-9-octadecenoic acid (c-9-18:1 or 18:1, n-9)
18 16 14 12 10 8. 6 4 2
\ / \ / \ / \ / % / \ / \ / \ / \ c O O H  
9 1
Eiaidic acid
trans-9-octadecenoic acid (t-9-18:1)
Polyunsaturated
COOH
13 12 10 9 1
Linoleic acid (n-6 family)
cis,cis-9,12-octadecadienoic acid {c,c-9,12-18:2 or 18:2,n-6)
17 14 11 8 6 4 2
A A A A V X A cooh
18 16 15 13 12 10 9 1
a-LinoIenic acid (n-3 family)
all-cis-9,12,15-octadecatrienoic acid (c,c,c-9,12,15-18:3 or 18:3, n-3)
COOH
Arachidoniq acid (n-6 family)
ali-cis-5,8,11,14-eicosatetraenoic acid (c,c,c,c-5,8,11,14-20:4
or 20:4, n-6)
Fig. 1.6 Fatty acids occurring in food and body lipids.
The zigzag lines represent hydrocarbon chains, with a carbon atom at the intersection of 
lines; thus / \ A y '  represents CH2- CH2- CH2- CH= CH- CH2 etc. According to a 
biochemical convention, the numbering of the carbon chain is from the carboxyl group (- 
COOH).Thus a substituent such as a methyl group on the 4th carbon from the carboxyl 
group of a 16-carbon saturated fatty acid would be 4-methyl-hexadecanoic acid, etc. If a 
double bond occurs between carbon atoms 9 and 10 of an 18-carbon acid, the fatty acid 
is called 9-octadecenoic acid. The nomenclature n-3, n-6, n-9 describes families of fatty 
acids in which the last double bond in the chain is 3, 6 or 9 carbon atoms from the methyl 
end of the molecule. The suffixes c and t below double bonds in the formulae denote the 
geometrical configuration of the double bond, cis=c or trans=t. A common shorthand 
notation for fatty acids has been used. In this system, the fatty acid is identified by a 
number denoting the number of carbon atoms in its hydrocarbon chain, followed by a 
colon, followed by a number denoting the number of double bonds. Thus, stearic acid (18 
carbon atoms with no double bonds) is represented as 18:0 and octadecenoic acid (18 
carbon atoms with one double bond in an unspecified position and with an unspecified 
geometrical configuration) as 18:1, etc. If the unsaturated acid needs to be identified 
more precisely, it can be done by indicating the position (s) and configuration (s) of the 
double bonds, thus: oleic acid, c9-18:1; linoleic acid, c9,c12-18:2, etc. In some cases it is 
useful to specify the family to which the fatty acid belongs; thus, 18:3 may be either 
18:3n-3 (a-linolenic acid, all-cis-9, 12, 15-18:3) or 18:3n-6 (a-iinolenic acid, all-cis-6,9,12- 
18:3) (Gurr, 2000).
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Fig. 1.7 Saturated fatty acids have rigid straight structure.
This compacts more readily than bent or kinked unsaturated fatty acids 
(http://www.essentialceIlbiology.com).
Table 1.1 Some common fatty acids in foods 
(Youdim et al., 2000).
Common name Chemical name Shorthand
nomenclature
Saturated
Short-chain
Butyric Butanoic 4:0
Caproic Hexanoic 6:0
Medium-chain
Caprylic Octanoic 8:0
Capric Decanoic 10:0
Long-chain
Laurie Dodecanoic 12:0
Myristic Tetradecanoic 14:0
Palmitic Hexadecanoic 16:0
Stearic Octadecanoic 18:0
Monounsaturated
Oleic cis-9-Octadecenoic 18:ln-9
Elaidic trans-9-Octadecenoic 18:lt
Erucic cis-13-Docosenoic 22:ln-9
Polyunsaturated
Linoleic cis,cis-9,12-Octadecadienoic 18:2 n-6
a-Linolenic all-cis-9,12,15-Octadecatrienoic 18:3n-3
Arachidonic all-cis-5,8,11,14-Eicosatetraenoic 20:4n-6
EPA all-cis-5,8,11,14,17-Eicosapentaenoic 20:5n-3
DHA all-cis-4,7,10,13,16,19-Docosahexaenoic 22:6n-3
See the caption to Figure 1.6 for an explanation of the notation used here.
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The most common monounsaturated fatty acid is oleic acid. Monounsaturates 
prevail in olives, avocados, rapeseed, peanuts, rice bran, soybeans. For 
example, olive, canola (rapeseed) and peanut oils have approximately 74, 59, 
and 46% monounsaturates, respectively (Nettleton, 1995). High-oleic-acid 
sunflower oil, developed through genetic modification, has 80% oleic acid. 
Unsaturates are found in virtually all plants and animals but they are most 
concentrated in seeds, nuts, certain fruits, and fish. Polyunsaturated fatty 
acids, of which linoleic acid is the most abundant in most vegetable oils. The 
common polyunsaturated vegetable oils, in descending order of 
polyunsaturated level, are safflower, sunflower, corn, soybean, cottonseed, 
peanut, and canola oil, the canola and soybean oils have 10 and 7%, 
respectively, a-LNA. Table 1.2 shows the dietary fatty acid composition of 
plant oils and nuts.
Leafy vegetables also have predominantly unsaturated fatty acids but the 
amounts are very small. A  few vegetable foods are exceptional in having 
fewer unsaturated than saturated fatty acids. The notable ones are palm, palm 
kernel, and coconut oil. Coconut oil consists of more than 90% saturated fatty 
acids, mostly of the 12- and 14-carbon chain fatty acids lauric and myristic 
acids. Evening primrose oil, blackcurrant oil, and borage oil provide significant 
amounts of y-linolenic acid (C18:3n-6) and some C18:4n-3 (stearidonic acid), 
particularly blackcurrant oil (Lawson & Hughes, 1988c).
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Table 1.2 Dietary fatty acid composition of plant oils and nutsa
Species Description  Fatty acids (mol%)
18:ln-9 18:2n-6 18:3n-3 n-6:n-3
Juglans cinerea Butternut 19.0 61.9 16.0 3.9
Aleurites moluccana Candlenut oil 10.5 48.4 28.5 1.7
Ricinus communis Castor oil 3.0 4.0 tr >4.0
Castanea mollisima Chestnut 54.0 24.9 2.7 9.2
Cocos nucifera Coconut oil 4.5 1.4 - -
Zea mays L. Com oil 30.5 52.0 1.0 52.0
Gossypium hirsutum Cottonseed oil 18.3 50.5 tr >50.5
Nr Evening primrose 7.5 74.9 - -
oil
Vitis Vinifera Grapeseed oil 22.0 67.0 0.9 74.4
Cannabis sativa Hemp seed oil 12.0 55.0 25.0 2.2
Linum usitaissimum Linseed oil 16.6 14.2 59.8 0.24
Brassica alba White mustard seed 23.2 8.9 10.4 0.85
oil
Olea europea Olive oil 78.1 7.3 0.6 12.2
Elaeis giuneensis African palm oil 37.7 10.6 0.2 53.0
Carya illioensis Pecan 66.9 22.1 1.1 20.1
Papaver somniferium Poppy seed oil 11.0 72.0 5.0 14.4
Brassica campestris Rapeseed oil 53.5 23.5 14.0 1.68
Carthamus tinctorius Safflower oil 13.8 75.2 tr >75.2
Sesamum indicum Sesame oil 38.2 45.0 0.6 75.0
Soja max Soybean oil 22.0 53.0 7.5 7.07
Helianthus annus Sunflower oil 19.5 68.5 0.1 685
Juglans nigra Walnut, black 29.1 58.3 4.9 11.9
Juglans regia Walnut, English 19.1 57.4 13.1 4.38
Trittcom aestiuum Wheat germ oil 21.8 57.9 5.1 11.4
Abbreviation: tr: trace amount. Data adapted from (Youdim et al., 2000)
A summary of the relative amounts of saturates, monounsaturates, and 
polyunsaturates in the most common food fats and oils is given in (Fig.1.8). 
Fats have been arranged in order of increasing amounts of saturated fatty 
acids to emphasize those with the lowest levels.
The other food group rich in polyunsaturates is fish. Those species with 
abundant amounts of fat usually have at least two-thirds of their fatty acids as 
unsaturates (Ackman, 1989). Fish species rich in oil such as salmon, trout, 
tuna, mackerel, herring, sardines, Atlantic bluefish, and lake trout are 
especially rich in w3 fatty acids. Also co3 fatty acids usually exceed w6 fatty 
acids in fish and shellfish. (Nettleton,1995). Table 1.3 shows the dietary fatty 
acid composition for marine and fresh water fishes.
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Table 1.3 Dietary fatty acid composition of marine and freshwater fishes3
Species Common Fatty acids (mol %)
name 18:3n-3
18:4
n-3
20:1
n-9
20:5
n-3
22:1
n-9
22:5
n-3
22:6
n-3
Mallotus villosus Capelin (female) nr nr 17.2 8.6 14.2 0.9 4.8
Gadus morhua Cod, Atlantic 0.1 0.1 1.2 17.7 1.1 0.9 37.5
Prognichthys agoo Flying fish (dorsal) nr nr nr 4.8 nr nr 25.6
Meianogrammus Haddock 0.3 nr 3.5 14.3 nr 0.7 24.3
Hippoglossus hippolossus Halibut nr 1.4 7.3 12.6 5.0 2.3 19.2
Clupea harengus Herring, Pacific 0.6 2.8 9.4 8.6 11.6 1.3 7.6
Scomber scombrus Mackerel 1.3 3.4 3.1 7.1 2.8 1.2 10.8
Brevoortia tyrannus Menhaden 0.9 1.9 0.9 10.2 1.7 1.6 12.8
Mugil cephalus Mullet, striped 1.4 3.0 0.7 7.5 0.7 3.9 13.4
Sebastes marinus Perch, ocean 0.6 1.6 8.0 9.3 8.7 0.6 12.0
Sardinops sagax Pilchards 0.9 2.0 5.4 6.7 9.4 2.3 16.1
Oncorhynchus tshawytscha Salmon, chinook 0.9 1.5 4.7 8.2 3.6 2.4 5.9
Oncorhynchus keta Salmon, chum 1.0 2.0 5.4 6.7 9.4 2.3 16.1
Oncorhynchus gorbuscha Salmon, pink 1.1 2.9 4.0 13.5 3.5 3.1 18.9
Nr Sardine 1.3 2.9 8.1 9.6 7.8 2.8 8.5
Lateolabrax japonicus Sea bass nr 2.6 nr 10.6 nr 1.8 21.8
Lamna comubica Shark, porbeagle nr nr nr 2.8 nr 13.7 29.0
Etelis evurus Snapper nr nr nr 3.7 nr 1.4 33.8
Microstomus kit Sole, lemon 2.0 1.6 3.9 11.9 tr 10.6 7.0
Nr Swordfish 0.4 0.7 4.6 4.4 2.0 3.1 17.8
Salmo gairdneri Trout, rainbow 5.2 1.5 3.0 5.0 1.3 2.6 19.0
Thunnus maccoii Tuna, bluefin tr 0.9 0.3 6.4 5.4 1.4 17.1
Katsuwonus pelamis Tuna, skipjack 1.2 0.5 2.0 13.2 tr 1.5 17.3
Protothaca stiminea Clam, littleneck 1.6 3.0 3.5 10.0 2.6 1.7 14.5
Callinectes sapidus Crab, blue 1.2 0.6 1.9 13.4 1.5 1.1 11.0
Mytilus californianus Mussel nr 1.6 2.6 14.0 nr 1.1 27.7
Crassostrea gigas Oyster, Pacific 1.6 4.3 tr 21.5 2.6 1.0 20.2
Placopecten magellanicus Scallop, sea 0.3 1.8 1.7 21.3 0.2 1.0 26.2
Abbreviation : 18:3n-3: alpha linolenic acid (a-LNA); 18:4n-3: stearidonic acid; 
20:1 n-9: eicosanoic acid; 20:5n-3: eicosapentanoic acid (EPA); 22:1n-9: docosaenoic 
acid; 22:5n-3: docosapentaenoic acid (DPA n-3); 22:6n-3: docosahexaenoic acid 
(DHA). Data adapted from (Youdim et al., 2000).
1.3 Cis and Trans Isomers
A distinguishing characteristic of fatty acids is the orientation of the molecule 
at the double bond: namely whether hydrogen atoms are configured on the 
same side, cis or opposite side trans of the double bond, (Fig.1.9), The cis 
configuration found in most naturally occurring fatty acids in plants and 
seafoods, creates a bend or kink in the fatty acid chain, making the molecule
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more flexible. In the trans configuration, each section on either side of the 
double bond faces in the opposite direction, yielding a straighter, more rigid 
molecule (Fig.1.9). Trans fatty acids are common in bacteria, including those 
in the rumen of herbivores, accounting for their origin in milk and dairy 
products, and also occur in commercially hydrogenated fats in margarine and 
foods (Small, 1986). Trans fatty acids behave more like saturated fatty acids 
than unsaturated fatty acids even though they have a double bond. This 
property is illustrated by comparing the melting points of three 18-carbon fatty 
acids: stearic 18:0, oleic 18:1 cis, and elaidic 18:1 trans, see Table 1.4 
(Nettleton, 1995).
3 %  — 1 %
V>/<
Dietary Fat
Canola Oil
Coconut oil
Cholesterol mg/Tbsp 
Saturated Fat
Safflower oil
Sunflower oil
Corn oil
Olive oil
Soybean oil
Peanut oil
Cottonseed oil
Palm oil
Beef tallow
Butterfat
Polyunsaturated Fat 
Linoleic Acid
Alpha-Linolenic Acid 
(An Omega-3 Fatty Acid) 
rLNA
Monounsaturated
Fat
2% —>^ 6%
*-2% 30%
Fig. 1.8 Relative amounts of saturates, monounsaturates, and 
polyunsaturates in fats and oils. After; Nettleton, (1995).
Table 1.4 The melting points of three 18-carbon fatty acids.
Fatty acid Melting point (°C) Form at room temp.
Stearic, 18:0 69.6 solid
Elaidic, 18:1 trans 46.5 solid
Oleic, 18:1 cis 13.4 liquid
After; Nettleton, (1995).
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Trans double bond: elaidic acid
Fig. 1.9 Structure of cis and trans configuration. (Nettleton, 1995).
1.4 Digestion and absorption of polyunsaturated fatty acids
The utilization of polyunsaturated fatty acids requires the digestion and 
intestinal absorption of 80-120 g per day of triglycerides the main dietary 
source at 96% of total dietary lipid, with 2-4 g per day of phospholipids. This is 
enriched with 7-20 g of endogenous phospholipids from the bile and from the 
shed intestinal cells, and with sterols, especially cholesterol, and fat-soluble 
vitamins (Carlier et al., 1991).
1.4.1 Stomach and intestinal steps of dietary lipid hydrolysis
In the stomach, the lingual lipase secreted by lingual glands in mice or gastric 
lipase in rabbit or in man (DeNigris et al., 1988) starts hydrolysis of 
triglycerides. This hydrolysis takes place at the low pH of the stomach lumen 
in the absence of bile salts. In adults, due to the preferential cleavage of the 1- 
and /or 1- and 3-positions of triglycerides, lingual or gastric lipase mainly 
produces partial glycerides and free fatty acids. Such amphiphilic molecules 
help disperse the fat in the stomach and in the proximal small intestine. This 
emulsification of lipids enhances further hydrolysis by pancreatic lipid
hydrolyses in the small intestine, since these enzyme activities depend on the 
emulsification of dietary fat.
In the proximal part of the small intestine, i.e. the end of the duodenum and 
the jejunum, the intestinal luminal phase of the digestion of lipids by 
pancreatic lipid hydrolases takes place. In presence of bicarbonate-rich 
pancreatic juice and bile, triglycerides are included in the emulsion phase 
previously made in the stomach. Pancreatic bicarbonates increase the 
intestinal luminal pH to a value allowing an optimal activity of pancreatic 
enzymes. Simultaneously under the detergent action of bile salts, the 
diameter of the emulsion oil droplets is decreased from 50 000 down to 2 000 
A (Carlier et al., 1991).
Pancreatic cholesterol ester hydrolase activated by bile salts completely 
hydrolyzes cholesteryl esters into free fatty acids and free cholesterol. Dietary 
phospholipids, less resistant than biliary phospholipids, are hydrolyzed by 
activated pancreatic phospholipase A2 in the presence of trypsin, calcium ions 
and bile salts. Pancreatic co-lipase, activated by trypsin, strongly binds to the 
lipase to allow the specific enzymatic action of the pancreatic lipase on 
triglycerides at the oil-water interface.
Due to the specificity of pancreatic lipid hydrolases, the hydrolysis products 
included free fatty acids, free cholesterol, 1-lysophospholipids and 2- 
monoglycerides. Free fatty acids and 2-monoglycerides are the major 
constituents of the terminal phase of dietary lipid intestinal lumen digestion.
1.4.2 Triglvceride fatty acid distribution in fats
Triglyceride fatty acid distribution is an important parameter in the digestibility 
of fats (Table 1.5). Unsaturated fatty acids occupy the 2-position of glycerol in 
fats of most mammals, except for pigs. Gamma-iinolenic acid (C18:3n-6), is 
found in 2-and 3-positions of evening primrose, blackcurrant, and borage 
(Lawson & Hughes, 1988c). In the same manner, saturated fatty acids are in 
1- and 3-positions and linoleic acid in the 2-position of glycerol in most plant 
oils. EPA and DHA acid are often found in the 2-position of triglycerides, but
28
they have been observed in the 3-position in mackerel, cod liver oil, and 
Atlantic salmon and for EPA in all three positions in sardine oil (Ackman & 
Ratnayake 1989).
In MaxEPA, a purified fish oil preparation, EPA occupies both the 2- and 1-, 3- 
positions and DHA acid preferentially the 2-position (Chernenko et al., 1989). 
Ackman and Ratnayake, (1989) summarized the distribution of EPA and DHA 
in fish triglycerides, indicating that DHA was overwhelmingly concentrated in 
the 2- position, while EPA showed relatively greater preference for the 2- and 
3-position, with smaller amounts in the 1-position. By contrast, marine 
mammals distribute EPA and DHA in their triglycerides mainly in the 1- and 3- 
positions (Ackman, 1988; Ackman and Ratnayake, 1989). Position in the 
triglyceride molecule determines susceptibility to hydrolysis by pancreatic 
lipase in the intestine. Fatty acids in the 2-position are not substrates for 
intestinal lipases (Ackman, 1988).
Weaver et al., (1989) investigated the importance of the location on the 
triglyceride chain for the ultimate delivery of n-3 fatty acids to tissues by 
examining the accumulation of EPA and DHA in plasma and platelet lipids in 
three human subjects following the ingestion of either whale or herring oil. 
Both oils have similar amounts of EPA and DHA, but in whale oil the fatty 
acids are distributed mainly in the 1- and 3-positions, while in herring oil EPA 
and DHA are predominantly in the 2-position (Ackman and Ratnayake, 1989; 
Weaver et al., 1989). What they found was that although EPA and DHA was 
incorporated into plasma and platelet lipids following the ingestion of both oils, 
enrichment with DHA in all lipids tended to be greater with whale oil, as did 
EPA although the differences in this case were not statistically significant.
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Table 1.5 Position of fatty acids (mol %) in triglycerides of some vegetable oils, 
land and marine animal fats.
After, Carlier et al., (1991).
Fatty acids
Depot fats *
or oils 1
icloTj o © p
*00 4j- © doOfU G G G G
Peanut 1 14 5
2 1 < 1
3 11 5
Corn 1 IB 3
2 2 < 1
3 13 3
Soy bean 1 14 6
2 1 < 1
3 13 6
Olive 1 13 3
2 1
3 17 4
Pig * 1 1 14 2 23
2 4 58 6 3
3 1 1 2 11
B eef* 1 4 41 6 17
2 9 17 6 9
3 1 22 6 24
Herring * 1 6 12 13 1
2 10 17 10 1
3 14 7 5 1
Mackerel * 1 6 15 11 3
2 10 26 6 1
3 3 6 7 2
Cod * 1 4 13 12 5
2 6 15 10 1
3 3 6 11 1
Seal* 1 4 11 15
2 11 13 30
3 1 4 14
Polar bear * 1 2 5 7
2 5 7 24
3 1 3 8
Os NO CO ON cn ON m m
h a eb eb eb eb ebT—1< <N P T—^ in NO
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59 18 1
58 39 <1
57 10 3
27 50 1
26 70 <1
31 51 1
23 48 9
21 70 7
28 45 8
72 10 < 1
83 14 1
74 5 1
40 12 < 1
18 8 < 1
61 23 < 1
20
41
37
16 3 25 3 14 1 1
10 3 6 18 5 3 13
8 1 20 4 50 1 1
20 2 8 4 16 1 2
9 1 5 11 5 2 15
24 2 14 8 24 1 4
31 2 13 3 9 1 2
9 1 7 11 6 3 26
24 2 18 12 9 1 9
29 18 3 8 2 3
30 3 1 1 1 1
26 16 8 7 6 10
27 31 4 7 6 7
45 4 1 1 2 2
30 25 4 2 13 13
30
Lawson and Hughes (1988 a, b) compared the absorption of different forms of 
fish oil fatty acids in human subjects using triglycerides, free fatty acids, and 
ethyl esters. They validated their findings by comparison with the absorption 
of a-LNA which was at least 95% absorbed. EPA and DHA were best 
absorbed as the free fatty acids, since these are the products of normal 
digestion. As triglycerides, EPA and DHA were absorbed at only 68 and 57%, 
respectively, compared with the free fatty acids (Lawson and Hughes, 1988 a). 
As ethyl esters, absorption was only about 20% of that observed with free 
fatty acids. The authors suggested that the decreased absorption of the 
triglyceride form was related to the distribution of these fatty acids in the 2- 
position of the molecule that is resistant to the action of pancreatic lipase.
The most dramatic finding of Lawson and Hughes’ study was the relatively 
poor absorption of the ethyl ester form of EPA and DHA. The authors 
suggested that resistance to pancreatic lipase activity was responsible for the 
low absorption. The authors cited evidence for the position of the double bond 
relative to the carboxyl end as a factor, i.e. the farther away, the better the 
absorption. Double bonds within the first six carbons from the carboxyl end 
increase the resistance of the fatty acid to lipase activity. Double bond location 
and position in the triglyceride would help explain why EPA is apparently 
better absorbed than DHA (Lawson and Hughes, 1988 b).
Extending their work, Lawson and Hughes, (1988 b) tested the absorption of 
three different forms of EPA and DHA in the presence of a high-fat meal. 
Absorption of EPA from the triglyceride increased from 69% in the low-fat 
meal to 90% with the high-fat meal. Absorption of DHA increased from 61 to 
68%. When EPA and DHA were presented as ethyl esters with the high-fat 
diet, absorption, measured over 8 hours, increased from 20 to 65% and 22 to 
59% respectively. In fact as indicated by other studies the fat can continue to 
be absorbed over a longer time scale than that measured by Lawson and 
Hughes, (1988 b). In rat studies Hamazaki et al., (1987) fed EPA in equal 
amounts as a triglyceride, phospholipids, or as the ethyl ester for 4 or 10 days 
via a gastric tube, and found that the triglyceride and ethyl ester forms led to
1.5 Effect of chemical form on absorption of polyunsaturated fatty acids
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a similar distribution of fatty acids in plasma phospholipids and cholesterol 
esters.
1.6. Fatty Acid Metabolism
Mammalian cells are able to synthesize saturated and unsaturated fatty acids 
of the n-9 and n-7 series de novo from acetyl CoA. However because of a 
lack of the delta (A) 12 and 15 desaturase enzymes necessary for insertion of 
a double bond closest to the methyl group of the fatty acid carbon chain at the 
n-6 and n-3 positions, respectively (Innis, 1991), mammalian cells are unable 
to synthesize unsaturated fatty acids of the n-3 or n-6 series. This means that 
these two series of fatty acids are essential. Thus because vertebrate animals 
cannot insert double bonds more proximal to the methyl end than the seventh 
carbon atom, with, all metabolic conversion occurring without altering the 
methyl end of the molecule containing the n-3 and n-6 double bonds, once 
ingested, n-3 and n-6 fatty acid are not interconvertible. This is important 
since in the absence of substantial dietary amounts of fish oil, the human diet 
primarily contains essential fatty acids in the form of linoleic (LA) and a- 
iinolenic (a-LNA) synthesized by plants. Within the human organism these 18- 
carbon precursors can be elongated and desaturated to the more highly 
unsaturated members of their families, principally arachidonic acid (AA) and 
docosahexaenoic acid (DHA) (Hansen, 1994; Innis et ai., 1999) (Fig.1.10). 
The liver is the primary site for essential fatty acid metabolism, although it 
does take place in other tissues as well.
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Fig. 1.10 Metabolic pathway of linoleic (LA) and a-linoienic (a-LNA).
For each fatty acid, two alternative pathways are shown, involving a A6- 
Desaturase plus a step of retroconversion or a A4-Desaturation. It is not clear 
which of these pathways that are correct, but most experimental data point to 
the one involving retroconversion (Gerster, 1998).
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Abbreviation:n-6 Series (18:2n-6:LA, 20:4n-6:AA, 22:4n-6:DTA, 22:5n-6:DPA n-6). 
n-3 Series (18:3n-3:a-LNA, 20:5n-3:EPA, 22:5n-3: DPA n-3, 22:6n-3:DHA).
The first part of this pathway to DTA and DPA n-3, respectively, takes place in 
the endoplasmic reticulum and consists of sequential alternating elongation 
and desaturation steps catalyzed by fatty acid elongase, and A6- or A5- 
desaturase; these desaturases are membrane-bound enzyme that occur in 
the endoplasmic reticulum of many tissues, for example, liver, intestinal 
mucosa, brain. They require electron transport from NADH or NADPH 
catalyzed by cytochrome b5, (Benyon et al., 1998) see (Fig.1.11). The A6- 
desaturase seems to be the rate-limiting step of the pathway. The mechanism 
of the final conversion to DPA n-6 and DHA is still not agreed upon it. 
Traditionally it has been thought to occur via a A4-desaturase (Holman, 1998; 
Tocher et al., 1998; Innis et al., 1999), but no proof of the existance of this 
enzyme has ever been found (Sprecher et al., 1995). Currently it is believed 
that the last part of the final conversion to DPA n-6 and DHA occurs primarily 
via chain elongation to 24:5n-3 or 24:4n-6 and A6-desaturation to 24:6n-3 or
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24:5n-6 followed by a retroconversion step of peroxisomal [3-oxidation, which 
is called the “Sprecher pathway” (Hansen, 1994; Petroni et al.,1998; Innis et 
al.,1999; Sprecher et al., 1999), although this pathway has been questioned 
(Infante & Huszagh, 1997; Infante & Huszagh, 1998). Evidence for the 
function of the “Sprecher pathway” is obtained from in vitro experiments on rat 
liver and testis homogenates, and from cultures of hepatocytes, retina cells, 
astrocytes, and fibroblasts including fibroblast from humans with defective 
peroxisomal function (Hansen, 1994; Innis et al.,1999). Analysis of the fatty 
acid composition of brain glycerophospholipids from patients with different 
peroxisomal disorders shows low levels of DHA, indicating a defect in DHA 
biosynthesis (Martinez, 1992; Petroni et al., 1998). Patients with Zellweger 
syndrome, also have low levels of DPA n-6 (Martinez & Mougan, 1999), but 
patients with other peroxisomal disorders have normal or increased levels of 
DPA n-6 (Martinez, 1992; infante & Huszagh, 1998). Infante and Huszagh 
(1997) believe that the current evidence support their proposal that the 
biosynthesis of DHA and DPA n-6 occurs via separate channeled 
mitochondrial pathways, which do involve a final A4-desaturation step. 
According to their view mitochondria could well be the sole site for DHA 
synthesis, whereas the other LC-PUFA, DPA n-6, EPA and AA, could be 
synthesized in the endoplasmic reticulum as well. They suggest that the 
mitochondrial and microsomal systems could be interregulated compensatory- 
redundant systems.
Whether the same or two different A6-desaturase enzymes catalyze the first 
and the second A6-desaturation in the “Sprecher pathway” is at present 
unclear (Marzo et al., 1996). A rat and a mouse A6-desaturase have now 
been cloned and they can both use the coenzyme A esters of both LA and a- 
LNA as substrate (Aki et al., 1999), but it was not reported whether coenzyme 
A esters of 24:5n-3 and 24:4n-6 could be desaturated. Evidence by Marzo 
and coworkers (1996) indicate that these steps are catalyzed by distinct A6- 
desaturase, as inhibitor of A6-desaturase reduced DHA production in 
retinoblastoma cells from a-LNA to a greater extent than from EPA.
From several in vivo and in vitro studies with different animal species it is 
well known that a-LNA, LA, and oleic acid (18:1 n-9) compete for the same 
enzymes in the metabolic cascade to their respective LC-PUFAs (this is the
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biochemical background for the formation of mead acid (20:3n-9), which is 
formed when the dietary intake of essential fatty acids is low and its presence 
in plasma has become an indicator of essential fatty acid deficiency) 
(Fig.1.12). Dietary studies on rats and other animals have shown that a-LNA 
is a strong suppressor of n-6 fatty acid metabolism, whereas 10 times as 
much LA is required to give an equal suppression of n-3 metabolism. In vitro 
studies on rat liver microsomes has confirmed that the n-6 and n-3 substrate 
competition occur at several steps in the microsomal pathway- desaturation 
as well as elongation steps (Mohrhauer et al., 1967) and that the efficiency of 
competition is a-LNA > LA > oleic acid (Tocher et al., 1998). This makes the 
dietary ratio of a-LNA/LA an important factor for the endogenous formation of 
DHA from a-LNA (Emken et al., 1994), but the dietary content of different LC- 
PUFAs may also interfere with this formation. It is known that an increased 
dietary intake of AA or DHA will inhibit the endogenous formation of AA from 
LA in humans (Emken et al., 1998; Emken et al., 1999), and dietary DHA will 
also inhibit the endogenous formation of DHA (Emken et al., 1999). 
Elongation and desaturation of the parent fatty acids to their long-chain 
metabolites are modified by many additional dietary factors, including 
Polyunsaturated/Saturated ratio so that their efficiency is highly unpredictable 
(Simopoulos, 1991). It is therefore usually considered doubtful whether a-LNA 
rich-vegetable oils are a reliable source of EPA and DHA (Gerster, 1998). 
These effects may not only be mediated by direct competitive mechanisms, 
but also very likely via regulation of the activity of desaturation and elongation 
enzymes at the level of gene expression (Raclot et al., 1997; Jump & Clarke,
1999). The proposed mitochondrail or microsomal system could be up- and 
down-regulated (Infante & Huszagh, 1997) and a mechanism of mutual 
transcriptional repression of the n-3 and n-6 specific mitochondrial 
desaturases could also be a potential way to regulate LC-PUFA synthesis 
(Infante & Huszagh, 1998). Prior to the recent cloning of mammalian A6- 
desaturase (Aki et al., 1999) no actual enzyme, cloned or reproducibly purified, 
has been available for investigation of the questions on LC-PUFA synthesis. 
However the exact mechanisms of LC-PUFA formation and its regulation will 
probably be clarified in the near future.
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Fig.1.11 The desaturation pathway.
This is located in the smooth endoplasmic reticulum and is responsible for the 
introduction of double bonds at positions A4, A5, A6, and A9. After; (Benyon et al., 
1998).
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Fig.1.12 Metabolism of n-9 series fatty acids (Gurr, 2000).
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1.7. Dietary Fatty Acid Deficiency
Prolonged dietary limitation of n-3 or n-6 fatty acids or of total fat affects 
cellular fatty acid balance, for example reducing DHA and increasing 
docosapentaenoic acid (DPA n-6) content in brain phospholipids of both rats 
and mice (Martins et al., 1984; Bourre et al., 1989 a), with a number of 
clinically obvious consequences. Human susceptibility to dietary PUFA 
limitation was first highlighted by Burr and Burr, (1929), with subsequent 
identification of linoleic (LA) and a-linolenic (a-LNA) (Burr & Burr, 1930). Their 
metabolism and nutritional importance has been widely studied since that time 
(e.g Holman et al., 1982; Bjerve et al., 1989), with evidence arising from 
studies on infants fed skim milk (Yamanaka et al., 1980) or individuals fed by 
parenteral feeds (Bjerve et al., 1989). The fetus is particularly susceptible 
relying on transfer of these essential fatty acids across the placenta from the 
maternal circulation (Neuringer et al., 1984) and neonates are susceptible 
because of low fat reserves (Clandinin et al., 1981). It is recognized that LA 
prevents water loss through the skin (Hansen & Jensen, 1985), and it is 
generally acknowledged that LA is the more important EFA in reversing the 
classical symptoms of EFA deficiency such as scaly skin, dry hair, and 
membrane dysfunction, although recent studies have raised important 
questions about the role of LA in EFA deficiency (Cunnane, 1999). In the last 
20 years the importance of the a-LNA family has been recognized in different 
terrestrial species (Crawford et al., 1976; Salem & Ward, 1993), with DHA 
playing an important role in membrane structure and function in excitable 
tissues such as the brain, retina, and heart (Horrobin et al., 1984; Neuringer et 
al., 1986; Litman & Mitchell, 1996; Billman et al., 1997).
Biochemical changes following a lack of dietary n-3 fatty acids include a 
reduction in a-LNA and an increase in DTA and DPA n-6, with clinical features 
including reduced learning (Lamptey and Walker, 1978), abnormal 
electroretinogram (Wheeler et al., 1975), impaired vision (Lamptey and 
Walker, 1978), and polydipsia (Connor et al., 1991).
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1.8 Dietary n-6 and n-3 fatty acid balance
It has generally been accepted that changes in the fatty acid composition of a 
nutritionally adequate diet alters the phospholipid components of cell 
membranes, (Spector and Yorek, 1985) and that deficiency in either or both n- 
6 and n-3 fatty acids causes physical and biochemical changes to cellular 
function. The balance between the n-6 and the n-3 fatty acids in cellular lipids 
depends on the ratio of parent fatty acids in the diet, with the absolute amount 
of each precursor also important, as there is competitive inhibition between 
the two series of fatty acids for A6 and A5 desaturation (Brenner, 1981). 
Where the amount of dietary a-LNA is almost equal to or exceeds the levels of 
linoleic acid, the former seems to competitively inhibit the conversion of 
linoleic acid to longer chain n-6 metabolites (Mohrhauer and Holman, 1963). 
The balance between dietary n-3 and n-6 fatty acids is an important 
determinant of eicosanoid production through influencing relative amounts of 
arachidonic acid, EPA and DPA and consequent interactions through 
competition as substrates for acylation and other enzymic steps especially the 
cyclooxygenase and lipoxygenase pathways, (see appendix 4 for further 
discussion). Thus increased EPA and DHA have the effect of reducing 
membrane AA content and availability to phospholipase A2 (PLA2), altering 
the eicosanoid profiles towards a more thrombotic state (Simopoulos, 1991). 
The inhibitory effect of a-linolenic (a-LNA) on conversion of linoleic acid (LA) 
to arachidonic acid (AA) is much greater than that of LA on conversion of a- 
LNA to EPA (Holman, 1964). Thus, inhibiting conversion of LA to AA by 
increasing dietary a-LNA has been suggested to reduce AA in tissue lipids 
(Mohrhauer and Holman, 1963; Morson and Clandinin, 1986). Reduction of 
AA caused by increasing a-LNA in the diet is greater in liver and serum lipids 
than in brain lipids (Anding and Hwang, 1986). Thus, the balance of essential 
fatty acids appears to affect various organs differently and its effect may also 
vary depending on the stage of an animal’s development (Farrell et al., 1988). 
Some concern has been raised about the health implications of the increased 
bleeding associated with high n-3 diets, which accompanies a reduction in 
inflammatory and immune responses (Leaf & Weber, 1988). Other concerns 
raised in n-3 clinical studies include possible adverse effects in non-insulin-
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dependent diabetes mellitus (Glauber et al., 1988) and in hypertriglyceridemic 
patients as their levels of LDL-cholesterol may increase (Harris et al., 1988). 
Fish oil may also have adverse effects on aspirin-intolerant asthmatics 
(Picado et al., 1988). Obviously, further research will be required to evaluate 
these adverse effects and to determine if they are outweighed by beneficial 
effects in particular patient groups.
Excessive PUFA peroxidation is also a concern with excessive fish oil, since 
PUFAs readily autooxidize in air, a potential problem in food or oil processing. 
These long-chain peroxides are toxic and can lead to yellow fat disease, a 
syndrome characterized by steatites, haemolytic anaemia, and myocardial 
fibrosis (Sanders, 1986). A related problem is the deficiency of vitamin E that 
can result from diets rich in PUFA. It has been shown that serum and liver 
alpha-tocopherol levels decline in direct correlation with increases in the 
amount of cod liver oil fed to rats (Mouri et al., 1984). Prolonged deficit of 
vitamin E can lead to neuropathy (Machlin, 1984) and therefore plays an 
important role in neurological function.
Other adverse effects of large intakes of n-3 include reduced platelet 
aggregation, inhibition of arachidonic acid metabolism for prostaglandin 
formation, and immunosuppression (Simopoulus, 1991). As large intakes of n- 
3 fatty acids may lead to adverse consequences, so may high levels of n-6 
fatty acids. a-LNA is essential for maintaining high learning ability in rats 
(Yamamoto et al., 1988) and high levels of n-6 fatty acids may impair learning. 
Some corn oil-based infant formulas contain excessive linoleic acid, and are 
deficient in a-LNA. Also in infants receiving total parenteral nutrition with 
Intralipid, the excessive LA influenced the developmental fatty acid patterns of 
liver and brain, reducing liver ethanolamine phosphoglycerides and choline 
phosphoglycerides DHA to half their normal value during a critical 
developmental stage. However the brain was resistant to changing its fatty 
acid composition despite such dietary manipulation (Martinez and Ballabriga, 
1987). These results indicate that the correct ratio of LA to a-LNA is not the 
only relevant factor in devising an essential fatty acid diet. Thus an excess of 
LA even with a theoretically correct ratio of LA to a-LNA, should be avoided if 
the tissue balance of long chain PUFA is to be kept unaltered, particularly 
important during brain development.
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LA, fed at 22% of calories, was shown to affect immune tolerance induction 
(Cinader et al., 1983). For the newborn infant, toxic effects of PUFAs 
reportedly include alteration in immunity (McCormick et al., 1977) and 
changes in myelin configuration and function (Friedman, 1980).
1.9. Relative metabolic importance of a-LNA, EPA and DHA
It is apparent that individual n-3 fatty acids have to a greater or lesser extent 
unique metabolic roles. Although the interconversion between EPA and DHA 
in several tissues makes these two fatty acids more equivalent, in most 
circumstances, the metabolic behaviour of a-LNA in animals and human 
beings differs substantially from that of EPA and DHA so that it cannot 
substitute for them and must be converted to these fatty acids before it can be 
metabolically useful.
Unlike EPA and DHA, a-LNA is not readily incorporated into plasma and 
tissue lipids when consumed in large amounts (Sanders & Roshanai 1983; 
Adam et al., 1986; Hwang et al., 1988), most likely because among fatty acids, 
a-LNA appears to be preferentially oxidized by the liver as reported by Leyton 
et al., (1987), reducing its availability for further metabolism. Other reasons 
may relate to its competition with the much greater amounts of linoleic acid in 
the diet (Nettleton, 1991).
Differences between individual n-3 fatty acids also include the uptake and 
tissue distribution of EPA and DHA in phospholipids. For example, EPA is 
avidly taken up by phosphatidylethanolamine (PE) and to a lesser extent by 
phosphatidylcholine (PC) in red blood cells, while dietary DHA accumulates 
equally in these phospholipids (Popp-Snijders et al., 1986; Gibson et al., 
1992). Liver, kidney, platelets, and blood cells take up more EPA than DHA, 
whereas heart, retina, and brain concentrate DHA preferentially (Bourre et al., 
1988; Sprecher, 1989; Anderson et al., 1990). Fischer et al., (1984) have 
shown that in platelets and neutrophils, although DHA may be incorporated 
into the membrane, only trace amounts are released under the same 
circumstances that stimulate EPA release.
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1.10 Bioavailability of a-linolenic acid
As discussed above the metabolic pathways involved in a-LNA conversion to 
EPA and DHA are known in considerable detail. However the extent of such 
pathways may be influenced by not only fat absorption, and competition from 
n-6 PUFA, but also by cofactor nutrients such as iron, zinc, & copper required 
for desaturase activity, and pyridoxine, required for chain elongation (Ackman 
& Cunnane, 1991). In addition a-LNA conversion to DHA varies with age, 
between species, during pregnancy and lactation, nutritional status, and with 
some degenerative as well as inherited diseases.i.e., Burdge et al., (2002 a) 
reported a greater apparent synthesis of DHA in women (reproductive age) 
compared with men, and suggested that one possible explanation for this may 
be up-regulation of the desturation/elongation pathway by oestrogen. If true, 
the capacity to regulate a-LNA conversion by the action of sex hormones may 
contribute to the physiological increase in maternal plasma DHA concentration 
in pregnancy (Neuringer et al., 1984; Postle et al., 1995; Burdge et al., 1994; 
Burdge & Postle, 1994; Otto et al., 1997).
Recent studies suggest that pressure from (3-oxidation during energy deficit 
or undernutrition has at least as great a negative effect on the bioavailability of 
a-linolenic as all of these other variables (see Section 1.15.3). Synthesis from 
the small amounts of dietary hexadecatrienoic has a modest positive effect on 
availability of a-LNA (Cunnane et al., 1995). However, (3-oxidation probably 
plays a greater role than almost any other factor in determining a- LNA 
availability for n-3 LC-PUFA synthesis during early development because (3- 
oxidation followed by carbon recycling into de novo lipid synthesis consumes 
significant amounts of dietary a- LNA in neonatal rats and fetal primates. 
Nutritional conditions that promote fatty acid (3-oxidation for energy are usually 
considered to exclude simultaneous fatty acid synthesis, but this not the case 
with a- LNA, at least in the neonatal period (Cunnane, 2001).
1.10.1 The effect of 6-oxidation and carbon recycling
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The importance of p-oxidation and carbon recycling of a-LNA lies in the 
significant negative effect these processes have on the availability of a-LNA  
for esterification or conversion to n-3 long-chain polyunsaturated fatty acids 
(LC-PUFA). While the health attributes of a-LNA in young mammals are most 
commonly linked to its conversion to n-3 LC-PUFA, principally DHA, in adults, 
a-LNA may have biological activity without conversion, i.e. reducing cancer 
risk, attenuating some cardiovascular risk factors and modulating the immune 
system (Cunnane et al., 1995a). However, the majority of a-LNA’s effects on 
the early development of the visual and nervous systems appear to occur 
through conversion to DHA. Therefore, it is important to know the 
bioavailability of a-LNA (i.e., the portion of consumed a-LNA that is actually 
available for desaturation-chain elongation). It is also important to understand 
the factors that are most likely to influence the partitioning of dietary a-LNA 
toward p-oxidation or carbon recycling compared to retention in the body as 
an n-3 polyunsaturated fatty acids (PUFA).
1.10.2 (3-oxidation under normal conditions
Carbon recycling depends on the availability of acetyl-CoA derived from the p- 
oxidized precursor, in this case, a-LNA. Thus, for carbon recycling to be a 
significant sink for the carbon skeleton of a-LNA, p-oxidation has to be an 
important route of a-LNA metabolism. Many different experimental models 
using both infants and adults demonstrate that a-LNA is readily p-oxidized: i.e. 
using tracer studies of oxidation (typically 14C, 13C) in vivo or in vitro, or using 
whole body fatty acid balance methodology. In fact rats oxidize about 70% of 
a normal requirement LA intake under normal growth conditions (Cunnane & 
Anderson, 1997; Cunnane et al., 1998). Of that which is P-oxidized, a similar 
proportion (20-30%) of linoleic is recycled into de novo lipid synthesis as is 
used to make arachidonic, even during extreme linoleic deficiency (Cunnane 
et al., 1998). In both rats and humans, the rate of a-LNA p-oxidation is 
probably as high or possibly higher than that of LA (Gavino & Gavino, 1991; 
McCloy & Cunnane, 1999), with broad agreement between tracer and balance 
data that upward of 65% of dietary a-LNA is p-oxidized under normal
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conditions of dietary energy sufficiency, growth, health, and at usual a- LNA 
intakes (Leyton et al., 1987; Chen et al ., 1996; Cunnane & Anderson , 1997). 
(3-oxidation of a- LNA maybe somewhat less in suckling rats (50-55%; Sinclair, 
1975) and in pregnancy. The clear conclusion is that, despite its apparent 
nutritional importance, most a-LNA is normally completely (3-oxidized for 
energy even in rapidly growing young animals with a relatively high 
requirement for all nutrients.
1.10.3 (3-oxidation under energy deficit
Whole-body balance data for a-LNA oxidation in pregnant rats during a 48-h 
fast at d 13-15 of pregnancy, increased a-LNA oxidation from 68% to 142% of 
intake, resulting in a net whole-body loss of a-linolenic, which was not 
recovered during 6 days refeeding (Chen & Cunnane, 1993). Whole-body loss 
of a-LNA was also observed with more chronic undernutrition caused by zinc 
deficiency during pregnancy (Cunnane et al., 1993). Weight cycling in young 
rats impairs a-linolenic accumulation and doubles its (3-oxidation, this despite 
adequate (3-oxidation intake (Chen et al., 1996).
In summary, these studies show that (3-oxidation of a-linolenic for energy can 
take precedence over all other known pathways of its metabolism, including 
the increased need for DHA during pregnancy. Consequently, energy 
sufficiency is probably the main prerequisite for normal rates of desaturation- 
chain elongation of a-LNA to DHA. However, energy sufficiency alone does 
not prevent the normal and, apparently, obligatory (3-oxidation of a-LNA.
1.10.4 Carbon recycling of a-linolenic
Sinclair, (1975) studied the recycling of 14C a-LNA into de novo lipid synthesis 
in suckling rats of which only a small part (0.3%) of the labeled a-linolenic was 
found in brain lipids at 48 h (of which 26% of the label was in cholesterol and 
65-70% in saturated and monounsaturated fatty acids) with 49% completely 
(3-oxidized. Subsequent studies with 14C a-LNA by Cunnane and co-workers 
showed tracer recovery in newly synthesized lipids exceeded its conversion to
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DHA by 5-7 fold and that after taking into account the proportion of a-linolenic 
that is (3-oxidized to C 0 2l loss of a-LNA to (3-oxidation and carbon recycling 
normally exceeds DHA conversion by about 11-fold (Menard et al 1998). 
Also much of the radiolabeled a-LNA fed to young guinea pigs was presumed 
oxidized (39%) or found as labeled-a-LNA in the fur and skin (46%) (Fu & 
Sinclair, 2000).
Recent studies with near-term foetal and infant rhesus monkeys showed 
similar data, confirming the importance of carbon recycling from a-LNA in 
primates in the foetal state as well as in neonates, and also showing that 
carbon recycling of a-LNA into de novo fatty acid synthesis was more 
extensive than for LA or DHA (Sheaff-Greiner et al., 1996).
In humans, a high oxidation rate of a-LNA has also been observed when it 
was found as much as 20% of the 13C-labeled a-LNA was oxidized and 
expired as C 0 2 within the first 12 h after receiving an oral dose (Vermunt et al., 
2000).
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Fig. 1.13 Overall scheme showing the predominant directions in a-linolenic 
metabolism. The main routes affecting bioavailability of a-linolenic are shown in 
larger, bold lettering. Most incoming a-linolenic is directly from the diet, but 3-4 % 
could be derived from dietary hexadecatrienoate present in green plant material. 
Most losses of a-linolenic are via p-oxidation, which is usually >65% but can increase 
to over 100% during energy deficit. Small amounts of a-linolenic intake (usually <3%) 
are excreted. Accumulation of a-linolenic itself is usually no more than 10% of intake 
but can be negative (body losses) with energy deficit. Conversion to n-3 LC-PUFA 
generally appears to be <5% of a-linolenic intake in young rats but may be as high as 
10% during pregnancy. The quantitative extent of recycling into de novo lipogenesis 
appears to be at least 10% of a-linolenic intake in neonates and is easily equivalent 
to conversion to n-3 LC-PUFA (Cunnane, 2001).
1.11 Why is Docosahexaenoic acid of interest?
DHA has the longest chain length and is the most unsaturated fatty acid 
commonly found in the hydrophobic interior of biological membranes 
influencing membrane order, thickness, domain size, stability, and 
permeability of the lipid phase through interaction with membrane proteins 
(Salem et al.,1986). Stillwell et al ., (1997) showed that an increase in 
membrane DHA either through diet or by fusing the mitochondria with oleic, 
DHA PC (phosphatidylcholine) large unilamellar vesicles (LUV) generated
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mitochondria with substantially enhanced H+ permeability. Membrane DHA is 
necessary for normal neurological development (Menkes et al., 1962) and 
vision (Neuringer et al., 1988), as well as having benefits for various disease, 
including atherosclerosis (Dyerberg & Jorgensen, 1982), autoimmune 
inflammatory disease such as rheumatoid arthritis (Calder, 1997; James et al.,
2000) and cancer (Bougnoux, 1999). How DHA exerts these health benefits is 
unclear but may act through several mechanisms including altering eicosanoid 
production from arachidonic acid, undergoing peroxidation, and affecting cell 
signalling and gene expression. Functional aspects of DHA and fatty acids in 
genrai is discussed further in relation to the brain, vision and membrane 
structure and function in appendices 2-4 .
1.11.1 Where is DHA found?
In mammals, high concentrations of DHA is found in three types of cellular 
membrane, i.e. the rod outer segment (ROS) with the epithelial cells lining the 
retina and forming a barrier between the photoreceptor cells and the blood, 
specialized for the uptake of n-3 fatty acids (Wang & Anderson, 1993); 
synaptosomes (Breckenridge et al., 1972) and sperm (Neill & Masters, 1973). 
In these cells it can represent >50% of total phospholipid acyl chains, is 
tenaciously retained at the expense of other fatty acids and is relatively 
unresponsive to dietary fluctuations (Salem et al., 1986). In all other tissues, 
DHA is found at much lower levels primarily in hetero acid phospholipids with 
the sn-1 chain composed mainly of the saturated fatty acids palmitic or stearic 
acid and the sn-2 chain DHA (Anderson & Sperling, 1971).
DHA is found predominantly in phosphatidylethanolamine (PE) and 
phosphatidylserine (PS), but it is also present in other phospholipid classes, 
including phosphatidylcholine (PC) and phosphatidylinositol (Pi) (Salem et al., 
1986; Zerouga et al., 1996). Under conditions of DHA depletion, there is a 
substantial reduction of brain PS. This was recently explained by the 
observation that the base-exchange reaction was favored only when DHA was 
present as one of the acylmoieties on the substrate PE or PI (Garcia, et al.,
1998). In conditions of DHA depletion, where docosapentaenoic acid (n-6
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DPA) is found in high concentrations in the PE and PI, the base-exchange 
reactions are inhibited and PS levels in the brain are reduced. Presumably, 
this differential activity is due to different conformations of PE when n-6 DPA 
is present compared to DHA Although the liver has long been recognized as 
an important site of PUFA biosynthesis (Pawlosky et al., 1992; Schenck et al., 
1996; Buzzi et al., 1997), a number of animal studies in various species have 
shown that DHA can be synthesized by the nervous system (Pawlosky et al., 
1994; Pawlosky et al., 1996). Cells of the nervous system, like other cells, 
take up DHA and other n-3 fatty acids from blood lipoproteins as a 
lysophospholipid rather than as a free fatty acid (Bernoud et a!., 1999) as an 
efficient transfer of DHA into the neuron. Although felines are the only species 
in the entire brain accretion of biosynthesized DHA is the result of production 
within the CNS (e.g., dietary a-LNA or EPA are converted into n-3 DPA in liver, 
which is then transported as lipoproteins to the CNS, where it is converted to 
DHA; Pawlosky et al., (1994) other species carry on similar intra-CNS 
processes to obtain at least part of their DHA (Pawlosky et al., 1996) (Moore 
et al ., 1991; Moore, 1993; Delton-Vandenbroucke et al ., 1997). In these 
reports it has been suggested that in the CNS, unlike the liver in which 
biosynthesis of DHA from a-LNA takes place entirely within the hepatocyte, 
more than a single cell type (either an astrocyte or endothelial cell) may act in 
a synergistic fashion to contribute to the synthesis and accretion of DHA.
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Di-DHA-PE
Ethanolamine
Di-DHA-PS
Di-DPA-PE
Fig. 1.14 Molecular models for the conversion of Di-DHA (PE) or DI-DPA (n-6) 
(PE) into (PS) by base exchange catalyzed by (PS) synthase. Molecular 
models were computed by energy minimization of the phospholipids structure given 
the di-DHA PE structure (Hamilton et al., 2000).
1.11.2 DHA biosynthesis and early development
Studies with felines illustrate the inherent capacity to synthesize long-chain 
PUFAs during the early developmental period (Pawlosky & Salem, 1996). 
Adult felines do not actively synthesize long-chain PUFAs from the 18-carbon 
precursors (Sinclair et al., 1979) but juvenile felines before weaning 
demonstrate hepatic long-chain PUFA synthesis from labeled-18-C precursors 
which appears in the blood, unlike the mothers where no conversion products 
occur in either blood or milk Pawlosky et al., (1994). Hence the demands of 
pregnancy and lactation did not provide sufficient stimulus to activate the 
biosynthetic pathway in adult cats. As young animals developed (and begin 
accepting meat in their diet), the ability to synthesize long-chain PUFAs 
diminished. This active capacity to synthesize long-chain PUFAs in juvenile 
felines suggests that development may be a significant factor, which triggers 
an enhanced biosynthesis of long-chain PUFAs during nervous system 
formation. It was observed that animals reared on any of several corn-oil- 
based diets had very low amounts of either DPA n-3 or DHA in brain at 8 wks 
(Pawlosky et al., 1997). Thus throughout feline development, the maternal diet
Serine
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must contain some preformed DHA for adequate accumulation of brain DHA 
(although n-3 EPA or DPA may partially substitute for DHA).
1.11.3 Docosahexaenoic Acid Supply and Conservation
Conservation of DHA in the central nervous system may be especially 
important for maintenance of DHA in the brain and retina, with DHA turnover 
in the brain of neonatal baboons very low, only 4% per week based on stable 
isotope analysis (Su et al., 1999). In the retina, isotope studies have 
demonstrated that DHA is conserved through recycling with the transfer of 
DHA between the pigment epithelial tissue and photoreceptor cells (Rodriguez 
et al., 1999) which is achieved by phagocytosis of sloughed off outer disk 
membranes by the retinal pigment epithelial cells maintaining the high 
concentration of DHA in photoreceptors as the disks undergo constant 
membrane biogenesis and renewal (Gordon et al., 1992).
1.11.4 Species and dietary influences on DHA formation
Quantifying the extent of long chain conversion of a-LNA to DHA is 
problematic because of both species and dietary influences. DHA formation 
from a-LNA or other n-3 fatty acids varies between species (Salem & 
Pawlosky, 1994; Pawlosky et al., 1994; Fu & Sinclair, 2000) so that different 
species have developed various independent strategies for obtaining DHA. As 
indicated above the low PUFA biosynthesis capability of the cat family 
(Sinclair et al., 1979) as well as an inherent inability to produce DHA in the 
feline liver (Pawlosky et al., 1994), results in a dietary requirement for DHA. 
(Pawlosky et al., 1997), and production of DHA from a-LNA may be a highly 
inefficient process in other species, as well (Menard et al., 1998; Su et al.,
1999). However it appears that the majority of species have some capacity to 
biosynthesize DHA from a-LNA in their livers.
Rodent studies suggest that 0.5% of energy as a-LNA is needed maintain an 
adequate level of DHA in the brain (Bourre et al., 1989 b). However, the 
composition of dietary fat influences hepatic long-chain PUFA production
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(Salem & Pawlosky, 1994; Pawlosky et al., 1994). For instance in nonhuman 
primates a diet with quite low levels of EPA and DHA (0.54% and 0.64% of 
dietary fat), inhibited labelled-a-LNA conversion to hepatic DHA (Pawlosky & 
Salem, 1993), even though DPA formation was observed as was LA 
conversion to AA. In contrast, with a diet devoid of EPA or DHA, hepatic DHA 
synthesis and accumulation in the blood was observed, suggesting that 
hepatic DPA to DHA conversion is partly controlled by dietary DHA. One could 
theorize that regulation of DHA biosynthesis from DPA is through transcription 
of a A-6 desaturase which mediates the DPA-+ DHA conversion (Marzo et al., 
1996). Such regulation could selectively control DHA production, without 
influencing synthesis of other long-chain PUFAs (e.g., arachidonic acid).
1.12 ‘Essentiality’ of fatty acids
1.12.1 ‘Essentiality’ as a dietary attribute alone
Cunnane, (1996) suggested reclassifying polyunsaturated fatty acids (PUFA) 
as ‘conditionally indispensable’ or ‘conditionally dispensable’ for the following 
reasons:
(1) Although linoleic and a-linolenic can be synthesized from their 16 carbon 
analogues (Cunnane et al., 1995 a), in the absence of those analogues, they 
cannot be synthesized de novo in mammals; (2) linoleic and a-linolenic give 
rise to longer chain PUFA with important membrane functions, which are 
precursors to eicosanoids, and which also cannot be totally synthesized de 
novo in mammals; (3) tissue levels of the n-6 and n-3 PUFA decline markedly 
when the parent PUFA are absent from the diet but increase after PUFA 
supplementation. The primary reason is that mild but distinctive deficiency 
symptoms are observed when either linoleic or a-linolenic are absent from the 
diet but disappear when they are present (Bourre et al., 1989 a; Cunnane et 
al., 1998). These symptoms are more severe in classical essential fatty acid 
deficiency than in specific linoleic deficiency, and in young compared with 
mature animals. These are valid reasons for designating crucial individual n-6 
and n-3 PUFA as 'essential' but which ones truly qualify and when?
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There are some important ambiguities and anomalies that arise when an 
entire interconvertible family of fatty acids is designated as essential in the 
diet:
1: the longer chain more unsaturated PUFA are traditionally thought of as the 
‘products’ and linoleic and a-linolenic as the ‘precursors’. However, the 
products can be retroconverted to the precursors (Hansen et al.,1986; 
Sprecher et al., 1995) so there is no longer a clear-cut unidirectional flow 
associated with this pathway;
2: the function of linoleic and a-linolenic themselves has always been 
somewhat unclear so whether they are ‘essential’ only as precursors or also in 
their own right is still uncertain;
3: under certain conditions (particularly early post-natal development), low 
tissue levels and symptoms of deficiency of longer chain PUFA such as DHA 
occur even if relatively high amounts of the parent PUFA (a-linolenic) are 
present in the diet (Gerster, 1998). Indeed, the parent PUFA may cause 
substrate inhibition of long chain PUFA synthesis; i.e. linoleic inhibits 
synthesis of arachidonic and a-linolenic inhibits synthesis of DHA (Ackman & 
Cunnane, 1991). Hence, linoleic and a-linolenic cannot always fulfil, and can 
actually inhibit, their mandate as the ‘essential’ parent fatty acids.
4: calling the longer chain PUFA ‘essential’ is also anomalous because, in the 
presence of dietary linoleic and a-iinolenic, n-6 and n-3 long chain PUFA can 
be synthesized by ail mammals that have been studied and, at all ages from 
late fetal life to old age. However, like linoleic and a-linolenic, the long chain 
PUFA cannot be totally synthesized de novo, i.e. in the absence of any dietary 
or stored linoleic and a-linolenic, respectively.
1.12.2 Capacity to synthesize or conserve long-chain polyunsaturates
With the capacity to convert parent to longer chain PUFAs affected by many 
nutritional, metabolic and disease processes, capacity is central to the use of 
“essentiality” as distinct from conditional indispensability or dispensability for
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fatty acids. Invariant insufficient capacity to synthesize arachidonic or DHA, 
according to functional criteria, would identify their ‘indispensability’ as distinct 
from invariant adequate synthetic capacity which would identify their 
‘dispensability’ (non-essential). Thus variation in the synthetic capacity with 
consequent low or negligible risk of inadequate tissue long chain PUFA levels, 
as with arachidonic acid, under some but not all conditions requires the use of 
the term “conditional” as a modifier of their dispensability. Thus a biochemical 
ability to make DHA might reduce its dietary need but would not make it 
‘dispensable’ if that capacity was ever insufficient. In fact the wide-ranging 
benefits of balanced vegetarianism suggest that dietary DHA is probably 
‘conditionally dispensable’ in healthy adults (Cunnane, 2000).
Thus emphasis shifts from definition of essentiality based on all members of a 
fatty acid pathway with a precursor which cannot be synthesized de novo, 
towards determining actual capacity and necessity for conversion and/or 
conservation, as well as the functional outcomes that define deficiency or 
sufficiency.
1.12.3 Synthesis of Linoleic and a-linolenic
Contrary to common belief, LA can be synthesized in rats (Sprecher, 1968; 
Cunnane et al., 1995 b) and humans (Demmelmair et al., 1997) by chain 
elongation from hexadecadienoic (16:2n-6). Hexadecadienoic is present at 1- 
2% in common edible green vegetables including broccoli and spinach. In 
tracer form, it is converted to linoleic in rats at a rate of about 3-4% /24 hr. 
This appears to be a modest conversion rate but is equivalent to the rate of 
conversion of LA to longer chain n-6 PUFA (Cunnane & Anderson, 1997). 
Thus, hexadecadienoic reduces the dietary requirement for LA by a modest 
proportion.
Similarly, chain elongation of hexadecatrienoic (16:3n-3) contributes to the 
synthesis of a-LNA in mammals. Considerably more a-LNA can be made from 
hexadecatrienoic because the latter is found in common edible green 
vegetables at up to 14% of total fatty acids (Cunnane et al., 1995a). Therefore,
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in predominantly vegetarian individuals and in sub-human species, 
hexadecadienoic and hexadecatrienoic may contribute appreciably to PUFA 
intake and would decrease the dietary requirement for LA and a-LNA.
In fact, tetradecadienoic (14:2n-6) and tetradecatrienoic (14:3n-3) are 
convertible to their respective 18-22 carbon PUFA derivatives (Sprecher, 1968) 
but no known dietary sources of these 14 carbon precursors exist. 
Furthermore, AA can be retroconverted to LA (Hansen et al., 1986) which 
could also affect the dietary requirement for LA p e r  se. Nevertheless, in 
estimating the conditional dispensability or indispensability of individual PUFA, 
the potential contribution of the 16 carbon precursors should not be 
overlooked.
1.12.4 a-Oxidation and carbon recycling into de novo Lipid synthesis
The considerable degree of [3-oxidation and carbon recycling into de novo 
lipid synthesis, as discussed above, raise another issue about the 
‘essentiality’ of linoleic or a-linolenic. Thus with the extensive recycling of a  
tracer dose of 14C-linoleic is into cholesterol and ‘non-essential1 fatty acids 
even under conditions in which dietary and body stores of linoleic are severely 
compromised, it would appear obligatory to use ‘essential1 fatty acids to make 
‘non-essential’ fatty acids.
1.12.5 Structural. Metabolic or Dietary Requirement
‘Essentiality’ is a concept currently applied only to compounds that are 
regularly needed in the diet. Cholesterol is interesting in this context because, 
regardless of the level of cholesterol in the diet, the brain does not import 
exogenous cholesterol (Edmond et al., 1991; Turley et al., 1996); it is obliged 
to synthesize its own cholesterol, and has the biochemical capacity to do so. 
Three ‘non-essential’ fatty acids are inaccessible to the brain from the diet 
(palmitate (16:0n-7), stearate (18:0n-9), oleate (18:1n-9) (Edmond et al., 1998) 
yet are all present in relatively high proportions in neuronal lipids. As with
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cholesterol, the brain’s capacity to synthesize palmitate, stearate and oleate is 
sufficient to meet its own needs.
Hence, the presence or absence of cholestrol, palmitate, stearate or oleate in 
the diet appears irrelevant to the brain, a situation which would make these 
lipids ‘dispensable’ from the diet yet, structurally, they are ‘indispensable’ to 
the brain. This apparently unique situation of the brain’s lipid requirements 
being partially independent of dietary sources or hepatic synthesis implies that 
endogenous synthesis in the brain is needed to control availability of these 
lipids and that dietary sources are not sufficiently reliable. This is directly 
opposite to the current definition of ‘essential’ fatty acids, a paradox that 
argues against defining ‘essentiality’ as a dietary attribute alone (Cunnane,
2000).
1.12.6 Conclusion
The arguments developed by Cunnane are similar to those now widely used 
within the amino acid field where the need to move away from use of just 
essential and non essentiality has been recognised for some years (Jackson, 
1983), although the emphasis has been more on the reclassification of 
previously defined non-essential amino acids such as glycine and glutamine 
as conditionally indispensable, rather than the opposite issue for fatty acids. 
According to these arguments of Cunnane, (2000) the full spectrum of 
definitions for long-chain fatty acids would be: dispensable; conditionally 
dispensable; conditionally indispensable.
AA and DHA, serve structural functions in membranes throughout the lifespan. 
However, vegetarian adults can probably remain healthy without consuming 
them; therefore, it could be suggested that AA and DHA are conditionally 
dispensable in adults, but conditionally indispensable throughout pregnancy to 
adolescence (at least up to 10 years old; Table 1.6). When dietary energy is 
not limiting, LA is usually abundant and readily stored in the body, especially 
in healthy adults (> 20 years old). As with AA and DHA and probably all the 
other intermediate PUFAs, it could be suggested that LA is conditionally 
dispensable after adolescence. Disease and nutritional deprivation potentially
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change the conditions and may make some or ail these PUFA conditionally 
indispensable (Cunnane, 2000). It is noteworthy that Cunnane has not used 
the term “indispensable”, arguing that, “indispensable” is an absolute term 
without exception for physiological, developmental or pathological state. Given 
the conditional nature of symptoms of dietary deficiency, on age, nutrient 
intake and/ or presence of disease, “conditionally indispensable” is much 
more appropriate. Current recommendations for adequate intakes of n-3 and 
n-6 fatty acids is discussed in appendix 5.
Table 1.6 Reclassification of some essential polyunsaturated fatty acids 
(PUFA) as conditionally dispensable and conditionally indispensable at 
various stages during the lifespan*.
Infancy, childhood, pregnancy and lactation Adulthood (>20 years)
Conditionally
dispensable
Conditionally
Indispensable
Conditionally
dispensable
Conditionally
Indispensable
Eicosapentaenoic
(EPA)f
Linoleic (LA)
a-Linolenic (a-LNA) 
Arachidonic (AA)
Docosahexaenoic
(DHA)
Linoleic (LA)
Arachidonic (AA)
Eicosapentaenoic
(EPA)f
Docosahexaenoic (DHA)
a-Linoienic (a-LNA) $
* Since there is much information on the dietary need for PUFA during early 
development, a distinction is shown between infants and adults. Adolescence is 
omitted due to lack of sufficient data. Further research is needed to more fully identify 
the conditions (nutrient deficiencies such as Zn) and diseases (cystic fibrosis, 
Zellweger syndrome) in which conditionally-dispensable fatty acids become 
indispensable in the diet.
t  Included with Eicospentanoic are other intermediate PUFA, i.e. y-linolenic, dihomo- 
y-linolenic, n-6 docosapentaenoic, n-3 docosapentaenoic, and also C<18 PUFA and 
C>22 PUFA.
$ a-Linolenic is listed as Conditionally indispensable in adults due to its role in 
mitigating risk of chronic killer diseases, even though the specific mechanism is 
unknown. After, (Cunnane, 2000).
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1.13 Epidemiological evidence and intervention studies of the 
cardioprotective effects of EPA and DHA
Interest In the cardioprotective effects of EPA and DHA derive from the 
observed lower mortality from acute myocardial infarction and atherosclerosis 
in the Greenland Inuit compared with the Danes (Bang & Dyerberg, 1980) and 
in the Japanese compared with North Americans (Holub, 1989), with only 
small differences in blood cholesterol levels. In each case the main difference 
was fish or marine animal intake, providing several grams of EPA and DHA at 
least with the traditional Inuit diet (Greenland; Nunavik, Que.). Since then 
other studies and interventions have confirmed that 2-3 servings per week of 
fish is associated with lower primary and secondary heart attack rates and 
death from cardiovascular disease (Burr et al., 1989 ; Daviglus et al., 1997; 
Schmidt et al., 2000). With EPA and DHA in serum and plasma phospholipids 
as a biomarker for EPA and DHA intake, n-3 fatty acids in general and DHA 
levels in particular are inversely correlated with coronary heart disease in men 
(Simon et al., 1995). This is also recently confirmed among the Inuit of 
Nunavik, where EPA and DHA in plasma phospholipid both reflect their 
dietary intakes and are beneficially associated with key risk factors for 
cardiovascular disease (Dewailly et al., 2001). These and other 
epidemiological studies resulted in the widespread view that an intake of 1.25 
g EPA + DHA, as it is provided by two weekly portions of fatty fish, not only 
can prevent deficiency disease but also afford special health benefits (The 
British Nutrition Foundation 1992).
Mechanisms of the beneficial effects of EPA and DHA for cardiovascular 
disease are thought to involve by both eicosanoid-dependent and eicosanoid- 
independent processes. For example, the reduced blood platelet reactivity 
(antithrombotic effect) observed with increased EPA and DHA intakes 
involves the reduced formation of the proaggregatory thromboxane A2, 
(Herold & Kinsella, 1986). See discussion of the n-3 eicosanoids in appendix 
(2k
Another mechanism involves the potent ability of EPA and DHA to significantly 
reduce circulating triglyceride levels (Harris, 1989), for which only moderate 
elevations (approaching 1.33 mmol/L or 118 mg/dL, or above) are associated
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with progressively increased risk of ischemic heart disease (Jeppesen et al., 
1998). In a placebo-controlled, double-blind trial Stark et al., (2000) recently 
demonstrated a 26% lowering in fasting triglycerides in postmenopausal 
women by 4 g/d of EPA + DHA over 28 days. Goodfellow et al., (2000) 
reported that 3-4 g EPA + DHA in fish oil enhanced systemic large artery 
endothelial function in male hyperlipidemic subjects. The Italian GISSI- 
Prevenzione trial (GISSI-Prevenzione Investigators, 1999) showed that in a 
cohort of 11324 myocardial infarction patients treated with a moderate fish 
consumption Mediterranean-type diet as well as aggressive treatment with 
various pharmaceutical agents for cardiovascular care, supplemental 
intervention in half the patients with 850-882 mg/day EPA plus DHA as fish oil 
over 3.5 years reduced overall cardiovascular deaths and sudden cardiac 
death, the latter by about 45%. Vitamin E supplementation had no significant 
effect. These finding support the concept that, independent of blood 
cholesterol lowering, EPA and DHA intakes as fish or as supplements, 
impprove cardiovascular disease mortality, particularly sudden cardiac death.
In the first decade of research in the area of n-3 long-chain metabolites the 
beneficial effects of fish oil were attributed almost entirely to EPA. However, it 
has become increasingly evident that DHA may have an independent function 
although mechanism remain to be identified. DHA may produce triglyceride 
lowering independently of EPA. Thus Conquer & Holub, (1997) gave healthy 
vegetarians purified DHA alone and observed a moderate decrease in the 
total cholesterol: HDL ratio as well as serum triglycerides which was not 
explained by the 10% retroconversion of DHA to EPA. Grimsgaard et al., 
(1997) showed with separate administrations of EPA and of DHA that DHA 
was consistently more effective in triglyceride lowering and in increasing HDL 
cholesterol values. Also Davidson et al., (1997) confirmed in hyperlipidemic 
patients that 1.25 g/d DHA decreased triglyceride and increased HDL 
cholesterol without significantly affecting LDL. Nitric oxide production is 
enhanced by DHA but not EPA (Harris et al., 1997) thus potentially reducing 
atherosclerosis risk through its augmentation of endothelium-dependent 
vasodilatation in peripheral and coronary arteries.
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Other conditions in which impaired DHA status specifically has been 
associated include neurological dysfunction, especially depression Hibbeln 
and Salem, (1995), attention deficit hyperactivity disorders (Stevens et al., 
1995), and disorders of peroxisomal biogenesis such as the Zellweger 
syndrome, where brain DHA is lowered. Preliminary findings suggest that 
treatment with purified DHA may partly improve visual function in these 
patients (Martinez, 1996).
1.13.1 a-LNA and CVD risk
In the absence of fish oil a-LNA can provide some EPA at high doses 
although as discussed above conversion to DHA is severely restricted 
(Gerster, 1998). The Nurses Health prospective cohort study revealed an 
inverse relation between a-LNA intakes and the risk of fatal ischemic heart 
disease among women (Hu et al., 1999). However, the Zutphan Elderly Study 
(Oomen et al., 2001) did not observe a beneficial effect of dietary a-LNA on 
the 10-year risk of coronary artery disease and most human intervention 
studies with a-LNA (e.g., using flaxseed oil) have not exhibited any lipid- 
lowering effects, only improved arterial compliance at relatively high dose as 
flaxseed oil, (Nestel et al., 1997). The improved arterial and endothelial 
functioning in hypercholesterolemic subjects (Goodfellow et al., 2000) and 
type 2 diabetics (McVeigh et al., 1994) with EPA and DHA involved 
considerably lower supplementation levels.
1.14 Dietary interventions with a-LNA
In western diets the predominant polyunsaturated fatty acid is linoleic acid (LA; 
18:2n-6). However as discussed above (section 1.6) the low efficiency of long 
chain conversion of a-LNA in man means that it would not be expected that 
the biological effects of a-LNA are equivalent to EPA and DHA (Gerster, 
1998). Nevertheless with abundant plant sources of a-LNA the actual extent 
of its conversion is of great interest.
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Sanders and Roshanai, (1983), found a modest increase in platelet EPA in 
volunteers with 9.4 g a-LNA as flaxseed oil but no change in DHA compared 
with marked increases in EPA and DHA with 6 g EPA+ DHA as marine oil. 
Singer and coworkers, (1986) supplied healthy volunteers and hypertensive or 
hyperlipidemic patients with a 60 g flaxseed oil (38 g a-LNA or sunflower-seed 
oil (45 g LA), or 5 g EPA + DHA as mackerel showing that flaxseed oil failed 
to markedly increase EPA or DHA in plasma cholesteryl esters.
The phospholipid enrichment with a-LNA observed in previous studies has 
varied. One explanation is variation in the doses used in interventions. 
However, it also appears that it is the n-3: n-6 fatty acid ratio, in particular a- 
LNA:LA, rather than the absolute amount of a-LNA which influences the 
incorporation. Increases in dietary a-LNA:LA from 1:170 through to 1:4, 1:2 
and 1:1 were associated with increasing percentages of EPA in rat plasma, 
lung and liver phospholipids (Hwang et al., 1988) while increases in the 
amount of a-LNA but with constant a-LNA:LA ratio produced no differences 
(Boudreau et al., 1991). Chen et al., (1993) reported that in men an a-LNA: LA 
value of 1:3 Increased platelet EPA compared with 1:27 and 1:7, and that if 
the quantity of a-LNA was doubled while the ratio was kept constant no further 
increases occurred. Further confirmation that the a-LNA:LA ratio is important 
was provided by Emken et al., (1993) who found that the conversion of a-LNA 
to longer-chain metabolites, measured after infusions of deuterated a-LNA 
and LA, was reduced by 30% after feeding a diet with 29.8g LA vs. 15.1g LA. 
Kelley et al., (1993) fed flaxseed oil to volunteers for 56 days reporting no 
increase in EPA or DHA in plasma and peripheral blood monocyte lipids but a 
16 fold increase in a-LNA
Still higher intakes of 50 g/d flaxseed oil also increased EPA but not DHA in 
plasma phospholipids and triglycerides Cunnane et al., (1995 a).
Mantzioris et al., (1994) compared LA-+ AA and a-LNA—► EPA showing no 
relationship between LA intake and AA at low LA intakes, but a clear 
correlation between a-LNA and EPA in phospholipids of plasma neutrophils, 
mononuclear cells, erythrocytes and platelets. They suggested that their 
subjects high LA & AA background diet would give high adipose tissue stores, 
preventing any identifiable diet LA: tissue AA relationship.
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In a subsequent study with healthy volunteers with a background diet low in 
LA Mantzioris et al., (1995) fed a-LNA (as flaxseed oil), showing again, no 
relationship between dietary LA and AA in plasma lipids and a linear 
relationship between dietary a-LNA and EPA but this time an inverse 
relationship between dietary a-LNA and DHA, arguing that a-LNA or EPA 
might displace DHA from phospholipids.
Allman et al., (1995) fed 40 g flaxseed oil showing increases in platelet EPA 
but not DHA.
Seppanen-Laakso et al., (1997) compared plasma lipid fatty acid composition 
in subjects who excluded fish from their habitual diet with those eating fish up 
to twice a week, and showed higher AA, lower DHA and similar EPA in non­
fish eaters. 6-week supplementation of the non-fish eaters with rapeseed oil 
(10% a-LNA) increased a-LNA levels but not EPA or DHA.
A consistent finding of these studies with dietary a-LNA rich oils is that 
moderate increases in EPA can be achieved but many have argued that the 
high dietary LA inhibits the uptake of a-LNA and its potential availability as a 
precursor. Others point to its high oxidize-ability, the highest oxidation rate of 
ail unsaturated fatty acids (Nettleton, 1991).
As to actual values for the a-LNA to n-3 long-chain metabolites conversion 
rate Emken and his coworkers (1994) suggested about 15% to EPA, which 
was significantly reduced in the context of high n-6 PUFA intakes, but which 
was considerably higher than for LA conversion. He argues that a-LNA 
conversion is not linearly related to intake, since high intakes appear to inhibit 
conversion, though the mechanism is unknown. In contrast the incorporation 
of dietary EPA and DHA into phospholipids is dose-dependent (Sanders & 
Roshanai, 1983; von Schacky et al., 1985; Blonk et al., 1990). The impact of 
the P/S ratio and other dietary factors such as source of protein is not yet 
clear although it is known that optimum conversion requires a ratio of n-6/n-3 
PUFA within ~ 4-6. It is therefore difficult to define a valid conversion factor. 
The low efficiency of conversion means that relatively high intakes of a-LNA  
rich vegetable oils are needed, which carries the risk of increasing the dietary 
fat. Nevertheless, vegetarians whose consumption of a-LNA (18:3n-3) is 
usually higher than that of omnivores have a significantly lower DHA (22:6n-3) 
status in serum and platelets as well as in breast milk than omnivores (Gerster,
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1998). Emken and his group (1994) proposed a conversion rate to DHA of 
~3.8%, but most studies have noted no change in DHA with either moderate 
or high intakes of a-LNA which suggests interaction with other, unknown 
factors.
An independent role for DHA is emerging. Thus, future attention will have to 
focus on its adequate provision. The studies available so far indicate that high 
doses of a-LNA may provide a limited amount of EPA, but are a very poor 
source of DHA.
(Table 1.7) summarizes some of the dietary intervention with n-3 PUFA.
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1.15 Fatty acid metabolism and stable isotopes
The use of stable isotope tracers for investigating fatty acid metabolism in 
human subjects has increased substantially over the last decade, on the basis 
of advances in analytical instrumentation, commercial availability of labelled 
substrates, and safety considerations.
Stable isotope studies have been used to address a variety of questions 
related to unsaturated fatty acid metabolism in humans. In the present study 
the question addressed is the extent of the desaturation and elongation of a- 
LNA, and the formation of long-chain n-3 fatty acids with a background diet 
high in n-6 fatty acids vs. a diet high in n-3 fatty acids.
Stable isotope studies with n-3 fatty acids are summarised in (Table 1.8), 
whilst the principle of GC combustion-isotope ratio mass spectrometry as a 
new technique in the analysis of fatty acids metabolism is briefly discussed in 
appendix (6).
Table 1.8 Stable isotope studies with n-3 and n-6 fatty acids.
Emken et al., (1994)
Study aim: saturated versus PUFA-rich diet on long chain conversion.
--n=7 males, 23 -  26yrs fed either saturated fat +15 g/d of LA (saturated diet) 
or with 30 g/d of LA (PUFA diet) for 12 days.
Deuterated LA and a-LNA (n=4) given as mixture of TAGs plus 3 subjects fed
only deuterated a-LNA. Multiple blood sampling, t=0-48hrs
Findings
-- conversion of a-LNA to total n-3 LCP metabolites reduced to 40% by PUFA 
diet.
-  conversion of LA to n-6 LCFA metabolite was low with no dietary effects 
--concentrations of deuterated LA and a-LNA were lowered by the PUFA diet, 
--conversion of a-LNA greater than for LA with deuterated 22:6n-3; (19.8 
pg/ml) representing 3.8% of the total amount of labeled a-LNA in total plasma 
lipid.
Demmelmair et al., (1999)
Study aim: Bolus versus multiple small doses of 1 mg kg-1 U-13C LA.
- bolus dose: young adults (n=5), blood sampling at t=24,48,72,96,168  
-multiple small doses: n=5 9 equal portions given over 3 days with blood 
sampling at t=0,24,48,72,96,120,144,168,192, and 216 hrs (fraction group). 
Findings
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--Maximal enrichment in LA: bolus application> fraction group; differences 
small in DGLA&AA.
-bolus group: maximal enrichment: LA 8 h, DGLA 48 h.
-  small multiple doses: maximal enrichments: LA day3: no other fatty acids 
labelled.
Vermunt et al., (1999)
Study aim: effects of MUFA, a-LNA or EPA/DHA rich diets on long chain 
conversion of [U-13C] a-LNA
-  Elderly (n=5) fed diets rich in a) oleic acid, b) a-LNA [6.8 g/d (n=2)], or 
EPA/DHA [1.0 g EPA/d plus 0.6 g DHA/d (n=3)] for 7 wk.
-  younger subjects n=5 fed a-LNA-rich diet. All given 45 mg of [U-13C]a- LNA 
methyl ester with blood sampled at t=0, 5, 11, 24, 96, and 336 h.
Findings
~ 13C in a-LNA, EPA, DPA (n-3), DHA detected in plasma but enrichment of all 
fatty acids lower on n-3 rich diets compared with MUFA group.
-little LCP 13C labelling in EPA/DHA group.
Conclusion: Oxidation of a-LNA not dependent on age or dietary a-LNA, but 
may be slightly increased on diets rich in EPA/DHA.
Emken et al., (1999)
Study aim: Influence of high DHA diets on C18 long chain conversion.
-  young men (n=6); fed DHA for 90 d at either 6.5g/d (high) or <0.1 g/d (low) 
DHA.
~15g/d fish oil added as the source of DHA in high-DHA diet; 15g/d safflower 
oil added to low-DHA diet.
-A fter 90d, subjects fed a mixture of deuterated triglycerides containing 
18:1 n-9 [d6], 3.1g, LA [d2], 2.4g, and a-LNA [d4] 2.3g with plasma lipid 
classes isolated at t=0,2,4,6,8,12,24,48, and 72 h 
Findings
-D ietary DHA significantly reduced total n-6[d2] and n-3[d4] LCP metabolites 
synthesized but did not affect uptake and turnover of dietary 18:1 n-9, LA and 
a-LNA in plasma TAG, PL, or CE.
Vermunt et al., (2000)
Study aim: dietary a-LNA, EPA/DHA or MUFA rich diets on 13C-a-LNA 
conversion.
-  men and women (n=15, 21-66 yrs) fed oleic acid-rich diet for 3 wk followed 
by 7wks o f :
(a) same diet n=5; (b) a-LNA rich diet in (8.3 g/d) n=7; (c) EPA (0.9g/d) + DHA 
(0.5g/d) rich diet (n=3).
-  all given 45 mg of C-a-LNA as a methyl ester given with measurement in 
plasma total lipids att=0, 5, 11, 24, 96, and 336h
Findings
-  13C- a-LNA conversion into LCP lowered by dietary a-LNA: oxidation of 13C- 
a-LNA negatively correlated with its conversion into LCP.
-  very low conversion of 13C- a-LNA into 13C-LCP on EPA/DHA-rich diet,
-  low enrichment of 13C-DPA (n-3) and 13C-DHA on a-LNA or MUFA diets 
although somewhat lower on a-LNA compared to MUFA -rich diet.
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Pawlosky et al., (2001)
Study aim: compartemental modelling to study long chain conversion of [U- 
13C] a-LNA in adults.
-- young men (n=4), females (n=4), fed beef-based diet for 21 day (i.e. only 
small amounts of LCP). 1g oral dose of (d5- a-LNA) ethyl ester with 
measurements in total plasma lipids at t=0,8,24,48,72,96, and 168 h.
Findings
--0.2% of plasma a-LNA converted to EPA; 63% of EPA converted to DPA (n- 
3), and 37% of DPA (n-3) converted to DHA.
--High flow rate of a-LNA (240 mg h-1) exiting the biosynthetic pathway. 
Burdge & Wootton (2002)
Study aim: [U-13C] a-LNA conversion in men versus women 
n=6, 28±4 yr given 700 mg [U-13C] a-LNA as free fatty acid.
Plasma TAG, PC, NEFA, CE isolated at t=0, 24, 48, 72 h and 1, 2 and 3
weeks
Findings
--Greater conversion of both EPA and DHA in women compared with men. 
--Lower a-LNA oxidation in women.
--Differential partitioning of a-LNA, EPA and DHA between plasma lipid 
classes.
Burdge et al., (2002)
Study aim: Long chain conversion of [U-13C] a-LNA in men.
-- n=6 males, 27-40yrs. 700 mg of [U-13C] a-LNA administered as free fatty 
acid. Plasma lipid classes & erythrocyte phospholipids sampled at t=0, 2h 
intervals for 24h, then at 48, 72h, and 1,2, and 3 weeks 
Findings
--incorporation of 13C into a-LNA, EPA, and DPA (n-3), none in DHA.
-- Maximum 13C incorporation (erythrocyte PC) EPA & DPA (n-3) < [13C] a- 
LNA: none in DHA.
Pawlosky et al., (2003)
Study aim: modelling beef vs. fish diet on long chain conversion of [U-13C] a- 
LNA in adults.
n=5 males and females, 22-37 yr, fed beef diet (low LCP) for 3 wk, then fish 
diet for 3 wk.
1g oral dose of d5-a-LNA ethyl ester: plasma sampling at t=0, 8, 24, 48, 72, 
96 and 168 h.
Findings
--Plasma concentrations of EPA and DHA higher during fish-based vs. beef- 
based diet.
-- DPA (n-3)-+ DHA was ~18 mg/d (beef-diet), ~5 mg/d (fish-diet).____________
Abbreviation: PUFA; polyunsaturated fatty acids, LCP; long chain polyunsaturate, MU FA; 
monounsaturated fatty acids, TAG; triacylglycerol, PC; phosphatidylcholine, NEFA; non 
esterified fatty acids, CE; cholesterol ester, PL; phospholipids, LA; linoleic acid, DGLA; 
dihomo-Y-linoienic acid, AA; arachidonic acid, a-LNA; a-linolenic acid, EPA; eicosapentaenoic 
acid, DPA; docosapentaenoic acid, DHA; docosahexaenoic acid, 18:1n-9 (oleic acid).
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1.16 Aims and objectives of the current research
The overall aim of the project was to study the extent of the conversion of a- 
LNA to its long chain metabolites, EPA and most importantly DHA by a 
combination of human dietary intervention studies with erythrocyte 
phospholipid EPA and DHA concentrations as outcome variables and by use 
of 13C-stable isotope labelled a-linolenic and linoleic acid tracer studies. The 
hypothesis examined here was that by reducing the dietary LA:a-LNA ratio, 
the relative conversion of a-LNA to EPA and DHA will improve.
The dietary intervention trial was part of a FSA (standard food agency) funded 
study which aimed to change the ratio of dietary LA:a-LNA, by consuming a- 
LNA enriched products formulated from flaxseed oil within a low n-6 PUFA 
diet. The main hypothesis examined in the study was that a dietary-induced 
increased conversion of a-LNA to EPA and DHA would promote fish-oil like 
reductions in plasma lipid-related risk factors for cardiovascular disease as 
compared with a high n-6 diet and with a fish oil diet as a positive control. The 
dietary intervention was a 12-week parallel study with phospholipid 
concentrations in red blood cells measured at 6 and 12 weeks and with the 
stable isotope studies conducted at the end of the dietary interventions. In 
addition, the dietary intervention aimed to determine the nutritional 
equivalence of high flaxseed diet vs. the fish-oil diet.
The purpose of the stable isotope study of the conversion of uniformly labelled 
13C-a-LNA and LA in total plasma and erythrocytes membrane lipids, was to 
gain further insight into the extent of and dietary influences on a-LNA long 
chain conversion to EPA and DHA, in addition to the information gained from 
changes in phospholipid fatty acid profiles, especially whether lack of change 
in DHA concentration with high a-LNA diets meant lack of any synthesis. It is 
hoped that such studies improve understanding of the importance of dietary a- 
LNA as a precursor for the biosynthesis of long-chain length n-3 fatty acids.
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CHAPTER 2: THE EFFECT OF FLAXSEED OIL DIET ON THE 
INCORPORATION OF LONG-CHAIN FATTY ACIDS IN 
ERYTHROCYTE MEMBRANES
2.1 Background
As indicated in the introduction, in western diets the predominant 
polyunsaturated fatty acid is linoleic acid (LA) which is elongated to AA. The 
corresponding n-3 fatty acid, a-linolenic (a-LNA) is converted to EPA via the 
same enzymatic pathways. Several studies have investigated the inhibition by 
dietary n-6 fatty acids of the conversion of a-LNA to n-3 long-chain fatty acids 
(LCFA) (Nettleton, 1995; Gerster, 1998). The replacement of some LA with a- 
LNA may increase tissue EPA via its elongation (Mantzioris et al., 1995) but 
the efficiency of this conversion in man was previously questioned (Dyerberg 
et al., 1983) and the DHA content of tissue lipids is not greatly increased by 
diets containing large amounts of a-LNA, (Gerster, 1998). a-LNA is preferred 
to LA as substrate of A-6 desaturase but AA is favoured over EPA as a 
substrate for acylation into phospholipids (Emken et al., 1992). Feeding EPA 
through consumption of fatty fish, by-passing the conversion step, is obviously 
a more efficient way to increase tissue EPA and decrease AA, but it may not 
be feasible to increase fish consumption for all people on a global basis. 
Therefore the use of a-LNA in plant oils to increase tissue EPA and DHA 
warrants research. This chapter describes the dietary intervention to 
investigate the consequences of the reduction of the n-6:n-3 ratio through 
feeding a low LA, a-LNA enriched diet on the conversion of a-LNA to long 
chain n-3 polyunsaturated fatty acids as assessed by the changes induced in 
membrane phospholipid fatty acid profiles.
2.2 Study Design
The dietary intervention was a 12-week parallel study which aimed to 
compare a diet enriched in a-linolenic (flaxseed-oil; n-3) with dietary long 
chain n-3 PUFA from fish-oil and a high linoleic diet (sunflower-oii; n-6), in
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free-living males considered to exhibit moderate risk of cardio vascular 
disease. Because of the primary aim of assessing the effects of the high a- 
LNA diet on those cardiovascular disease risk factors which are modifiable by 
fish oil, a fish oil-enriched diet was included as a positive control. Phospholipid 
concentrations in erythrocyte membrane lipids were measured after 6 and 12 
weeks of the dietary interventions. The subjects were randomly allocated into 
one of the three diet groups: high n-6 diet, a test diet (flaxseed diet), and fish 
oil diet (Fig. 2.1).
-8
i
Screening blood 
sample
-1 0-wk
□
6-wk
O
i i
Blood sample 
□  7-day food diary 
O  3-day food diary
12-wk
□
i
Blood sample Blood sample
Fig. 2.1 The dietary intervention design.
Subjects visited the research unit three times: at the baseline and after 6 wk 
and 12 wk. Weight, blood pressure were measured at every visit. Blood 
samples for laboratory measurements were also taken at each visit after 12 hr 
fasting. Subjects were supplied with scales to monitor body weight throughout 
the intervention and weight was recorded daily for the initial two weeks and 
weekly for the reminder of the study.
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2.3 Dietary intervention protocol
The dietary aim was achieved by substituting approximately 45g of fat with 
either flaxseed oil (56% a-LNA; n-3 PUFA), sunflower oil (52% linoleic acid; n- 
6 PUFA) or sunflower oil plus fish-oil capsules supplying 3g EPA+DHA /day:
i.e. 6x1 g capsules (‘PikasoP, LUBE, Denmark), each capsule containing 50%  
eicosapenaenoic (EPA) and docosahexaenoic (DHA) acids. A target level of 
dietary intake for a-LNA of 18g / day was chosen to reduce the n-6: n-3 ratio 
to <1 compared with 20 g/d linoleic acid (n-6: n-3 ratio of >20). The feasibility 
of achieving this level of intake had been previously established in a pilot 
study in normal volunteers using flaxseed as the principal dietary source of a- 
LNA (Wilkinson et al., 1999). The flaxseed and sunflower oils were supplied to 
subjects in laminated foil sachets (17g oil / sachet), the oils having been 
packaged under nitrogen and stored at -4 0 °C  prior to use. In order to avoid 
the potentially adverse effects of direct heating, the oils were introduced into 
the diet by incorporation into cooked foods, including pasta sauces, salad 
dressings and milk shakes. Subjects were also provided with cooking oils: 
either rapeseed oil, a MUFA-based oil containing 9% a-LNA for the for 
flaxseed group, or the linoleic acid-based sunflower oil for both the high n-6 
and fish-oil together with specially formulated rapeseed oil spreads from St 
Ivel which were either the standard ‘Mono’ for the control and fish-oil groups 
or a modified spread with a higher rapeseed content (13%) for the flaxseed 
group (high a-LNA), see Table 2.1 The foil sachets, cooking oils and 
spreads were identified by the letters ‘X ’, !Y ’ and ‘Z ’ (flaxseed, sunflower, 
sunflower-fishoil)
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Table 2.1 Food products and supplements consumed by subjects in the three 
diets.
Type o f  
intervention diet
Oil sachets 
(17g x 2/day)
C apsules 
( lg  x  6/day)
Spreads C ooking oil
High n-6
(High-LA) 
Flaxseed-oil 
(High a-LA) 
Fish-oil
(High-LC n-3 +LA)
Sunflower oil 
Flaxseed oil 
Sunflower oil Fish oil
Rapeseed based ‘Mono’ 
Modified ‘Mono’ 
Rapeseed based ‘Mono’
Sunflower oil 
Rapeseed oil 
Sunflower oil
Abbreviations:d: day, g: gram
All subjects were instructed to use 2 oil sachets and in addition, if in the fish 
group, 6 oil capsules a day with meals providing a total of 3.02 g of EPA/DHA 
(1.68 g of EPA and 1.34 g of DHA).
The three single-step diets, each 12 weeks in duration, ran in parallel in 3 
separate cohorts over 18 months. The habitual diet of the subjects was 
assessed by 7-day food diaries. Before each dietary intervention, subjects 
received dietetic counselling on an individual basis by another investigator. 
This consisted of giving advice to subjects in the flaxseed group (high a-LNA) 
to avoid foods containing high levels of n-6 PUFA, and to high n-6 group to 
abstain from consuming any source of long chain n-3 PUFA, chiefly oily fish. 
Subjects attended the Clinical Investigation Unit at the University of Surrey on 
3 occasions after an overnight fast (12-14h); at baseline (pre-diet), and after 6 
and 12 weeks (post-diet). Height, total body weight, an estimate of percentage 
body fat and blood pressure were measured at each visit. Blood samples 
were taken by venepuncture for the analysis of plasma lipids, lipoproteins and 
haemostatic variables.
Dietary compliance was assessed through the intervention (6 weeks) by 3-day 
food diaries and at the end of the intervention (12 weeks) by a 7-day food 
diary interpreted by another investigator. The outcome variable discussed 
here, the composition of erythrocyte membrane phospholipid fatty acids at 
baseline, 6 and 12 weeks, is also an indication of dietary compliance.
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2.4 Foods
Fish oil capsules ‘Pikasol’ (1 g capsules) were supplied by LUBE (Denmark). 
Spreads (rapeseed based ‘Mono’ and a modified ‘Mono’ were supplied by St. 
Ivel (Swindon). Sunflower oil and Flaxseed oil sachets were supplied by 
Savant Distribution Ltd (England) on behalf of Flora manufacturing and 
distribution (Canada). Rapeseed and Sunflower cooking oil were supplied by 
Sainsburys supermarket.
2.5 Subject recruitment
The Ethics Committees of the University of Surrey, Guildford and the Royal 
Surrey County Hospital, Guildford, Surrey, UK approved the study. Informed 
consent was also obtained from the participating subjects. Subjects were 
recruited through GP surgeries in the Guildford area and local newspaper 
advertisements. The subjects were normal, healthy, free-living male 
volunteers aged between 35-60 years, and expressing an atherogenic 
lipoprotein phenotype (ALP). Subjects with a moderately raised plasma 
triacylglycerol (>1.5mmol/l) and low HDL cholesterol (<1.1mmol/l) were 
screened for the predominance of small, dense LDL (LDL-3 >40%). Subjects 
expressing an ALP were invited by letter to take part in the dietary intervention. 
Exclusion criteria included BMI >30, hypertension (>135/85mmHg), smoking, 
excessive alcohol consumption (>30 units /  week) or therapy known to affect 
lipid metabolism. In addition, any biochemical evidence of abnormal liver, 
kidney or endocrine function or abnormal haematology. The mean baseline 
characteristics of subjects in each dietary group are shown in Table 2.2.
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Table 2.2 Subjects baseline characteristics.
Flaxseed-oil 
(High a-LA)
Fish-Oil
(High-LC n-3 +LA)
High n-6 
High LA
No. Subjects n=21 n=19 n=17
Age (range) yrs 47 (36-58) 50 (38-57) 51 (35-60)
Weight (Kg) 87 ± 17 90 ± 13 90 ± 17
BMI (Kg/m2) 28.4 ±3.8 29 ±5.1 28.1 ±3.5
%  Body fat 23.8 ±4 .4 23.7 ± 4.7 26.1 ±5.6
Blood Pressure 
(mmHg)
112/97 119/102 123/99
Plasma cholesterol 
(mmol/1)
6.04 ± 1.45 6.48 ±1.27 5.93 ± 0.94
Plasma triacylglycerol 
(mmol/1)
2.05 ± 1.06 2.30 ±0.67 1.98 ±0.86
HDL-Cholesterol
(mmol/1)
1.05 ±0.24 1.10 ±0.27 1.08 ±0.24
LDL-Cholesterol
(mmol/1)
3.92 ±0.99 3.89 ±0.76 3.81 ±0.78
Data are presented as mean ± SD. LDL; Low Density Lipoprotein, HDL; High Density 
Lipoprotein, BMI; Body mass index.
2.6 Materials
Chemicals, compounds and consumable used are presented under the 
heading of the company from which they were obtained.
Sigma-Aldrich company Ltd
(Fancy road, Poole, Dorset, BH12 4QH, UK)
Supelco 37 Component FAME Mix 
Docosapentaenoic Methyl Ester (22:5n-3)
Docosatetraenoic Methyl Ester (22:4n-6)
Acetic acid, glacial (C2H 402)
Chloroform (CHC13)
Methanol (CH30H)
Sodium Chloride (NaCI)
Sodium methoxide (CH3NaO)
Hexane (C6H14)
Butylated hydroxytoluene (BHT)
LIP Equipment & Services Ltd
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(Dockfield rd., Shipley, W. Yorkshire, BD17 7SJ)
EDTA tubes (10 ml)
Glass blood tubes (without anticoagulant)
Sligo, Republic of Ireland
Butterfly needles gauge no. 21 were supplied by Abbot laboratories.
Terumo (Leuven, Belgium)
0.8.x 40 mm gauge no. 2 needles.
2.7 Methods
Anthropometry and blood pressure: Subjects were weighed and their 
percentage body fat determined by electrical impedance. Blood pressure was 
measured using as semi-automated sphygomanometric cuff.
Dietary compliance: This was assessed in three ways
1. 7-food diaries pre and post-diet, and a 3-day food diary at 6 weeks. Each 
subject was given clear instructions on how to complete their food diary, which 
also contained clear instructions about portion sizes and photographs. These 
were analysed using Dietplan 5 for Windows version 3.1 (Forestfield Software 
Ltd 1991-1999) by another investigator.
2. A capsule count on the fish-oil diet.
3. Measuremant of changes in the relative abundance of fatty acids in 
erythrocyte membrane phospholipids by gas chromatography.
2.8 Blood Sampling
Venous blood samples (20 ml) were taken immediately prior to starting the 
intervention at (week-0) then (week-6) and (week-12) at the end of the study. 
On the day before sampling subjects were asked to fast overnight (14 hr) and 
refrain from any strenuous exercise or alcohol consumption for 24 h prior.
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2.9 Plasma lipids and lipoproteins
Total plasma cholesterol, triacyglycerol, and HDL and LDL cholesterol were 
measured by commercially available enzymatic kits and by LDL and HDL 
‘Direct’ respectively (Randox,)
2.10 Erythrocyte Preparation
The blood samples were aliquoted into appropriate containers (EDTA and 
sodium citrate). The plasma and blood cells were separated by low speed 
centrifugation (1100 x g for 15 min at 2°C). Red blood cells were washed 
three times with sodium chloride (NaCI, 0.9%), the washed solution was 
centrifuged (3100 x g for 15 min at 2°C) and the top saline portion removed. 
Finally the blood cells were transferred to a glass tube, were wrapped in para- 
film and 250 pi Butylated hydroxytoluene in propan-2-ol (0.1% ) was added 
as an antioxidant, mixed and stored at -80°C until analysed.
2.11 Erythrocyte membrane fatty acid analysis
Lipids were extracted from the erythrocyte membranes with a mixture of 6 mL 
chloroform: methanol (2:1; vol/vol), containing butylated hydroxytoluene (0.01 
% BHT) as an antioxidant, according to the Folch method (Folch et al., 1956). 
Fatty acid methyl esters were prepared with 1 mL sodium methoxide (0.5 M 
solution in methanol), incubated at 60°C for 15 minutes, acidified with 50 pL 
glacial acetic acid, and finally extracted twice with 3 mL of hexane.
The resulting fatty acid methyl esters were analysed with a gas 
chromatography (GC) using a 3400 Gas Chromatograph (Varian). PAG 
Capillary Column:30m x 0.25mm x 0.25pm film thickness (Supelco, Inc) and a 
flame ionization detector (250°C), with helium as the carrier gas. Temperature 
was programmed at 4°C/min from 150 to 220°C. The fatty acid peaks were 
identified against a standard fatty acids mixtures of known composition run on 
the same column under identical conditions (Supelco 37 Component FAME 
Mix) which was obtained from Sigma (Sigma Chemical Co., UK). Individual
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standards (Docosapentaenoic acid; DPA n-3, Docosatetraenoic acid; DTA) 
were also used since it was not included in the standard mixture. The injection 
volume was 2 pL and the run 45 min. Results are expressed as percentages 
of the sum of all identified peaks. The assumption is made that no changes 
occurred in the overall phospholipids content of individual red blood cells, 
therefore it will be assumed that the peak area as a percentage of total will 
directly reflect relative peak area in absolute terms.
2.12 Statistical Methods
Statistical analysis was performed using the windows compatible computer 
package, Statistica (version 5, StatSoft, Inc.) and Excel (Microsoft Excel 2002) 
computer programme. A P-value <0.05 was considered significant.
For most data tabulated results are presented as mean values and standard 
deviations (SD). Differences within each dietary group (pre versus post-dietary 
effects) were tested by paired student t-test. Differences between groups were 
tested by ANOVA where appropriate according to Levene and Brown- 
Forsythe Tests of Homogeneity of Variances, or by a non parametric test, 
Kruskal-Wallis ANOVA by Ranks. Post-hoc comparisons involved either the 
Tukey HSD test or the Mann-Whitney U Test, when P-values for ANOVAs 
were <0.05.
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CHAPTER 3 RESULTS
Table 3.1 Dietary composition: Habitual (pre-dietary) and intakes on the 
experimental diets of total energy and energy from macronutrients and n-6
3.1 Dietary Intake
and n-3 polyunsaturated fat.
Diets Total energy Fat Carbo­ Protein 11-3 PUFA n-6 PUFA n-6:n-3
(Kcal/ d) hydrate g/ d (% Energy) g/d (% Energy) ratio
M------ % energy ------►
Flaxseed-oil (High a-LA; n -21)
Pre-Diet 2355.9±443 38±7** 42±7* 16±3 1.2±2.2 (0.6)*** 5.8±5.4 * (2.4) 8.6±5.5***
Post-Diet 2566±636 43±6 37±7 15±3 19±1.3 (6.9) 8.4±3.1 (3.1) 0.4±0.16
Fish-oil (High LC n-3 +LA; n=19)
Pre-Diet 2655±430 37±6* 40±6 16±2 0.6±0.4 (0.2)*** 5.7±3.9 (1.9)*** 9.2±4.9***
Post-Diet 2540±374 41±7.6 38±7 15±2 5±0.9 (1.6) 23.4±3.1(8.4) 5.2±0.81
High n-6 (High LA; n=17)
Pre-Diet 2395±274 37±6* 43±7 15±2 0.7±0.4** (0.3)** 7.2±6.3 (3.0)*** 10±4.2**
Post-Diet 2411±494 41±6 40±7 15±3 1.3±0.8 (0.5) 25±5.8 (9.3) 30±29
Values are means (± SD). g/d: gram/day.
*p<0.05 **p<0.01 ***p<0.001 (pre versus post-diet).
ANOVA showed no significant difference between the three groups in their 
habitual diet.
(Table 3.1) illustrate that there was an increase in the percentage energy 
originating from total fat intakes with the fish oil group increasing its fat to 41%  
(p < 0.05), the high n-6 group to 41% (p < 0.05) and the flaxseed group to 43
% (p < 0.01).
The dietary oils were well tolerated and the flaxseed and sunflower oils 
successfully incorporated into foods. Dietary compliance was excellent as 
indicated by the highly significant increases in the intake of n-3 PUFA, the 
flaxseed-oil group has reached a dietary intake of 19 g/d (p< 0.001) as 
compared to the habitual diet (1.2 g/d) whereas the intake of n-6 PUFA has 
increased from 7.2 to 25 g/d and from 5.7 to 23.4 g/d in the high n-6 and fish-
77
oil diets respectively. The three diets were accompanied by significant 
changes in the ratio of dietary n-6 to n-3 PUFA from 8.6 to 0.4 (fiaxseed-oil, 
p<0.001); 9.2 to 5.2 (fish-oil, p<0.001) and 10 to 30 (high-n-6, P<0.01) (Table 
3.1).
Table 3.1 shows the significant increase in the percentage of energy derived 
from n-6 PUFA in the high n-6 and fish-oil group from a mean of 3.0 to 9.3 % 
and from 1.9 to 8.4 % respectively (both p < 0.001).
A similar increase in the percentage of energy derived from n-3 PUFA was 
observed in the flaxseed-oil and fish-oil diets from 0.6 to 6.9 % and from 0.2 to
1.6 % respectively.
Table 3.2 Comparison 
intervention groups.
between the post-dietary intakes for the three
Diets n-3 PUFA n-6 PUFA n-6: n-3
g/d
Flaxseed-oil 19 ±1.3***
% energy 
6.9 ± 1.4***
g/d 
8.4± 3.1***
% energy 
3.1 ±1.2** 0.4 ±0.16**
Fish-oil 5 ± 0.9 1.6 ±0.24 23.4 ±3.1 8.4 ± 1.56 5.2 ±0.81
High n-6 1.3±0.8 0.5± 0.26 25± 5.8 9.3 ±1.89 30 ±29***
Values are means (± SD), g/d: gram/day. ***p<0.001 (between groups).
As shown in Table 3.2 The n-3 PUFA intake was 19g/d or 6.9% energy in the 
flaxseed-oil group, values which were significantly higher, (p < 0.001 in each 
case), than the values for high n-6 and the fish-oil group. The n-6 PUFA intake 
at 8.4g/d or 3.1% energy, was lower in the flaxseed group p=<0.001. However 
n-6 PUFA intakes did not differ significantly between the high n-6 and fish-oil 
group. These values are shown graphically in Fig.3.1.
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Post-dietary intervention
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40- m Flaxseed-oil
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Fig-3.1 Estimated daily dietary intakes of nutrients in the flaxseed-oil (n=21), 
high n-6 (n=17), and fish-oil (n=19) groups after 12-week of intervention. 
Data are presented as the means of nutrient intake g/d ± SD. ***(p <0.001) where p 
refer to the difference between habitual (pre-diet) and dietary diet (post-diet) in each 
dietary intervention.
3.2 Body weight and lipids
Diets were relatively well tolerated during the intervention and no side effects 
among subjects were reported. The body weights and body fat of the subjects 
at baseline (0 weeks), and at the end of the intervention (12 weeks) are 
presented in Table 3.3. At baseline neither body weights or body fat differed 
significantly among the three dietary group using ANOVA. However during the 
intervention, while subjects on the flaxseed diet maintained a constant body 
weight, there were significant increases in weight in both the high n-6 group, 
(p<0.05) and within the fish group (p<0.001).
Table 3.3 shows that there were progressive and significant decreases in the 
concentration of total plasma cholesterol at 6 and 12 weeks relative to 
baseline, changes which were most pronounced in the flaxseed-oil group. 
Also approximately 75% of subjects in each dietary group showed a decrease
79
in plasma LDL-cholesterol, although overall mean changes were not 
significant.
There were small but consistent changes in the concentration of plasma HDL- 
cholesterol: i.e. decreases, in the flaxseed-oil (-10.5%, p=0.05) and high-n-6 (- 
5.6%, ns) groups, and increases after fish-oil (+3% ns). Only the fish-oil 
group significantly decreased the ratio of total to HDL-cholesterol (6.0 to 5.4,
p=0.001).
The flaxseed and fish-oil diets produced consistent decreases in plasma TAG 
which were highly significant in the fish-oil group (from 2.3+0.7 %  (0 wks) to 
1.7±0.4 % (12 wks), p=<0.001), but not significant in the flaxseed-oil group 
(although the fail at 6 weeks was significant for the flaxseed diet). There was 
no overall change in the high-n-6 group (Fig.3.2).
Table 3.3 Body weights and lipids of the subjects at baseline (0 wk) and at the
end of the intervention (12 wks).
Characteristics High n-6 
(n=17)
Flaxseed Diet 
(n=21)
Fish Diet 
(n=19)
0 wk 12 wks 0 wk 12 wks 0 wk 12 wks
Weight (Kg) 89.9+17.3 90.9+16.9* 87.2+17 87.9+18.1 90.3+12.5 91.7+12.8**
Body Fat (%) 26.1+5.6 26.3+5.8 23.8+4.4 24.6+4.3* 23.7+4.7 24.4+4.94*
Plasma Cholesterol 5.9+0.9 5.5+0.96* 6.04+1.45 5.30+1.01** 6.5+1.3 5.98+1.23*
mmol/1
LDL- Cholesterol 3.81+0.78 3.4+0.6 3.9+0.99 3.50+0.7 3.89+0.76 3.75+0.77
(mmol/1)
HDL- Cholesterol 1.08+0.24 1.02+0.23 1.05+0.24 0.94+0.15* 1.10+0.27 1.13±0.25**t
(mmol/1)
Plasma TAG (mmol/1) 1.98+0.9 2.06+0.8 2.05+1.1 1.7+0.65 2.30+0.7 1.71+0.47***
Values are means (± SD).
Where p-values refers to the differences between the 0 wk & 12 wk for each dietary 
intervention. *(p<0.05); ** (p<0.01); *** (p<0.001). 
t  The difference between fish and flaxseed diet.
HDL ; High Density Lipoprotein , LDL; Low Density Lipoprotein, TAG;Triacylglycerol.
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Flaxseed oil High n-6 Fish oil Flaxseed oil High n-6 Fish oil
CHOL
Flaxseed oil High n-6 Fish oil Flaxseed oil High n-6 Fish oil
Fig. 3.2 The effect of dietary intervention on plasma lipids.
These were, measured at 0, 6, and 12 weeks for LDL-C (Low Density Lipoprotein- 
Cholesterol), HDL-C (High Density Lipoprotein-Cholesterol), CHOL 
(Cholesterol),TAG (Triacylglycerol). Data are presented as the means ± SD. *(p 
<0.05), **(p <0.01) where p refer to the difference between week-12 and week-0 in 
each dietary intervention.
3.3 Fatty Acid Composition of Erythrocytes
The fatty acid composition of erythrocyte membranes at baseline (0 wks), 6 
wks and 12 wks, are shown in Table 3.4 ANOVA indicated that at baseline 
there were no significant differences in any fatty acid between the three diet 
groups, and Fig.3.3 shows the erythrocyte membrane fatty acids at 0, 6 and 
12 weeks on the three diets with significance tests between 0 and 12 weeks.
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Table 3.4 Erythrocyte Membrane Fatty Acids (% area) in the three dietary 
groups at 0, 6 and 12-week expressed as Mean (± SD).
High n-6 Diet (n=17) (% area) Fish Diet (n=19) (% area) Flaxseed Diet (n=21) (% area)
FA 0 wk 6 wk 12 wk 0 wk 6 wk 12 wk 0 wk 6 wk 12 wk
PA 24.4+6.5 21.7+4.2 22.4+5.0 25.6±6.1 21.2±4.4c 21.7±4.2b 26+5.2 22.4+4.1 a 22.3±4.2b
ST 13.8+4.3 14.8+4.4 14.1+4.5 14.9±5.6 14.9+5.9 14.0+5.3 15+3.7 17.7±6.3a 15.2+5.3
OL 15.9+2.9 14.2+3.1 14.8±3.1 17.2±4.1 12.4+3.2C 13.2±3.8a 16.3+2.1 12.6±4.6b 13.8±3.7a
LA 13.7±3.6 16.3+4.7 16.0±2.3a 13.6±3.6 14.3+2.5 14.4+3.2 13.7+4.4 12.0±2.8b 12.5+3.1
a-LNA 0.3+0.2 0.3+0.2 0.39+0,2 0.5±0.6 0.3+0.2 0.5+0.4 0.4+0.3 1.1+O.Sc 1.33±0.8c
DGLA 2.1±2.0 2.8+2.0 2.8±2.7 1.7±1.5 2.8±2.5 2.4+3.2 2+2.2 3.1+2.2 a 4.0±2.9a
AA 16.0+3.9 16.4+3.2 16.0+2.7 13.6±5.9 14.6+4.1 13.6+3.5 14.7+2.8 15.5+2.2 14.9+2.6
EPA 2.7±3.2 1.6+1.3 2.1+2.0 2.5±1.9 5.3+3.4C S.6±3.3c 1.5+1.3 3.6±2.0c 3.8±2.6c
DTA 2.3±0.9 2.8+0.6 3.2±2.1 2.3±1.2 2.3+0.8 1.8+0.8 2.8+1.6 2.7+1.0 2.5+1.5
DPA n-3 2.7+0.7 2.8+0.6 2.8±0.6 2.5±1.3 3.6+l.Oc 4.1±1.7b 2.7+1.0 3.4±0.7b 3.4±0.9a
DHA 4.2+1.9 4.9±1.6a 4.7±1.4 4.7±2.8 7.2±2.2c 7.5±2.4c 4.1+1.7 4.4+1.3 4.2+1.6
Total n-6 34.2±7.0 38.2+5.6 38.1±4.9a 31.3±9.0 34.0+4.3 32.3+5.4 33.1+6.6 33.3+3.5 33.8+3.8
Total n-3 10.0+3.8 9.6+2.9 9.9±3.2 10.3±5.5 16.5+5.6 17.7iS.7c 8.7±3.3 8.4+2.7 12.8+4.2C
n-6:n-3 3.8+1.2 4.3+1.5 4.1±1.0 4.4±4.1 2.2+0.7 2.1+1.la 4.2+1.3 4.3+1.3 2.9±0.8c
AA:EPA 10.9+8.2 19.8+31.1 15.2±10.6c 10.7±11.6 3.4+1.7 3.1±2.2a 13.9+5.8 5.5±2.7 5.5±3.2c
LA:aLNA 54.4+30 87.3±81.4 51±27 51+36.4 55.5+31.2 49.2+35.3 60.4+48 16.3±lSc 16.2±16c
P/S 1.3+0.6 1.4+0.4 1.4±0.4 1.2+0.6 1.6+0.7 1.5+O.Sc 1.1+0.5 1.2+0.3 1.4±0.4a
-Values are expressed as the percentage of the total area of all fatty acids measured. 
a The difference between weeks 0 and 6 or 12 of the intervention was significant at 
p<0.05
The difference between weeks 0 and 6 or 12 of the intervention was significant at
p<0.01
c The difference between weeks 0 and 6 or 12 of the intervention was significant at
p<0.001
-palmitic acid (PA), stearic acid (ST), oleic acid (OL), linoleic acid (LA), a-linolenic 
acid (a-LNA), dihomo-y-Linolenic acid (DGLA), arachidonic acid (AA), 
docosatetraenoic acid (DTA), eicosapentaenoic acid (EPA), docosapentaenoic acid 
(DPA n-3), docosahexaenoic acid (DHA), P/S; polyunsaturated/saturated.
-Total n-3 is the sum of (a-LNA, EPA, DPA, DHA), total n-6 is the sum of (LA, DGLA, 
DTA, AA).
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Fig. 3.3 Erythrocyte membranes fatty acids during the 12-wk period on the 
previous diets.
Flaxseed diet (n=21); Control diet (n=17); Fish Diet (n=19). Data are presented as 
the mean of fatty acids (% area) ± SD. *(p <0.05), **(p <0.01), ***(p <0.001) where p 
refers to the difference between week-12 and week-0 in each dietary intervention. 
SFA: Saturated Fatty Acid, MUFA: Monounsaturated Fatty Acid, PUFA:
Polyunsaturated Fatty Acid. See Table 3.4 for the nomenclature of fatty acids.
83
3.3.1 Within groups changes over the intervention
The following responses relate to the results of changes from baseline to 
week-12 assessed by paired t-tests.
F la xseed -o il group: Decreases were observed in both palmitic acid (26 ± 5.2 
% to 22.3 ±4.2 %: p<0.01) and oleic acid (16.3 ± 2 . 1  % to 13.8 ± 3.7 % 
p<0.05). However there was no significant fall in LA as might have been 
expected.
Among the n-3 fatty acids there were increases in a-LNA: from 0.4±0.3 % to 
1.33±0.8 %; p<0.001), in EPA (from 1.5±1.3 % to 3.8 ± 2.6 %; p<0.001), and 
DPA (n-3) (from 2.7 ±1 . 0  % to 3.4 ± 0.9 %; p<0.05), but no change in DHA. 
Thus total n-3 PUFA increased from 8.7 ± 3.3 % to 12.8 ± 4.2 % (p<0.001) 
with a concomitant decrease in n-6: n-3 ratio from 4.2±1.3 to 2.9±0.8
(p<0.001).
Ratios for AA: EPA ratio fell markedly from 13.9±5.8 to 5.5±3.2 (p<0.001) 
respectively (see Fig. 3.4).
Also the LA/a-LNA ratio fell (60.4±47.7 vs. 16.2±16; p=0.0001), while the 
PUFA/saturated ratio increased (1.1 ±0.5 vs. 1.4±0.4: p=0.04).
I  Flaxseed-oil D  High n-6 I  Fish-oil
§
£_<
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AA: EPA ratio
Fig. 3.4 The ratio of Arachidonic (AA) to Eicosapentaenoic acid (EPA) for the 
three diets.
Mean ± SD. *The difference between 0-wk and 12-wk is significant, p < 0.05, ***The 
difference between 0-wk and 12-wk is significant, p < 0.001.
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H igh n -6  g ro u p : In these control subjects fed a high n-6 diet, increases at 
week-12 from baseline were significant for l_A from 13.7 ± 3.6 % to 16.0±2.3 
%; p<0.05). Consequently total n-6 fatty acids also increased from 34.2 ± 7.0 
% to 38.1 ± 4.9 % ; p<0.05) as did the AA:EPA ratio from 10.9±8.2 % to 
15.2±10.6 % although this was not significant (Fig. 3.4).
The ratio of LA/a-LNA did not change (54.4±30 vs. 51 ±27) neither did the 
PUFA/saturated ratio (1.3±0.6 vs. 1.4±0.4).
Fish-oil g ro u p : Decreases from baseline were observed at week-12 in both 
C16:0 from 25.6±6.1 % to 21.7±4.2 %; p<0.01) and C18:1, from 17.2±4.1 % to 
13.2±3.8 %; p<0.05).
As expected significant increases was observed in both EPA (from 2.6±1.9 % 
to 5.6±3.3 %; p<0.001) and DHA (from 4.7±2.8 % to 7.5±2.4 %; p<0.001). In 
addition DPA (n-3) increased from 2.5±1.3 % to 4.1±1.7 %; p<0.01). Because 
of these changes total n-3 PUFA increased from 10.3±5.5 % to 17.7±5.7 % 
(p<0.001) with concomitant decreases in both the n-6:n-3 ratio (from 4.4±4.1 
to 2.1 ±1.1; p<0.05) and the AA: EPA ratio, from 10.7±11.6 to 3.1 ±2.2 (p<0.05) 
(Fig 3.4).
The ratio of l_A/a-LNA did not change (51 ±36.4 vs. 49.2±35.3), but the 
PUFA/saturated ratio was significantly increased (1.2±0.6 vs. 1.5±0.5; 
p=0.003).
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Fig. 3.5 End-point (12-wk) n-6 and n-3 fatty acid concentrations for the three 
diets.
Flaxseed diet (flax; n=21); Control diet (high n-6; n=17); Fish Diet (n=19). Data are 
presented as the mean of fatty acids (% area) ± SD. Where P-values are < 0.05, 
differences between groups (tukey test) are shown as letters where for any individual 
fatty acid, those with different letters are significantly different, linoleic acid (LA), a- 
linolenic acid (a-LNA), arachidonic acid (AA), eicosapentaenoic acid (EPA), 
docosapentaenoic acid (DPA n-3), docosahexaenoic acid (DHA).
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Fig. 3.6 Time course of changes in erythrocyte n-6 and n-3 fatty acid content. 
Flaxseed diet (n=21); Control diet (n=17); Fish Diet (n=19). ***The difference 
between the various diets is significant at 12-weeks, p < 0.001. Data are presented 
as the mean of fatty acids (% area) ± SD. a-LNA; a-linolenic acid, EPA; 
eicosapentaenoic acid, DPA (n-3); docosapentaenoic acid, DHA; docosahexaenoic 
acid, LA; linoleic acid, AA; arachidonic acid.
3.3.2 Between group changes over the intervention
To correct for variable baseline values, the responses to the interventions 
were calculated (as 12wk value -  baseline) and the effects of diets were 
analysed by either ANOVA or by non parametric methods where appropriate. 
In line with the within group changes reported above ANOVA revealed
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significant differences between the three dietary groups at week 12. Post-hoc 
testing was carried out to test for significance between the groups and these 
differences are shown in Table 3.5.
Table 3.5 Analysis of variance between dietary groups at 12 weeks.
A N O V A Kruskal W allace m ean values (change in  % total fatty acids)
P va lu es fla x seed -o il h igh  n-6 fish -o il
P A .89
ST .70
O L .34
L A .06 -1 .2 1 a 1.89 b 0 .8 ab
a -L N A 0.0001 0 .9 7 a 0 .08  b -0 .0 7  b
D G L A .23
A A .96
D T A 0.018 -0 .0 4 a O V© c
r
-0 .0 5 a
E P A 0 .0 0 0 6 NJ p
a
0 .03 b 3 .1 5 “
D P A  (n -3) 0 .0 0 2 0 .7 4 a 0 .0 4 b 1 .60“
D H A
______
0 .0 0 0 2 0 .0 7 a 0 .2 9 a 2 .8 b
Values with different letters in the same row differ significantly (p=<0.05). See Table 
3.4 for abbreviation of fatty acids.
The following changes differed between the three dietary groups: Changes in 
LA were marginally significant (p=0.06), through a fall in the flaxseed-oil group 
compared with an increase in high n-6 group. However responses were not 
different between flaxseed oil and the fish-oil group.
The increase in a-LNA concentration in the flaxseed-oil group differed 
significantly from the no change responses in both high n-6 and fish-oil groups. 
For DTA (22:4n-6) the increase in its concentration in the high n-6 group 
differed from the no change value observed in the flaxseed-oil and fish oil 
groups.
For EPA whilst the mean value for the increase was higher in the fish oil 
compared with the flaxseed oil group these responses did not differ (Mann- 
Whitney U Test: p=0.24), although they were in each case different from the 
no change response in the high n-6 group.
For DPA (n-3) like EPA, whilst the mean value for the increase was higher in 
the fish oil compared with the flaxseed oil group these responses did not differ 
(Mann-Whitney U Test: p=0.16), and they were in each case different from the 
no change response in the high n-6 group.
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For DHA, the lack of change for the flaxseed-oil did not differ from that of the 
high n-6 group and was lower than the fish oil group.
The comparison between the three diets for EPA, DPA (n-3) and DHA is 
particularly important showing whether any long chain conversion of a-LNA 
occurred. This is shown in Fig 3.7 as box plots and as the results of ANOVA 
for EPA, DPA (n-3) and DHA.
Change in EPA over 12 weeks Change in DPA over 12 weeks
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Fig 3.7 Changes in very long chain n-3 fatty acids (EPA, DPA and DHA) in the 
three dietary intervention groups. EPA; eicosapentaenoic acid, DPA (n-3); 
docosapentaenoic acid, DHA; docosahexaenoic acid.
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3.3.3 Equivalence of a-LNA and EPA
Where there was evidence for long chain conversion, the approximate 
equivalence between a-LNA in flaxseed oil and the preformed EPA can be 
calculated. As judged by the changes in Fig 3.7 for EPA with no difference 
between the increase in EPA in the flaxseed oil and fish oil diets it could be 
assumed that the 18g intake of a-LNA was equivalent to the intake of 1.7g of 
preformed EPA: i.e. a-LNA having 10% of the efficacy of dietary EPA. On the 
basis of the mean increases in the red cell EPA content of 2.3 & 3.1 (% total 
fatty acids) for the flaxseed and fish oil diets respectively, assuming a linear 
relationship between a-LNA or preformed EPA intake and red cell 
phospholipid concentration, this implies increases in EPA of 0.128/g a-LNA 
intake/d and 1.82/g of preformed EPA intake/d. These values imply that a- 
LNA has 7%  of the efficacy of dietary EPA.
For DPA (n-3) the increases of 0.74 and 1.60 imply an equivalence of 0.041 
and 0.94 for increases in red cell EPA per g of either flaxseed or fish oil 
intakes: i.e. a-LNA has 4%  of the efficacy of dietary EPA in terms of DPA (n-3) 
synthesis.
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CHAPTER 4 INTERVENTION STUDY DISCUSSION
The measurements reported in chapter 3 sought to test the hypothesis that a 
diet enriched with dietary a-LNA, in the presence of a low intake of dietary 
linoleic acid, could allow long chain conversion of a-LNA, changing the 
composition of membrane phospholipids and specifically increasing the 
relative amounts of EPA, DPA (n-3) and DHA. In this way it was hoped to 
reproduce the favourable effects of fish-oil on cardiovascular risk factors. The 
results need to be discussed in the context of the subjects and diets studied.
4.1 Subjects and Dietary Analysis
4.1.1 Body weight and overall energy and fat intake
Dietary intake analysis, as 7 day food diaries, indicated an increase in fat 
intake in all three intervention groups. Although the subjects on the flaxseed- 
oil diet increased their fat intake, their body weight was constant throughout 
the study period. This could be explained by the fact that for this group the 
percentage energy derived from the carbohydrates was decreased (P <0.05). 
However a significant increase in body weight occurred in both the high n-6 
group (p<0.05) and in the fish-oil group (p<0.01), which coincided with the 
increased fat intake. This was not intended, especially in the context of 
examining CHD risk reduction, but is a demonstration of the difficulty involved 
in managing dietary interventions involving manipulation of the fat intakes. 
Previous studies in this department involving manufactured foods enriched 
with n-3 fatty acids (Lovegrove et al., 1997) also resulted in some weight gain, 
although others have been able to maintain a constant weight throughout the 
intervention period (Kestin et al., 1990; Chen et al., 1993; Mantzioris et al., 
1995).
In the present study the subjects were asked to consume foods which were 
not routinely eaten, as a means of consuming their sachets of oil twice per 
day, e.g. milkshakes as well as orange juices. The increased weight of high n-
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6 and fish oil subjects indicate that in addition to complying with specific fat 
intakes of the diets, the subjects failed to compensate by reducing fat intake in 
other foods especially pre-prepared or convenience foods and consequently 
consumed additional fat with an increase in energy intake, and weight gain. In 
this event, the oils would have been supplementary to the habitual intake of 
total fat rather than a dietary substitute, as was intended. The increase in the 
percentage energy from fat intake observed in the high n-6, and fish-oil group, 
is equivalent to a dally intake of ~30 g of sunflower oil during the intervention. 
Allman and his co-workers (1995) also observed a failure to compensate in 
subjects who were supplemented with 40 g/d of sunflower oil with similar 
increases (up to 40.3 %). These finding, and the more general problem of how 
to deliver increased intakes of n-3 PUFA, highlights the need to develop real 
foods enriched with these fatty acids, not only for use in future dietary 
interventions but also to ensure substitution rather than supplementation in 
the human food chain.
4.1.2 The composition of the fat intakes from the experimental diets
The flaxseed-oil group achieved a reduction in dietary n-6 :n-3 ratio from a 
mean of 8.6:1 in the habitual diet to 0.4:1 after the intervention diet. This was 
achieved largely by the incorporation of flaxseed, rapeseed oil and the 
enriched form of ‘Mono’ spread in significant amounts so as to increase the 
amount of n-3 PUFA from a mean habitual intake of 1.2 g/d to 19 g/d. The 
dietary n-6: n-3 value achieved in the present study was lower than that in 
previous dietary intervention trial (Mantzioris et al., 1994; Valsta et al., 1996) 
which observed ratios of 0.6:1 and 2.7:1 respectively. The observed increase 
in the n-3 PUFA intake in the high n-6 diet was due to the consumption of the 
spread (‘Mono’) manufactured from rapeseed which was consumed by all 
groups.
The n-6:n-3 ratio decreased in subjects fed the fish-oil diet as a result of the 
fish oil capsules since as planned there was no significant difference in the 
percentage energy derived from the n-6 PUFA between the fish-oil (8.4 %)
92
and the high n-6 group (9.3 %), and this resulted in a 43 %  reduction in the 
dietary n- 6:n-3 ratio to a mean value of 5.2 (p <0.001) after the intervention.
4.2 The effects of n-3 fatty acids on plasma lipids
Although the subjects were normal males, the selection criteria included 
characteristics which together classify subjects as having an atherogenic 
lipoprotein phenotype (ALP), since subjects with an ALP were assumed to be 
the most appropriate target group for testing the effects of dietary a-LNA. This 
group are known to be predisposed to increased CVD through a clustering of 
risk factors, including dyslipidaemia, a pro-coaguable state and endothelial 
dysfunction all of which have been shown to be responsive to fish-oil 
supplements (Griffin &Zampeias, 1995).
4.2.1 Plasma total cholesterol. LDL-C and HDL-C
No differences between dietary groups were found in plasma lipids at the start 
of each study period. Dietary fish-oil of 3g of EPA and DHA per day produced 
predictable changes in plasma lipids and lipoproteins after 6 weeks that were 
consistent with decreased CVD risk in subjects with an ALP (Minihane et al., 
2000) and cardiovascular mortality (GISSI, 1999).
Total cholesterol did not change in the high n-6 group although the mean 
values (Fig 3.2) suggest a downward trend, a change often seen in such high 
n-6 PUFA diet.
This study has clearly shown an effect of the flaxseed diet on plasma lipids 
since after the 12-weeks of consuming the flaxseed diet, total and HDL 
cholesterol concentrations had decreased 12 %  and 10 %  (both p < 0.05), 
respectively, compared with baseline values. When compared between 
groups at week-12, HDL-cholesterol in the fish-oil diet (p=0.017) was lower 
compared with the flaxseed-oil diet. Plasma LDL-cholesterol, did not differ 
from baseline values throughout either feeding period (Table 3.1).
While the LDL-lowering effect of linoleic acid (LA) is well established and may 
well account for the cholesterol response in this case, the similar effect of 
flaxseed-oil reinforces the idea that dietary a-LNA, when fed in physiologically
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relevant concentrations, reduces serum lipids to the same extent as dietary 
linoleic acid (Harris, 1997). This may also apply to the small decreases in 
HDL-cholesterol on the flaxseed-oil diet. Interestingly, the raising effect 
associated with fish-oil, most notably in subjects with raised plasma TAG 
(Minihane et al., 2000), was not apparent in the present study, possibly 
because of the counter-effect of a high intake of dietary linoleic acid.
4.2.2 Plasma TAG
The fish oil intervention diet was associated with a significant decrease 
(p<0.01) in fasting plasma TAG compared to the flaxseed and high n-6 diets 
with levels at 12 weeks falling by 26 %. The magnitude of the decrease on the 
long-chain n-3 PUFA diet was similar to that found previously (Harris 1989, 
1996, Saldeen et al., 1998). In a subsequent meta-analysis of 36 cross-over 
and 29 parallel studies, Harris found fasting plasma TAG was reduced by 
between 25-30 %  on a long-chain n-3 PUFA diet (Harris, 1997). A  possible 
explanation for the TAG-lowering action of long-chain n-3 PUFA is provided 
by studies in cultured hepatocytes, in which the synthesis and secretion of 
TAG is reduced on exposure to EPA and DHA, predominantly through a 
decrease in plasma VLDL-TAG (Rustan et al., 1988). These fatty acids also 
exert an inhibitory effect on the esterification of other fatty acids, thereby 
promoting an overall diminution in the flux of fatty acids directed into TAG 
synthesis (Clarke, 1990).
In contrast to the fish oil effects, a dietary intake of 15g of a-LNA per day, 
together with a ratio of total n-6 to n-3 PUFA of less than 1, did not reproduce 
fish-oil like effects, although it did have a moderate impact on plasma TAG, (- 
18% n.s.). This is consistent with previous studies that have shown no 
significant effect of dietary a-LNA on plasma TAG when substituting sunflower 
oil with a similar daily intake of flaxseed-oil (20-30g) and over a similar period 
to the present study (Kelley et el., 1993, Mantzioris et al., 1994). Small 
decreases in serum TAG have been reported but only in response to very 
high and thus unphysiological intakes of a-LNA (>20g / d) (Singer et al., 1986), 
and usually in subjects with initially raised plasma TAG, as in the present
94
study. Despite the high n-6 PUFA intake from sunflower oil (~ 20 g/d), the high 
n-6 group failed to show any significant reductions in TAG demonstring the 
differences between the n-3 and n-6 PUFAs.
4.3 The influence of the dietary interventions on fatty acid profiles in 
erythrocyte membrane phospholipids
In addition to testing the effect of an increased intake of a-LNA, the 
intervention also aimed to reduce the ratio of n-6 to n-3 PUFA to 1:1 or less in 
order to minimize competition between a-LNA and the more abundant linoleic 
acid (n-6) and, in theory, increase the conversion of a-LNA to LC n-3 PUFA. 
This was achieved by delivering approximately 18 g of a-LNA per day in the 
form of flaxseed-oil. The daily consumption of this amount of a-LNA was 
shown to be practically feasible in a preliminary pilot study via the 
incorporation of flaxseed-oil into various foods and meals (Wilkinson et al.,
1999).
4.3.1 The effect of the fish-oil diet
At baseline the n-6: n-3 ratio of the fatty acid profile in the membrane 
phospholipids was surprisingly low at 3.8 mainly due to relatively abundant 
levels of DHA at 4-5%. However the AA: EPA ratio, the main determinant of 
the overall pattern of eicosanoid production, was on average 1 1 , the same 
value achieved at the end of the 12  weeks on the high n-6 diet.
As expected the fish-oil diet produced a significant increase in EPA (20:5n-3) 
to 5.6±3.3%; p <0.05), DPA (n-3), DHA concentration, (p < 0.001), within 
erythrocyte membranes, largely at the expense of a decrease in palmitic (PA) 
and especially oleic acid (OL) which fell from a baseline value of 17.2±4.1% to 
13.2±3.8% at week 12. There were no significant change in arachidonic acid 
(AA), dihomo-y-Linolenic (DGLA) and docosatetraenoic acid (DTA) so there 
was a consequent significant decrease in n-6: n-3 fatty acid ratio (p<0.05). A 
reduction was also observed in oleic acid (OL).
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The increase observed in EPA and DHA are in agreement with previous 
studies which have shown that fish-oil supplements containing high levels of 
preformed EPA and DHA increase the levels of these n-3 LC-PUFAs in 
plasma lipids and cell membrane phospholipids of a variety of cells by several 
fold within a matter of weeks (Roberts & Byleveld, 1993; Allman et al., 1995; 
Brown et al., 1991b; Harris, 1997, Katan et al., 1997, Minihane et al., 2000).
In the present study the fish-oil diet induced a greater than 2-fold increase in 
EPA and 50% increase in DHA in erythrocytes within 6 weeks, largely at the 
expense of a decrease in palmitic (PA) and oleic acids (OL). Some other 
studies with similar intakes of EPA and DHA (3g/d) have shown much greater 
increases in EPA of up to 7-fold and a doubling of DHA in plasma lipids 
(Kestin et al, 1990), although the increases in cell membranes tend to be 3-4- 
fold (Minihane et al, 2000), even at higher levels of intake (6g EPA/DHA/d) 
(Sanders & Roshanai, 1983).
There was no change observed in LA in this study the fall in LA has been 
reported by others (Brown et al., 1991b; Popp-Snijders et al., 1984; Cartwright 
et al., 1985). Only at the highest dose (8 g/day fish oil) was a fall in 
arachidonic acid (AA) evident (Roberts & Byleveld, 1993). Although others 
have observed this fail (Popp-Snijders et al., 1986, Agren et al., 1988), not all 
investigators have been able to demonstrate it (Cartwright et al., 1985).
Several investigators have observed the reduction in oleic acid (OL) (Brown et 
al., 1991a; Agren et al., 1988). As oleic acid preferentially occupies the sn-2 
position of the phospholipid, it is likely that it is displaced by EPA and DHA, 
which also have an affinity for this position (Roberts & Byleveld, 1993).
The wide range of biological effects ascribed to fish-oils which are assumed to 
result from the enrichment of cell membranes with LC n-3 PUFA are mediated 
through changes in the physical structure and thus function of membrane itself 
through the production of less pharmacologically active eicosanoids or 
through direct effects on gene expression. These effects include the anti­
thrombotic action of fish-oils through suppression of platelet aggregation, anti­
inflammatory effects and modulation of the immune responses through 
cytokine production.
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4.3.2 The effect of flaxseed-oil diet
In the flaxseed group the concentration of a-LNA increased 3.0-fold at week 
12, with an approximate 2.5-fold increase in EPA concentration was also seen. 
However the proportion of DHA was unaffected by the flaxseed oil 
consumption. Mantzioris et alM (1994) suggested that the incorporation of a- 
LNA into plasma lipid fractions appears to be at the expense of LA, which was 
reduced in the flaxseed group. However the level of LA was not changed 
through the study. Adam et al., (1986) found no depression in LA 
concentrations with a-LNA feeding. The unchanged level of LA seen here, 
might be because of the typical western diet, containing high levels of n-6 fatty 
acids, consumed by the subjects prior to the study. Studies have confirmed 
10-15% of LA is incorporated into the adipose tissue of those consuming an 
average western diet (Wood et al., 1987; Hodgeson et al., 1993). High levels 
of LA within adipose tissue may have influenced the study, by creating an 
additional supply of LA, in addition to dietary sources (Mantzioris et al., 1995; 
Allman et al., 1996).
The arachidonic acid level was not reduced in the current study. Both Chen et 
al., (1993) and Mantzioris et al. (1995), found AA levels to be unaffected by a- 
LNA intake in humans. The relationship between EPA and AA was examined, 
especially the extent to which EPA might replace AA. If this occurred then an 
inverse relationship might be observed. However there was no evidence of 
this in either the flaxseed or fish oil groups, with no relationship between EPA 
and AA (r2 = 0.02 and 0.07 respectively. However in the control group there 
was a significant positive correlation (r2= 0.25, p=0.04).
Mantzioris et al., (1994) found a reduction in the membrane concentration of 
oleic acid which has also been observed in the present study.
The n-6: n-3 ratio decreased (p=0.001) at week-12 compared with week-0. 
This change is seen as desirable because of the beneficial health effects of n- 
3 fatty acids and the undesirable effects of excess n-6 fatty acids in 
cardiovascular disease and inflammatory conditions (Lands, 1991). This 
reduction in n-6: n-3 ratio (-69 %  over baseline levels), was accompanied by a
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3-fold increase in a-LNA content of the erythrocyte membrane. Hwang et al., 
(1988) suggested that, it is the n-6: n-3 ratio, in particular a-LNA: LA, rather 
than the absolute amount of a-LNA which influences the incorporation. Chen 
et al., (1993) reported that in men an a-LNA: LA value of 1:3 increased 
platelet EPA compared with 1:27 and 1:7, and that if the quantity of a-LNA 
was doubled while the ratio was kept constant no further increases occurred.
In the present study the ratio of LA/a-LNA was significantly decreased in the 
flaxseed group by week-12 (P=0.0001), with no change in either high n-6 or 
fish oil groups.
The polyunsaturated/saturated ratio has been seen as a dietary factor which 
will modify the elongation and desaturation of the parent fatty acids to their 
long-chain metabolites (Simopoulos, 1991), in the present study the P/S has 
increased at week-12 in the flaxseed group (p=0.04), and in the fish group 
(p=0.003), where it was not significantly different for the high n-6 group.
In the present study, EPA concentrations resulting from flaxseed-oil 
consumption in conjunction with a background diet low in n-6 fatty acids 
reached 68 %  of those achieved with the 3g EPA+DHA /d fish-oil consumption 
over the same period of time. These results are consistant with the several 
reports of endogenous EPA formation after a-LNA ingestion (Adam et ai., 
1986; Kestin et al., 1990).
There has been growing interest in DHA specifically as an independent 
function of DHA becomes increasingly evident. Recently DHA has been found 
to be carried in plasma in two forms; as non-esterified fatty acids (NEFA), 
which supply this fatty acid to platelets and as lysophosphatidylcholine (LPC), 
which delivers it to erythrocytes (Lemaitre-Delaunay et al., 1986).
An increase in DHA after a-LNA ingestion was not detected in this study. This 
is consistant with other studies in which no rise in DHA concentration was 
detected (Dyerberg et al., 1983), so that there is now a convincing body of 
evidence, comprehensively reviewed by Gerster (1998), to show that dietary 
a-LNA, when fed as fiaxseed-oil, has differential effects on EPA and DHA in
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plasma and cell membrane phospholipids as in the current findings. Indeed 
Mantzioris et al., (1995) reported that, although a positive relationship 
between dietary a-LNA and tissue EPA was observed, there was an inverse 
relationship between dietary a-LNA and the DHA content of phospholipids of 
the plasma, neutrophils, mmononuclear cells, and platelets. The author 
suggested that the increase in EPA, or even a-LNA concentrations observed 
after a-LNA consumption may result in the displacement of DHA from the 
phospholipids. If this occurs, it may not be seen in studies involving fish-oil 
supplementation in which ingestion of both EPA and DHA is increased.
Thus the current results, taken together with previous studies suggest that a- 
LNA is likely to be unable to efficiently replicate those fish oil effects which 
depend on DHA supplementation. Nevertheless the conversion of a-LNA into 
EPA and the subsequent falls in the AA: EPA ratio can be assumed to 
influence those processes mediated through eicosanoids, especially the 
inflammatory environment, and this should enable a-LNA to play a role in 
protection against CHD (Allman et al., 1995; Freese & Mutanen, 1997). 
Indeed this has been observed after the long term a-LNA supplementation 
study reported by Bemelmans et al., (2002). They reported favourable effects 
on markers for inflammation (C-reactive protein, fibrinogen) and as these 
authors commented this may be an important change in relation to 
cardiovascular disease risk.
4.3.3 The Effect of the high n-6 diet on the levels of fatty acids
The pattern observed in the high n-6 group was, a decrease in the levels of 
palmitic acid, oleic acid, but an increase in the levels of LA (p < 0.05), and 
total n-6 fatty acids at week 12. Surprisingly, the level of DHA rose at week 6 
compared to week 0 (p=0.047), this increase was not observed at week 12, 
perhaps, at that time the increased level of LA from 13.7±3.6 to 16.0±2.3 
affected the level of DHA.
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4.3.4 The nutritional equivalence of high flaxseed diet
The changes in red blood cell EPA content induced by the flaxseed oil diet 
can be compared with the fish oil-induced increases to calculate an 
approximate equivalence between the dietary a-LNA in the flaxseed oil and 
dietary EPA in the fish-oil capsules.
EPA concentrations resulting from flaxseed-oil consumption in conjunction 
with a background diet low in n-6 fatty acids reached 68 %  of those achieved 
with the 3g EPA+DHA /d fish-oil consumption over the same period of time. 
However these changes were not statistically different and when the fold 
increases were calculated, after trimming for two outliers in the fish oil group 
in which there were very low levels of EPA and DHA at baseline, the changes 
were 3.6 times compared with 2.7 times in the fish oil group (not different, 
p=0.4). To this extent then the intakes of a-LNA at 18g/d was roughly 
equivalent to the 3g/d of preformed EPA + DHA containing 1.7g of EPA. 
However as calculated in the results section, assuming a linear relationship 
between the intakes of a-LNA or preformed EPA, and the outcome in terms of 
the change in red cell EPA phospholipid concentration, the actual mean 
changes per g of intake imply increases in EPA of 0.128/g a-LNA intake/d and 
1.82/g of preformed EPA intake/d. These values imply that a-LNA has 7%  of 
the efficacy of dietary EPA as a source of tissue phospholipid EPA
4.4 Conclusions
The present study, indicates that a rich dietary source of a-LNA as flaxseed oil 
can result in alterations in the membrane fatty acid profile involving a 
decrease in the n-6: n-3 ratio which can assumed to be potentially beneficial. 
The a-LNA diet resulted in a significant increase in EPA confirming that 
conversion of a-LNA to EPA within tissues does occur. On the basis of the 
concentrations of EPA achieved in erythrocyte membranes, in relation to 
intakes of either preformed EPA or a-LNA, the efficiency of a-LNA conversion 
to EPA is about 7%  of dietary EPA. In contrast no conversion to DHA was
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demonstrated in these studies, with DHA levels were unchanged within the 
membrane of those consuming the a-LNA diet.
The current study recognises consumption of fish oil, containing increased 
EPA and DHA and thus bypassing the conversion step, is a more efficient way 
of increasing cellular EPA, although, the problem still exists concerning 
increased fish consumption for the whole population. The effects of a-LNA 
may have a future role combined with n-3 rich marine oils.
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CHAPTER 5: THE LONG-CHAIN CONVERSION OF a- 
LINOLENIC ACID FROM A HIGH FLAXSEED OIL DIET: THE IN 
VIVO METABOLISM OF 13C a-LNA AND 13C LA
5.1 Background
As indicated in the introduction and chapter 2, whilst numerous animal & 
human experimental and epidemiological studies have indicated the beneficial 
effect of dietary EPA and DHA for a variety of chronic diseases, recent 
reviews of the physiological and health effects of n-3 fatty acids (Nettleton, 
1995; Gerster, 1998) have raised the question of whether long chain 
conversion of a-LNA to EPA and DHA in humans is sufficient to enable a-LNA 
to act as an effective alternative dietary source of these fatty acids. Chapter 2 
reported direct measurement of biological effects and compositional changes 
in membrane fatty acid profiles induced by a rich dietary source of a-LNA, 
flaxseed oil. Tracer studies allow added insight into the metabolism of a-LNA 
and its long chain conversion and such studies are described here.
5.2 Aims
The purpose of this study was to investigate, with in vivo 13C stable isotope 
tracer studies, the effect of a high a-LNA diet compared with a high LA diet on 
the conversion of a-LNA and LA to their respective very long chain n-3 and n- 
6 metabolites by elongation and desaturation.
5.3 Materials and methods
5.3.1 Materials
[U-13C] a-LNA and LA (>98 atom%) were purchased from Martek Biosciences 
Corporation (Columbia, Maryland, USA). This preparation contained 97.1% a- 
LNA and 98% LA, the remainder being short and medium chain fatty acids. 
Solvents were from Fisher Chemicals Limited. (Loughborough, Leicestershire,
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U.K.). Fatty acid standards and ail other reagents were obtained from Sigma 
(Poole, Dorset, U.K.). BondElut solid phase extraction (SPE) cartridges were 
from Varian Limited (Surrey, U.K.).
5.3.2 Subjects and study design
The subjects in this study (n=12) were mainly sub-groups of the 12-week 
parallel dietary trial described in chapter 2 (n=10) with two additional female 
subjects with a high n-6 background diet. Thus total numbers were flaxseed- 
oil diet, n=6, high n-6 diet n=5, and fish-oil (n=1). Subject recruitment and 
baseline characteristics are described in chapter 2. See Fig. 5.1a and 5.1b for 
the tracer study design.
Backgro und- diet
F la x seed -o il diet; n=6
Sunflow er d iet (h igh  n-6); n=5
F ish -o il diet; n = l
Introducing the [t/-13C] a -LNA 
and [t/-l 3C] LA, then a standard test 
breakfast.
V ----V----- V-----V---- V------V
Oh 24h 48h 72h 168 h 336 h
M------------  Blood sampling-------------- ►
12-week
Parallel study
Fig. 5.1a Tracer study design: experimental.
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Flow of lipids
 •••►
Flow of tracer
Dietary a-linolenic acid 13C a-linolenic acid
Intestine
■
V
► co2 #
Hepatic phospholipid 
pool
Conversion to n-3 LC - 
PUFA
(3-Oxidation and carbon 
recycling as cholesterol & 
fa tty  acid synthesis
Fig. 5.1b Tracer study design: conceptual
Metabolic fate of dietary (solid line) and trace labelled (dotted line) a-linolenic acid in 
relation to the two sampled pools in this study, the plasma and red blood cell 
phospholipid pool.We shall assume, for this discussion, that an average meal 
contains all three of the major nutrients: carbohydrate, protein, and fat with 
carbohydrate constituting most of the meal’s energy content.
The diagram shows a very simplified flow chart for the unlabelled and labelled fatty 
acids studied in these experiments. Fat is absorbed into the lymph, as triacylglycerols 
in chylomicrons; the lymph then drains into the systemic venous system, so that 
chlomicrons are distributed throughout the main organ systems as part of the plasma 
lipid pool. Thus, the liver does not get preferential exposure to absorbed fat but will 
contain some of it. Free fatty acids are released from plasma chylomicrons, mainly 
within adipose tissue and muscle capillaries and in the fed state are taken up by 
these tissues. This fraction of the ingested fat taken up by tissues is either stored or 
oxidized to provide energy, depending largely on the content of the meal.The liver is 
the main site of any de novo fatty acids synthesis so that linoleic or a-linolenic acid 
may be converted into very long chain products within liver. Such products will enter 
the plasma lipid pool mainly as very low density lipoproteins (VLDL), which like 
chylomicrons, contain predominantly TG. Their function is to transport the TGs from 
the liver to peripheral tissues.The plasma lipid pool will provide fatty acids for 
phospholipids within cell membranes such as those sampled in this study from red 
cells. In the post absorptive state the plasma pool will also contain non esterified fatty 
acids deriving from the catabolism of adipose-tissue triacylglycerol, by hormone
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sensitive lipase together with glycerol. This can be a source of stored linoleic or a- 
linolenic acid which can contribute to hepatic long chain conversion products.
The flow of the tracer; 13C will follow the unlabelled a-linolenic acid and will appear in 
long chain conversion products in plasma and red cell phospholipid as shown. In 
addition, fractions will be oxidized either to C02 or recycled into de novo fatty acid 
synthesis, and some stored in the adipose tissue.
In the present study, the conversion of labelled a-linolenic acid was studied by 
sampling the total plasma lipid and red blood phospholipid pools in which the tracer 
will be diluted by existing long chain conversion products in the storage pools and 
any from the diet. This meant that true precursor product relationships could not be 
studied because of lack of information about the 13C labelling within the hepatic pools 
where long chain conversion was occurring. Thus only semi quantitive information 
can be obtained. More detailed studies would involve isolation of specific lipid 
particles such as VLDL and its subfractions enabling more information about the 
contribution of the the hepatic pool and changes with time to be studied.
5.3.3 Administration of rU-13Cl a-LNA and specimen collection
The [U-13C] a-LNA and [U-13C] LA (400mg each; free fatty acid) were 
administered as an emulsion (Table. 5.1) according to a modification of Jones 
et al., (1999). The emulsion had a thin milk shake consistency and was 
prepared by blending casein and the labelled fatty acid with the double cream, 
followed by the addition of a sugar solution that had been preheated to 60- 
70°C. The labelled fatty acid mixtures were fed at 8 a.m. and within 5 min 
after drawing a 0 h blood sample. The subjects ate a standard test breakfast 
(Table. 5.2). Blood samples (approx. 10 ml each) were collected from a 
forearm vein by venipuncture at 0, 24, 48, 72, 168, and 336 hr, in most 
subjects with more frequent early time points in one subject (i.e. 4, 8, 12, 24, 
48, 72 and 196 hrs).
Table 5.1 Composition of the emulsion.
C o m p o sitio n Q u a n titie s
D ou b le  cream 2 2  g
C aesin  (Tropicane W orld Ltd, A ston , B irm ingham ,U K ) 12 g
B eet suger 4 .5  g
G lu cose (Thornton &  R o ss Ltd, H uddersfield , France) 9 g
N esq u ik  m ilkshake pow der (N estle , V ev ey , Sw itzerland) 10 g
W ater 160 m l
13C a -L N A 0.4  g
13c l a 0 .4  g
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Table 5.2 Composition of breakfast given to the subjects.
F o o d Q u a n tity
w h o le  m ilk  
orange ju ice
150 m l 
2 0 0  m l
w hite bread (toast) 72  g  
14 g
2 0  g
50  g
M argarine 
m arm alade 
rice krispies
5.4 Stable isotope analysis
Two sets of stable isotope analysis are presented here. At the outset it was 
intended that the analysis would involve GC-MS (gas chromatography mass 
spectrometry) analysis using the instruments then available in the department 
at the University of Surrey. However it was established in initial experiments 
that the level of enrichment was too low to allow accurate measurement by 
this technique and that GC-combustion isotope ratio mass spectrometry would 
be more suitable. Whilst such an instrument was eventually installed at Surrey 
and used in these experiments, with the data presented here, there was a 
long delay in its purchase and commissioning so that an initial analysis was 
performed under subcontract by Drs Steve Wooton and Graham Burdge at 
the University of Southampton who had experience of the GC combustion 
1RMS analysis of 13C labelled fatty acids. This analysis involving mainly 
phosphatidylcholine fractions isolated from plasma and red blood cells. This is 
presented here as Analysis 1.
It became apparent during the analysis of this data that there were two major 
problems. Firstly in the preparation of the blood samples for analysis there 
was no internal standard added so that no accurate measure of amounts of 
fatty acids could be determined, only values for enrichment together with 
estimates of fatty acid amounts which were mean values for each subject 
rather than individual values for each time point measured. Secondly because 
of compartmentation of fatty acids in various phospholipid fractions, analysis 
within individual fractions was not necessarily representative of the overall 
metabolism. Thus a better and simpler answer to the main questions of the
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research programme could be obtained from an analysis of fatty acids isolated 
from total plasma lipids. Furthermore at this stage in the research a suitable 
instrument had been acquired and commissioned at Surrey enabling the 
present investigator to perform the analysis. This is identified as Analysis 2 
and involves
a) a complete set of measurements made on the total plasma lipid pool 
prepared from the original plasma samples with internal standards added 
enabling accurate measures of 13C enrichment, fatty acid amounts and 
consequently total 13C within fatty acids,
b) a set of some but not all samples of red blood cell phospholipids (flaxseed 
oil; n=2 and high n-6; n=3). This set was incomplete because for some 
subjects there was not sufficient red blood cell sample remaining to enable the 
analysis.
5.4.1 Blood lipid analyses Analysis 1
Blood samples were separated into plasma and erythrocytes by centrifugation 
at 1,125 g for 15 minutes at 4°C.
Erythrocytes were washed twice with 0.9% (w/v) saline and resuspended in 
the original blood volume. Washed erythrocytes (2ml) or plasma (1ml) were 
extracted with 6 mL chloroform/methanol 2:1 (v/v) (Folch et al., 1957) 
containing BHT, but in contrast to analysis 2 no heptadecanoic acid (C17:0) 
was added as an internal recovery standard. PC and PE were then isolated 
from the lipid extracts by SPE  (solid phase extraction) using aminopropylsilica 
cartridges (100mg) (Caesar etal., 1988).
Preparation of fatty acid methyl esters from plasma and erythrocyte PC  and 
P E  lipid extracts. Purified lipids were dissolved in toluene and converted to 
their corresponding fatty acid methyl esters (FAMEs) by addition of 2 mL 
methanol containing 2%  (v/v) sulphuric acid (H2SO 4) and incubation at 50°C 
for 18 hours. The reaction mixture was neutralised with 2 mL of a solution 
containing 0.25 M potassium hydrogen carbonate (KHC03) and 0.5 M 
potassium carbonate anhydrous (K2C 0 3), the FAMEs was then extracted with 
2 mL hexane. Samples were dried under nitrogen and redissolved in 50 pL of
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hexane; 2 pL aliquots of this solution were used for analysis of isotopic 
enrichment (Burdge et al., 2000). All samples were run in duplicate.
5.4.2 Blood lipid analyses Analysis 2
Preparation of fatty acid methyl esters from total plasma lipids and erythrocyte 
PC. These analysis were performed on stored plasma and packed red cells 
initially prepared as described above. Total lipids were prepared from plasma 
(1ml) by extraction with 6 ml_ chloroform/ methanol (2:1, v/v) (Folch et al., 
1957) containing butylated hydroxytoluene (50mg/ml). Heptadecanoic acid 
(C17:0) was added as an internal recovery standard.
Purified lipids were dissolved in toluene and converted to their corresponding 
fatty acid methyl esters (FAMEs) by addition of 2 mL of methanol containing 
2%  (v/v) sulphuric acid (H2SO4) and incubation at 50°C for 18 hours. The 
reaction mixture was neutralised with 2 mL of a solution containing 0.25M 
potassium hydrogen carbonate (KHCO3) and 0.5M potassium carbonate 
anhydrous (K2CO3) and the FAMEs extracted with 2 mL of hexane. Samples 
were dried under nitrogen and redissolved in 200 pL of hexane; 2 pL aliquots 
of this solution were used for analysis of isotopic enrichment (Burdge et al.,
2000). All samples were run in duplicate, and all samples from an individual 
were analyzed in one series to eliminate inter-assay variation in the results. 
The concentration of the individual fatty acids were calculated by using the 
peak area counts in comparison with the internal standard.
Erythrocytes were washed twice with 0.9% (w/v) saline and resuspended in 
the original blood volume. Washed erythrocytes (2ml) was extracted with 
chloroform/methanol 2:1 (v/v) containing BHT using diheptadecanoyl 
phosphatidylcholine (PC) as internal recovery standards. The FAMEs was 
prepared as previously mentioned.
5.4.3 Analysis 1 (Southampton instrument)
[13C] Enrichment of n-3 fatty acids was determined by GC-combustion- 
isotope ratio mass spectrometry (GC-C-IRMS) consisting of an HP6890 GC
108
(Hewlett Packard, Wokingham, Berkshire, U.K.). FAMEs were converted to 
C 0 2 by heating to 860°C in the presence of PtCuO using an Orchid I RMS 
interface (PDZ-Europa) and 13C02/12C 0 2 ratio determined by a 20/20 Stable 
Isotope Analyser (PDZ-Europa) using tricosanoic acid methyl ester as isotopic 
reference standard (5 -  31.99 %o). Baseline resolution was achieved for all n-3 
FAME, a-LNA, EPA, DPA (n-3) and DHA were all resolved to baseline 
including complete separation of DHA from 24:0 and 24:1. FAMEs were 
identified by their retention times relative to standards. Concentrations of total 
fatty acids were calculated by integration of baseline-corrected peak areas on 
chromatograms generated from the total ion current by the GC-C-IRMS.
For gas chromatographic separation, a split injector at 250° C (split ratio 2:1) 
and a 30m PAG capillary column (Supleco, Inc) with a 0.25 mm inner 
diameter and a film thickness of 0.25 pm were used. The column head 
pressure was set to 1.5 bar and the GC temperature programme started at 
130 °C, rising 3 °C min-1 to 180 °C. From there on the temperature rose 4 °C 
min-1 to 200 °C, and finally 1 °C min-1 to the final temperature of 215 °C, 
which was held for 15 min.
5.4.3.1 Quantification of the 13C fatty acids
In this analysis in the absence of an internal standard, only crude estimates of 
total 13C content of fatty acid peaks could be obtained. Thus representative 
separate measurements of RBC and plasma phospholipid profiles for each 
subject were used and tracer concentration (in arbitrary units) were 
calculated by multiplying the relative concentrations of each fatty acid within 
the measured fatty acid profile by the 13C increase over basal 13C (at %  
excess).
From the carbon isotope ratio (13C/ 12C) the percentage contribution of 13C to 
the total C in the substance was calculated. The atom percentage excess of 
13C (APE) was obtained by subtracting the baseline 13C percentage from the 
values at corresponding time points after tracer dosage. This procedure also 
has the effect of correcting for the contribution to isotope ratio made by methyl
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C added in derivatization, so no separate correction was necessary (Sheaff et 
al., 1995).
5.4.4 Analysis 2 (Surrey instrument)
[13C] Enrichment of n-3 fatty acids isolated from the plasma total lipid fraction, 
was determined by GC-C-IRMS consisting of an HP6890 GC (Hewlett 
Packard, Wokingham, Berkshire, U.K.). FAMEs were converted to C 0 2 by 
heating to 860°C in the presence of PtCuO using a Thermofinnegan GC 
combustion III IRMS interface and with 13C 0 2/12C 0 2 ratio determined by a 
Thermofinnegan Delta plus X  Stable Isotope Analyser. At suitable time points 
pulses of C 0 2 with known isotopic ratio were introduced as reference 
standards (5 -  32.84 %o) this was achieved by calibration of C 0 2 gas against 
the international standard Pee Dee Belemate limestone (PDB) (Goodman & 
Brenna ,1992). GC settings and programming were as described above.
5.4.4.1 Quantification of the 13C fatty acids
This was based on isotope ratio analysis by integrating the signals of mass 44 
C 0 2 produced from the individual fatty acids and relating it to the signal 
resulting from the C-17:0 heptadecanoic acid methyl ester standard. Tracer 
concentration (pg 13C per mL of plasma) were calculated by multiplying the 
concentration of pg of carbon found in the form of a given fatty acid multiplied 
by the 13C increase over basal 13C (at %  excess). This quantity, designated 
“total label”, defines the overall conversion of labelled tracer to a particular 
metabolite in a tissue, and is the quantity required to test the hypothesis that 
overall conversion levels depend on diet (Sheaff et a!., 1995).
5.5 Statistical analysis & calculations
A two-tailed, unpaired t-test was used to test for significant differences 
between AUC values from subjects fed the high n-6 and flaxseed-oil diet. In
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some cases for the time courses of the enrichment curves ANOVA with 
repeated measures was used with post hoc testing where significant time 
versus dietary interactions were shown.
5.5.1 Analytical Model
The objective of the analysis was to identify any dietary differences in the 
conversion of the 13C-LA and 13C-a-LNA PUFAs into their long chain 
derivatives. A  simple kinetic analysis was adopted based on that described by 
Emken et al., (1994) and this was used in analysis 1 and 2. In this approach 
measurements are made of the time course of 13C-labelled fatty acid of 
interest expressed as pg 13C fatty acid per ml of plasma, calculated as 
measured isotopic abundance expressed as at %  excess, corrected to the 
same average body weight since a fixed dose was given to each subject, 
multiplied by the amount of the fatty acid. The area under this curve (AUC) is 
assumed to be proportional to the flux of either the administered 13C-iabelled 
fatty acid (for a-LNA or LA) or longer chain fatty acid metabolites deriving from 
their appropriate precursors. Estimates of conversion are made from 
comparisons of the relative magnitudes of these 13C fatty acid AUCs in either 
the n-3 or n-6 series. In analysis 1 the AUCs of concentration (pg13C/m! 
plasma) of the labelled fatty acids and their metabolites were calculated from 
the time course curves based on the labelled fatty acid data (as at %  excess 
13C) for the six samples collected between 0 hr and 336 hrs and, in the 
absence of an internal standard, from a single, separately-measured value for 
the plasma or red cell fatty acyl concentrations in each subject used for the 
entire time course acting as the substrate mass. In analysis 2, the use of an 
added C-17:0 internal standard allowed actual concentration of each 
individual labelled fatty acid to be directly measured, so that the AUC values 
for 13C fatty acids were more accurate, in each analysis the total AUC values 
were used to calculate both the relative distribution of isotope deriving from 
either the 13C a-LNA or 13C LA precursors throughout the n-3 or n-6 pathways 
(percent distribution), and the percentage of the 13C a-LNA or LA converted to 
long chain products, by dividing the AUC of the pg/ml-time course plots for
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each labelled product by the AUC for the series precursor (Emken et al., 
1994). None of these calculations indicate precise rates of conversion since 
this would require modelling which takes into account actual precursor- 
product enrichment relationships (as at %  excess). This is likely to be an 
important issue since the pool sizes of the various fatty acids did differ 
between the diets and this would influence relative enrichment independently 
of any dietary-induced differences in metabolic rates. However since 
precursor enrichments within the cellular compartments where elongation and 
desaturation occurs is not known such calculations cannot be performed with 
any confidence.
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CHAPTER 6 RESULTS OF STABLE ISOTOPE STUDIES
6.1 ANALYSIS 1: Southampton data: Europa instrument
6.1.1 Primary 13C enrichment data 
13C enrichment (APE) RBC PC
13C enrichment (APE) plasma PC
13C enrichment (APE) RBC PC
13C enrichment (APE) plasma PC
Time: days Time: days
Fig 6.1 13C enrichments (APE) for the phosphatidylcholine fatty acids from 
plasma (flaxseed diet, high n-6 diet) and red blood cells (flaxseed diet, high n- 
6 diet).
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See the list of abbreviation.
The primary mass-spectrometric measurements of 13C enrichments 
expressed as atoms %  excess for the PC fatty acids from plasma and red 
blood cells of subjects from the two dietary groups are shown in Fig 6.1. In all 
cases a-LNA enrichment had peaked by or before 24 hrs falling rapidly after 
this. EPA enrichment was less extensive than a-LNA but was easily 
measurable peaking at 2 days. In contrast the enrichment of DPA (n-3) and 
especially DHA was very much less. However DHA enrichment was observed 
in all cases as shown in Fig 6.2. Significant enrichment was observed at 24 
hrs in plasma.
DHA 13C enrichment: high n-6 diet DHA 13C enrichment: flax diet
•Plasm a
°RBC
days days
■Plasma
DRBC
Fig 6.2 DHA enrichment (atoms %)
Significant enrichment was observed at 24 hrs in plasma DHA 
(docosahexaenoic acid) on both diets and after 7 days in RBC DHA (as 
indicated by a paired t-test between values at time = t and baseline).
6.1.2 Relative rates of long chain a-LNA conversion
a-LNA turnover was rapid in both plasma and RBC PC fractions. Rate 
constants derived from a single exponential decay of a-LNA APE were 57%d- 
1 and 32% d-1 for the high n-6 and flax plasma PC fractions and 39.8% d-1 & 
29% d-1 for the corresponding RBC PC fractions, equivalent to half lives 
which varied between 1.2 and 2.4 days The slightly lower a-LNA turnover 
rates in subjects fed the flaxseed diets presumably reflected the higher a-LNA 
pool sizes in this group. Although conversion rates cannot be precisely
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calculated from the current blood pool sampling, because there is no certainty 
of any true precursor product relationships within the sampled plasma and 
RBC pools, the extent of the conversion can be visualized from the total 13C 
enrichment curves (i.e. APE x amount (% total FA) of FA in the membrane. 
However as discussed in the methods section, in this set of measurements 
quantitation of fatty acid concentrations in the fractions studied could not be 
achieved precisely because no internal standard had been added to the blood 
samples prior to extraction. Thus approximate values were used based on 
analysis of fatty acid profiles of representative samples of plasma and red cell 
phospholipids.
The results of these calculations are shown in Fig 6.3 where the total 13C is 
expressed as APE x amount (% total FA) in arbitrary units.
Total 13C in RBC PC Total 13C in RBC PC
Flaxseed diet
a-LNA
Total 13C in plasma PC 
Flaxseed diet
Total 13C in plasma PC 
high n-6 diet
Fig 6.3 Total 13C enrichment curves (i.e. APE x amount (% total FA) of FA in 
the membrane (arbitrary units).
See the abbreviation list.
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It is clear from the data in Fig 6.3 that there was substantial conversion of a- 
LNA into EPA with very much less further conversion to DPA (n-3) or DHA. 
The relative areas under the total 13C enrichment curves indicate the 
distribution of the isotope between these four fatty acids over the 14 days of 
the study and these values are shown in Table 6.1 The 14 day total 13C 
distribution between a-LNA, EPA, DPA and DHA, was 29%, 54%, 13% and 
4%  respectively (mean values for plasma-PC and erythrocyte-PC on both 
diets). These data make it quite clear that the a-LNA —► EPA conversion is 
extensive and accounts for about 70% of the tracer over the 14 days of the 
study. Clearly EPA—► DPA—> DHA (n-3 series) occurs to only a minor extent 
with only a few %  of the tracer appearing in the DHA pool.
Table 6.1 Distribution of total isotope through plasma and RBC-PC pools over
14 days in n-3 fatty acids series (% total AUC).
a-LNA EPA DPA DHA
mean sd mean sd mean sd mean sd
Plasma PC High n-6 31.5 9.0 52.7 3.5 11.7 6.6 4.0 3.7
Flaxseed 21.6 3.2 54.9 6.9 16.1 5.6 7.3 4.8
Dietary effects us ns ns ns
RBC-PC High n-6 25.7 18.9 58.2 64.6 13.2 7.4 2.9 3.1
Flaxseed 36.4 18.7 49.8 24.6 12.2 13.6 1.6 2.3
Dietary effects ns ns ns ns
grand mean 28.8 12.5 53.9 24.9 13.3 8.3 3.9 3.5
Fish oil(n=l) 89.5 8.5 2.0 0
Abbreviation: RBC-PC; red blood cells-phosphatidylcholine, a-LNA; a-linolenic acid, 
EPA; eicosapentaenoic acid, DPA; docosapentaenoic acid, DHA; docosahexaenoic 
acid.
6.1.3 Effect of background diets on 13C a-LNA conversion rates
The 14 day total 13C distribution between a-LNA, EPA, DPA (n-3) and DHA 
shown in Table 6.1 indicate no effects of the background dietary a-LNA: LA 
ratio on a-LNA conversion. However in the one subject studied after the fish 
oil diet, conversion was very much less than in any other subjects (see Fig 6.4) 
suggesting that provision of preformed very long chain n-3 fatty acids does 
suppress long chain conversion of a-LNA. Distribution of total 13C between a- 
LNA, EPA and DPA (n-3) was 89.5 %, 8.5% and 2.0%.
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days
Fig 6.4 Total 13C enrichment curves for RBC-PC fatty acids in one subject fed 
fish oil.
Abbreviation: RBC-PC; red blood cell-phosphatidylcholine, a-LNA; a-linolenic, EPA; 
eicosapentaenoic acid, DPA (n-3); docosapentaenoic acid, DHA; docosahexaenoic acid.
6.1.4 Overall implications of analysis 1
Whilst it is clear that there was substantial conversion of a-LNA to EPA, the 
higher proportion of label in EPA than in a-LNA suggesting >100% conversion 
is theoretically impossible for a unidirectional, true precursor product 
relationship. One potential explanation is that there is a marked 
underestimation of the a-LNA labeling if peak labeling of a-LNA occurred 
before the first blood sample at 24 hrs. However as discussed below the 
extent of this underestimation of the a-LNA AUC is only likely to be about 10%. 
Another potential explanation is that compartmentation of trace labeled 
products. If the relative enrichments of a-LNA and EPA in the measured pools 
differs from that in other pools, these results would be unrepresentative of 
overall metabolism. A  third explanation is that the lack of an internal standard
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and the use of crude estimates of actual fatty acid concentrations to calculate 
total 13C activity resulted in series error. Whatever the explanation it is clear 
that this analysis overall is unsatisfactory.
6.2 ANALYSIS 2: Surrey data: Finnegan instrument
The preceding section demonstrated concerns with the experimental design 
in terms of problems posed by compartmentation of labelled fatty acids 
between the various phospholipid pools and lack of an internal standard in the 
analysis. This section describes the measurements obtained by the 
investigator on the Surrey instrument of the total plasma fatty acid pool.
6.2.1 Threshold of detectability
Prior to any review of the results or statistical analysis it was necessary to 
decide on criteria for judgement of the limits of detectability for enrichment. 
This was necessary since the experience gained in analysis 1 indicated that 
level of 13C incorporation into DHA was at the threshold of detectability. This 
required the identification of a minimum value for enrichment which would be 
considered as a reflection of true enrichment. The analysis of DHA can be 
used as an example of the approach used for each fatty acid. Analysis of the 
19 baseline values for DHA isolated from the total plasma pool indicated 
mean and SD  values for 13C enrichment of 1.0702 & 0.0064 at%. Thus a 
value of 1.0811, as 2SD above the mean, was chosen as a threshold value for 
enrichment. Any measured DHA values below this were set at 0 at %  excess. 
The data for DHA is further discussed below.
6.2.2 Measurements of precision of GC combustion isotope ratio 
measurements of 13C enrichment and Iona chain conversion of labelled fatty 
acids
A  number of measurements were made to assess the reproducibility of the 
instrumental measurements.
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6.2.2.1 Assessment of reproducibility of both GC retention time and isotope ratio 
during multiple injections of a standard fatty acid mixture
Methods. Analysis of several standard mixtures of known composition that 
simulated the composition of the actual samples. The mixture consisted of LA, 
DGLA, AA, a-LNA, EPA, DPA (n-3), DHA, ail the fatty acids standard were 
FAMEs, and they were prepared at concentration of 0.2 mg/ml, 2 pi was 
injected into the GC, data was determined from six replicate analysis. The 
relative retention time (RRT) was calculated compared to a reference peak 
which was C17:0 (heptadecanoic acid) by dividing the retention time (RT) of 
target individual fatty acid by the RT of the reference peak.
Results. As shown in Table 6.2 for each fatty acid the chromatography, as 
shown by the relative retention times, was highly reproducible with CVs 
ranging from 0.03 to 0.4%. There was more variation in the measurements of 
isotope ratios with CVs ranging from 0.08 to 2.1%.
Table 6.2 Reproducibility for a fixed sample size (n=6 injections), 
fatty acid relative retention time (RRT) 13C enrichment
m ean sd cv% m ean sd CV%
L A 1.207 0.001 0 .0 7 4 1.072 0 .0 2 2 2 .0 9 0
a -L N A 1.286 0.001 0.081 1.039 0 .0 1 9 1.846
D G L A 1.579 0 .0 0 7 0 .4 1 6 1.098 0 .0 1 7 1.559
A A 1.603 0.001 0 .068 1.113 0 .0 1 2 1.048
E P A 1.723 0.001 0 .063 1.110 0 .0 0 4 0 .3 2 7
D P A 2 .3 4 9 0.001 0 .033 1.110 0 .0 0 2 0 .176
D H A 2 .4 4 9 0.001 0 .0 5 2 1.122 0 .0 0 4 0 .3 7 2
Abbreviation: LA; linoleic, a-LNA; a-linolenic acid, DGLA; dihomo-y-linolenic acid, AA; 
arachidonic acid, EPA; eicosapentaenoic acid, DPA (n-3); docosapentaenoic acid, DHA; 
docosahexaenoic acid.
6.2.2.2 Assessment of sample size dependency of isotope ratio at natural abundance 
for a standard fatty acid mixture
Methods. Analysis of the same FAMEs mixture was used at different 
concentration range (20ng, 40ng, 80ng, 130ng, 150ng, 200ng) by using 
different split ratio, hence controlling the amount of the fatty acids going to the
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column. The concentration of the FAMEs was 0.2mg/ml, the analysis was 
determined from four replicate.
Results. As shown in Table 6.3 reproducibility of enrichments measured at 
natural abundance for a fixed sample size was generally better than with 
varying sample size since with the exception of AA, there were significant 
effects of sample size as judged by significant differences between 
measurements made at varying sample size as measured by ANOVA. 
However this was not a simple dose relationship. Thus enrichment was 
significantly higher at either 40ng (a-LNA, DGLA, EPA & DHA) or 80ng LA 
than at other values, highest values highlighted in bold). However differences 
when they occurred were small (i.e. about 0.001 at %). A  type II error cannot 
be ruled out, in other words the differences may not be truly significant.
Table 6.3 Reproducibility for increasing sample size (n=4 injections).1
LA a-LNA DGLA
Amount Means SD. P CV% Means SD P CV% Means SD. P CV%
20ng 1.1117 0.0002 a 0.02 1.1101 0.0005 a 0.04 1.1087 0.0006 b 0.06
40ng 1.1134 0.0006 ab 0.05 1.1124 0.0002 b 0.02 1.1119 0.0003 a 0.03
80ng 1.1148 0.0006 b 0.05 1.1105 0.0012 a 0.11 1.1091 0.0012 b 0.11
130ng 1.1129 0.0025 ab 0.23 1.1115 0.0011 ab 0.10 1.1101 0.0001 b 0.01
150ng 1.1120 0.0000 a 0.00 1.1107 0.0002 a 0.02 1.1097 0.0000 b 0.00
200ng 1.1116 0.0006 a 0.06 1.1108 0.0003 a 0.03 1.1096 0.0007 b 0.06
AllGrps 1.1127 0.0015 0.13 1.1110 0.0010 0.09 1.1098 0.0012 0.11
Anova (p value) 0.002 0.003 0.00007
AA EPA DHA
Amount Means SD. P cv% Means SD. P cv% Means SD. P cv%
20ng 1.1104 0.0004 a 0.03 1.1138 0.0022 b 0.19 1.1134 0.0026 b 0.24
40ng 1.1125 0.0004 a 0.04 1.1178 0.0007 a 0.06 1.1180 0.0004 a 0.04
80ng 1.1108 0.0002 a 0.02 1.1133 0.0012 b 0.11 1.1128 0.0018 b 0.16
130ng 1.1100 0.0016 a 0.15 1.1153 0.0002 ab 0.02 1.1151 0.0005 ab 0.04
150ng 1.1126 0.0004 a 0.04 1.1150 0.0003 b 0.03 1.1159 0.0003 ab 0.03
200ng 1.1178 0.0117 a 1.05 1.1141 0.0006 b 0.06 1.1156 0.0009 ab 0.08
All Grps 1.1124 0.0051 0.46 1.1149 0.0018 0.16 1.1151 0.0022 0.19
ANOVA (p-value)0.3 0.0004 0.001
Where P-values are < 0.05, differences between groups (tukey test) are shown as letters 
where values with different letters are different (p=<0.05). See the abbreviation list.
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6.2.2.3 Asessment of reproducibility of estimates of Iona chain conversion of total 
13C-labeled LA and a-LNA fatty acids
Methods. The reproducibility was determined from four replicate analysis of all 
the time points samples from one subject who was fed uniformly labelled 13C- 
LA and 13C-a-LNA fatty acids. The concentration (pg/ml) for the labeled fatty 
acids and their metabolites were calculated by integrating the areas under the 
time course curves (AUC), distribution of isotope and %  conversion data are 
calculated from AUC concentration data.
Results. Repeated measurements of the main derived parameters in this 
study are shown in Fig 6.5 (distribution of isotope) and Fig 6.6 (long chain 
conversion). These values require measurements of both amounts of fatty 
acids and 13C enrichments at multiple time points after the meal of enriched 
fatty acids so that the errors in the derived values include the sum of ail 
instrument errors likely to occur.
It is clear that errors increase markedly from between 10 & 20% for the initial 
conversion products (DGLA, and EPA), to much larger values of 50% to 150% 
for the longest chain products, as the extent of the enrichment falls to values 
close to natural abundance for both the n-6 and n-3 series.
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Distribution of isotope (4 injections)
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Fig 6.5 Distribution of 13C isotope between n-6 and n-3 series of fatty acids 
within one individual fed uniformly labeled 13C-LA and 13C-a-LNA fatty 
acids as assessed by 4 injections at each time point.
See the abbreviation list.
Long chain conversion (4 injections)
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Fig 6.6 Extent of long chain conversion of 13C-18 PUFAs within one individual 
fed uniformly labeled 13C-LA and 13C-a-LNA fatty acids as assessed by 4 
injections at each time point.
See the abbreviation list.
Discussion. It is clear that the chromatographic aspect of the instrument 
performance was excellent with CVs of <0.5% for retention times meaning 
that misidentification of peaks was unlikely. The result of most concern in 
these measurements of variability was the sample size dependence of the 
measurement of enrichment. The differences were highly significant (P=
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0.003). The lack of any simple dose relationship with this effect makes it 
difficult to explain but the fact that the highest enrichment values was 
observed at similar sample sizes implies that it is a machine characteristic. 
However for those fatty acid peaks where such differences where observed 
the overall between sample size CV was in fact quite low (<0.2%). 
Furthermore for arachidonic acid where there was no significant sample size 
effect the overall CV was higher at 0.5% a value which would still be 
acceptable.
The most important measure of variability is that of the derived values for 
isotope distribution and %  conversion. For these measures the CVs for the 
initial conversion products (DGLA, and EPA) were between 10 & 20%. Only 
with the longest chain products were the CVs very large as enrichment levels 
fell to barely detectable levels. In this case the important issue was the 
presence or not of detectable enrichment levels (i.e. any detectable 
conversion) rather than values for actual conversion rates.
In conclusion these measurements indicate that the reproducibility of the 
instrument was sufficient to identify nutritionally important dietary influences 
on LA and a-LNA fatty acid conversion.
6.3 Results of analysis 2
6.3.1 Fatty acid concentrations in the plasma total lipid pool
The concentration of the fatty acids is shown in Fig 6.7. The LA pool was 
much larger than any of the other n6 or n-3 PUFAs. For the n-6 series whilst 
mean values were higher in the control diet for LA, DGLA and AA, the 
difference was only significant for DGLA (p=0.039). The a-LNA pool was 
much smaller than the LA pool but was three times larger in the subjects fed 
flaxseed oil compared with the control diet (p=0.002). There were no 
differences between EPA, DPA (n-3) or DHA.
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Fatty acid concentration in total plasma
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Fig. 6.7 Concentration (pg/ ml of plasma) of labelled a-LNA and LA and their 
long-chain fatty acid metabolites in total plasma lipids.
P-Values are for comparison of flaxseed-oil (n=6) to high n-6 diet (n=4) for the 
same fatty acid in total plasma lipid, ns = not significant. See the abbreviation
6.3.2 Tracer analysis: Enrichment (Atom percent excess: APE)
The atom percent excess (APE) for the n-6 and n-3 fatty acids series are 
shown in Fig.6.8. (A) (n-6 series), and Fig.6.8. (B) (n-3 series). For the n-6 
series the peak enrichment of LA was about 20% higher in the flaxseed group, 
consistent with the slightly higher LA concentration which would have diluted 
the tracer more. There was marked enrichment in the DGLA, pool again with a 
higher level in the flaxseed group. However AA labelling was much lower with 
no obvious difference between the two diets.
For the n-3 series (Fig.6.8 (B)) the peak enrichment of a-LNA was about 30% 
higher in the control group, consistent with the markedly lower a-LNA 
concentration than in the flaxseed group which would have diluted the tracer 
less. There was marked enrichment in the EPA pool again with a higher level 
in the high n-6 group compared with flaxseed group. DPA (n-3) labelling was
list.
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much lower rising only slightly above background when significant enrichment 
was detected. The order of appearance of 13C labeled EPA, DPA (n-3), and 
DHA in plasma was in accordance with the conversion of 13C a-LNA into its 
long chain metabolites. This was also observed for the n-6 series.
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Fig. 6.8 Atom percent excess (APE) for the n-6 and the n-3 fatty acids in total 
plasma lipids in the flaxseed (n=6) and high n-6 (n=4) groups.
Data shown as means ± SD. See the abbreviation list.
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6.3.3 Enrichment of DHA
Given that the levels of enrichment of DHA was very low, judgements were 
made about the presence or absence of enrichment by assuming a common 
baseline value as mean + 2sds (as discussed above). The enrichment profile 
is shown in Fig 6.9. This data suggests that there was lower enrichment of 
DHA on the flaxseed compared with the high n-6 diet. Thus on the basis that 
enrichment which was greater than 2SDs above average baseline indicated 
significant labelling, all high n-6 subjects exhibited enrichment in either both 
or one of the duplicate measurements by 3 days and subsequently, whereas 
amongst the flaxseed diet subjects, there was less clear evidence of DHA 
enrichment. Thus two subjects showed either no detectable enrichment in any 
duplicate measurements or enrichment in one but not the other of two 
duplicate measurements; one subject showed enrichment only at the final 
time point, and three subjects showed enrichment at more than 
one time point.
DHA 13C enrichment High n-6 Diet DHA 13C enrichment Flaxseed Diet
1.15 
1.14 
1.13 
1.12 i 
1.11 
1.1 
1.09 
1.08 
1.07
1.06 f
1.05
■ ■
■
■
X X
•
t X* X
X + +J - ... . +
100
*
baseline 
+ 2 sds
200
hours
300 400
1.15
1.14
1.13
1.12
1.11
1.1
1.09
1.08
1.07
1.06
1.05
A
baseline 
+ 2 sds
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hours
300 400
Fig 6.9 Enrichment profiles (At% 13C) of DHA during the study.
Each subject is shown as a different symbol and with the duplicate measurements 
shown. The horizontal line is drawn at 1.081, 2sds above the mean of all DHA 
(docosahexaenoic acid) baseline values (n=20).
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6.3.4 The time-courses of the concentrations of labelled n-6 and n-3 fatty 
acids in subjects fed the flaxseed and high n-6 diets
The time courses of the concentrations of labelled n-6 and n-3 fatty acids in 
the two dietary groups are presented Fig.6.10 (n-6 series) and 6.11 (n-3 
series). For the n-6 series peak labelling had occurred by 24 hrs in LA, by 48 
hrs for DGLA and some time after this for AA. Repeated measures ANOVA 
analysis showed no dietary effects for any fatty acid. For the flaxseed oil diet 
group peak labelling had occurred by 24 hrs in a-LNA, by 48 hrs for EPA, by 
72 hrs for DPA (n-3) and probably some time after this for DHA although the 
level of labelling was too low to identify the time course with any certainty. 
Repeated measures ANOVA analysis showed that there were no dietary 
effects for any fatty acid except for DHA (p=0.007) with high n-6 diet labelling 
higher than for the flaxseed oil diet.
high n -6 flaxseed -o il
om
24 48 72 168 240 336
Time (hr)
Fig.6.10 Time-course plots for concentrations of labelled n-6 fatty acids in 
plasma total lipids.
Each time point is mean data ± SD from the flaxseed (n=6) and high n-6 (n=4) diets.
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Fig.6.11 Time-course plots for concentrations of labeled n-3 fatty acids in 
plasma total lipids.
Each time point is mean ± SD data from the flaxseed (n=6) and high n-6 (n=4) diets. 
See the abbreviation list.
6.3.5 Analysis of area under the 13C fatty acid labelling curves
The isotopic labelling expressed as AUC of the total 13C versus time plots for 
a-LNA and LA and their conversion products in plasma total lipids in individual 
subjects on both diets is shown in Table 6.4 and graphically in Fig 6.12-6.14.
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Table 6.4 Labelling (pg/ ml) of 13C-a-LNA and 13C-LA and their fatty acid 
metabolites in plasma total lipida.
Subject a-LNA EPA DPA DHA Sum LA DGLA AA Sum
n-3 metab.b n-6 metab.b
Flaxseed oil diet
FI 62 33.4 4.34 0.69 38.4 122 9.28 9.72 19.01
F2 100 6.2 0.81 0.45 7.5 134 2.68 2.58 5.26
F3 86. 17.9 3.39 0.60 21.9 105 5.32 3.39 8.72
F4 60. 41.1 5.66 0.91 47.6 75.2 7.12 8.50 15.62
F6 45. 15.3 1.80 0 17.1 86.4 9.40 5.62 15.02
F5 38. 12.1 3.79 0 18.9 75.3 4.58 3.42 8.00
Avg. 65. 21.0 3.30 0.44 24.2 99.6 6.40 5.54 11.94
Std. dev. ±24 ±13.4 ±1.75 ±0.37 ±15.2 ±24.6 ±2.69 ±2.97 ±5.36
High n-6 diet
Cl 36 14.2 4.43 2.21 20.8 113 7.01 10.30 17.31
C2 59 34.0 8.42 2.86 45.3 78.8 9.07 9.20 18.27
C3 34 24.9 2.90 0.84 28.6 82.2 7.27 8.70 15.97
C4 60 5.3 2.58 2.21 10.1 91.8 7.79 4.26 12.04
Avg. 47 19.6 4.58 2.03 26.2 91.5 7.78 8.11 15.90
Std. dev. ±14 ±12.5 ±2.68 ±0.85 ±14.8 ±15.5 ±0.92 ±2.66 ±2.74
Both diets
Avg. 57.9 20.4 3.81 1.11 25.4 96.4 6.95 6.57 13.52
Std. dev. ±21.7 ±12.3 ±2.13 ±0.96 ±14.2 ±20.8 ±2.19 ±3.00 ±4.76
Between diet comparisons
P-Value ns ns ns 0.003 ns ns ns ns ns
Between series comparisons (both diets)
P-Value a-LNA vs. LA; p=<0.001, n-3 metabolites vs. n-6 metabolites; p=0.01
a As previously described, the concentration (pg/ml) for the label fatty acids and their 
metabolites were calculated by integrating the areas under the time course curves. 
Boldface type for p-value indicates data for fatty acids that were the most influenced 
by diet.
b Sum n-3 or n6 metabolites: = sum of all either EPA, DPA & DHA, or DGLA & AA. 
See the abbreviation list.
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6.3.5.1 All Subjects (both diets)
As shown in Table 6.4, although labelling of LA was 50% higher than a-LNA 
(96.4±20.8 pg vs. 57.9±21.7 pg 13C/ml p=<0.001), the sum of the labelling for 
all n-6 fatty acid metabolites was 50% lower than the sum of the labelling for 
all n-3 fatty acid metabolites (25.4±14.2 vs. 13.5±4.8, pg 13C/ml p=0.01, n-3 
vs. n-6). This is illustrated graphically in Fig 6.12 which shows the amount of 
labelled a-LNA and LA and the distribution of labelling between the precursors 
and their n-3 and n-6 very long chain metabolites in total plasma lipids. Also 
shown in Fig 6.13 (B) is the %  distribution of 13C between the precursor and 
metabolite fatty acids in each series, higher in LA compared with a-LNA 
(87.4±4.6% vs. 69.2±13.4% p=0.0004) and lower in n-6 compared with n-3 
LC-PUFA metabolites (13.7±5.2 %  vs. 42.1 ±22 %, p=0.0005). These data 
clearly show that desaturation and elongation of the dietary a-LNA was 
greater than for LA in these subjects.
(Avg. All Subjects)
(A)
g  140 P=0.0004
P=0.01
a-LNA Sum n-3 Sum n-6 
metab. metab.
100
(All Subjects)
P=0.0004
(B)
P=0.0005
a-LNA Sum n-3 Sum n-6 
metab. metab.
Fig. 6.12 Amount (A) and distribution (B) of labelled n-6 and n-3 LCFA 
metabolites in total plasma lipids.
(A) Data are shown for average of all subjects (both diets). P-values are shown for 
comparison of a-LNA vs. LA (p=0.0004) and for the sum of n-3 metabolites vs. sum 
n-6 metabolites (p=0.01). Data plotted are for the total areas under the time-course 
curves per ml of plasma.
(B) Data are shown for distribution of total label for all subjects (both diets). P-values 
are shown for comparison of a-LNA vs. LA (p=0.0004) and for the sum of n-3 
metabolites vs. sum n-6 metabolites (p=0.0005). Percentage data are calculated from 
total-area-under-the-time-course curve concentration data. a-LNA; a-linolenic acid, 
LA; linoleic acid.
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6.3.5.2 Influence of diet: n-3 fatty acid series: incorporation/conversion
The results in Table 6.4 and Fig 6.13 indicate that the initial incorporation of 
the 13C a-LNA into the a-LNA pool in plasma lipids was on average higher on 
the flaxseed-oil diet, by 38 %  (65 ±23.8 vs. 47 pg/ml ±14.3, flaxseed vs. high 
n-6), though not significantly so. As judged by overall labelling of long-chain n- 
3 fatty acid metabolites (sum of EPA, DPA (n-3), DHA), the conversion of 
labelled a-LNA was not significantly different between diets (24.8 ±15 & 
26±14.8 pg/ml, flaxseed-oil and high n-6 diets respectively. However for 
individual metabolites (see Fig 6.14), whilst relative amounts of LCFA n-3 
metabolites were similar on both diets for EPA and DPA (n-3) (i.e. EPA: 
21 ±13 vs. 19.6 ±12.5pg/ml, ns; DPA: 3.3±1.7 vs. 4.6 ±2.7pg/ml ns flaxseed vs. 
high n-6) for DHA more 13C appeared in DHA in the control diet:, DHA: 
0.5±0.3 vs. 2.03±0.85 pg/ml, p=0.003). In fact the lower labelling of DHA 
coupled with an on average slightly higher initial incorporation in a-LNA on the 
flaxseed-oil diet indicates a clear lowering of DHA formation by increased 
dietary a-LNA.
6.3.5.3 Influence of diet: n-6 fatty acid series: incorporation/conversion
The pattern of labelling of 13C-LA and individual n-6 fatty acid metabolites in 
plasma total lipids shown in Table 6.4 and Figs 6.13 & 6.14, indicates no 
measurable dietary effect either on the initial incorporation of the 13C-LA into 
the LA pool in plasma lipids label or on long chain conversion (i.e. LA: 
99.5±24.6 vs. 91.5±15.5; DGLA: 6.4±2.7 vs.7.8±0.92; AA: 5.5±2.97 vs. 8 ±2.7; 
sum of DGLA, AA: 11.9 ±5.4 vs. 15.9 ±2.7 pg/ml, flaxseed vs. high n-6). The 
fact that dietary a-LNA did not depress the 13C-LA level (see Fig. 6.14), is in 
accordance with the results from the intervention study, which showed an 
unchanged level of LA in the flaxseed-oil group.
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Fig. 6.13 The amounts of labelled LA and a-LNA (A) and their total labelled n- 
3 and n-6 LCFA metabolites (B) in plasma total lipid of subjects fed the 
flaxseed-oil and high n-6 diets.
(A) Label concentration in a-LNA and LA (as pg 13C/ml) for flaxseed-oil (n=6) and 
high n-6 (n=4) diets. (B) Data are shown for total metabolites (pg 13C/ml) of flaxseed- 
oil and high n-6 diets. P-values for comparison of (a-LNA vs. LA) in the flaxseed, and 
in the high n-6 diets (A). P-values for comparison of (sum n-3 metab. vs. sum n-6 
metab.) in the flaxseed and in the high n-6 diets (B). Data plotted are for the total 
areas under the time-course curves per ml of plasma. a-LNA; a-linolenic acid, LA; 
linoleic acid.
■  Flaxseed-oil H  High n-6
n -3  Fatty Acids #_6 Fony Aclds
Fig. 6.14 The amounts of labelled individual fatty acids of the n-3 (A) and n-6
(B) series in plasma total lipid of subjects fed the flaxseed-oil and high n- 
6 diets.
P-values for comparison of fatty acids between the flaxseed-oil (n=6) and high n-6 
(n=4) diets for the n-3 (A) and n-6 (B) fatty acids series. Data plotted are for the total 
areas under the time-course curves per ml of plasma. See the abbreviation list.
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6.3.6 Desaturation and elongation as indicated bv distribution of isotope
The extent of conversion of 13C a-LNA and LA to long chain derivatives was 
determined, as defined above, by calculating the total mass of the 13C labelled 
fatty acid and in labelled elongation products per ml of plasma lipids (Sheaff et 
al., 1995). Results for the major n-3 and n-6 fatty acids are presented in Table 
6.5. Distribution of the total label was calculated from the concentration data 
by normalization of the concentration data in Table 6.4 to a 100% basis, 
dividing the pg of labelled fatty acid /ml plasma for each fatty acid in the series 
by the sum of all labelled fatty acids in the total plasma lipid pool (Emken et al., 
1999). The incorporation of 13C into long-chain n-3, n-6 metabolites of a-LNA 
and LA was used to indicate the capacity for elongation and desaturation of a- 
LNA and LA (Emken et al., 1998; Burdge et al., 2002 a,b).
6.3.6.1 All subjects (both diets)
The markedly lower conversion of the n-6 compared with the n-3 labelled fatty 
acids is apparent in terms of the percentage values shown for both diets in 
Table 6.5. Thus 13C EPA represents 24.6 %, of the total amount of labeled a- 
LNA in total plasma lipid in contrast to 13C AA which represents only 6 %  of 
total LA in total plasma, and with the mean total distribution of all labelled n-3 
metabolites (31%) also much higher than that of labelled n-6 metabolites (12.7
% , , p <  0 .0 0 1 ) .
6.3.6.2 Between diet comparisons: n-3 fatty acid series
Table 6.5 also shows that the distribution of the label in the flaxseed-oil diet 
was not significantly different from the high n-6 diet for a-LNA (72.1% ±13.2 vs. 
64.9% ±14.3) or EPA (23.5% ±11.6 vs. 26.3% ±13.8, flaxseed vs. high n-6,). 
However for DPA (n-3) (3.9% ±2.15 vs. 6.05%±2.2, flaxseed vs. high n-6) the 
differences was marginally significant, p=0.08 and for DHA the difference was 
highly significant being lower in the flaxseed-oil diet (0.5% ±0.25 vs 2.79% 
±1.07, p=<0.001). These results are visualised in Fig.6.15. This unexpected
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result indicates that the higher dietary n-6 did not depress 
conversion/incorporation of 13C a-LNA to its long chain n-3 derivatives but that 
on the contrary the conversion appeared to be higher at least after the a-LNA 
—► EPA conversion.
6.3.6.3 Between diet comparisons: n-6 fatty acid series
The profile of label detection for this series was similar to that of the n-3 series 
in that, there was no significant difference between the two diets for the 
distribution of the total label in LA (88.9% ±5 vs. 85% ±3.2 ns), DGLA (5.9% 
±2.57 vs. 7.4% ±1.6, ns) or AA (5.13% ±2.75 vs. 7.58% ±2.4, ns, flaxseed vs. 
high n-6).
6.3.6.4 Within diet comparisons of n-6 and n-3 conversions
In Fig 6.16 the distribution of total label appearing in the parent LA, a-LNA 
and their respective n-3 and n-6 fatty acid metabolites is shown. Thus any 
differences within each diet of the relative initial oxidation rates of the two 
administered labelled fatty acids, which would influence initial incorporation, 
can be assessed as well as within diet differences in n-3 and n-6 conversion 
rates.
For the flaxseed-oil diet label distribution was higher in LA (88.9% ±5), 
compared with a-LNA (72% ±13.2 for (p=0.002). In contrast, the distribution of 
the label in the n-6 metabolites in the same group was much lower, (11% ±5) 
than in the n-3 metabolites (27.9% ±13.3, p=0.003).
For the high n-6 diet a similar pattern of label distribution was observed with 
more initial labbeling of LA (85% ±3.2) than a-LNA (64.9% ±14.3, p=0.02) and 
much lower label in n-6 metabolites (14.9% ±3.2) compared with n-3 
metabolites (35% ±14.3, p=0.02).
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Table 6.5 Distribution of 13C labelling from ingested 13C labelled LA and a- 
LNA between n-6 and n-3 fatty acid series. Values show each fatty acid in a 
series expressed as a percent of the total observed labelling in the series.
Sub. ID a-
LNA
EPA DPA DHA Total n-3 
metabolites3
LA DGLA AA Total n-6
metabolites5
F la x seed -oil d ie t
F I 61.8 33.2 4.32 0.69 38.2 86.4 6.63 6.94 13.6
F2 93.1 5.8 0.75 0.42 6.9 96.2 1.92 1.85 3.8
F3 79.6 16.7 3.16 0.56 20.4 92.3 4.67 2.97 7.6
F4 55.6 38.3 5.28 0.85 44.4 82.8 7.84 9.36 17.2
F6 70.1 22.4 7.01 0.48 29.9 85.2 9.26 5.54 14.8
F5 72.3 24.7 2.89 0.13 27.7 90.4 5.49 4.11 9.6
A vg . 72.1 23.5 3.90 0.52 27.9 88.9 5.97 5.13 11.1
SD. 13.3 11.6 2.15 0.25 13.3 5.0 2.57 2.75 5.0
H ig h  n -6 d ie t
C l 63.3 25.0 7.81 3.90 36.7 86.7 5.36 7.88 13.2
C2 56.7 32.5 8.04 2.73 43.3 81.2 9.35 9.48 18.8
C3 54.1 39.9 4.65 1.35 46.0 83.8 7.40 8.86 16.3
C 4 85.5 7.6 3.70 3.16 14.5 88.4 7.50 4.10 11.6
A v g . 64.9 26.3 6.05 2.79 35.1 85.0 7.40 7.58 15.0
SD. 14.3 13.9 2.20 1.07 14.3 3.2 1.63 2.41 3.21
P - ns ns ns <.001 ns ns ns ns ns
V alu ec
B oth  diets
A v g . 69.2 24.6 4.76 1.43 30.8 87.4 6.54 6.11 12.7
SD. 13.4 11.9 2.33 1.34 13.4 4.6 2.26 2.78 4.62
P - Total n- 6 m etabolites v s. T otal n--3 m etabolites: p = <0.001
values
a Sum n-3 Metab. = sum of all n-3 fatty acid metabolites (EPA, DPA, DHA). 
b Sum n-6 Metab. = sum of n-6 fatty acid metabolites listed.
CP Values for comparison between subjects prefed the flaxseed-oil vs. high n-6 diets. 
See the abbreviation list.
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Fig. 6.15 Distribution of total label appearing in n-3 and n-6 fatty acids.
Label appearing in DHA, as a percent of total label, is significantly higher in the high 
n-6 (n=4) group than in the flaxseed-oil (n=6) group (p=0.0009). P-value for 
comparison between the two groups. Percentage data are calculated from total-area- 
under-the-time-course curve concentration data. See the abbreviation list.
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Distribution of label within each dietary group
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Fig. 6.16 Distribution of total label appearing in the parents LA, a-LNA (A) and 
their respective n-3 and n-6 fatty acid metabolites (B).
P-value for comparison within each dietary group. Percentage data are calculated 
from total-area-under-the-time-course curve concentration data. a-LNA; a-linolenic 
acid, LA; linoleic acid.
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6.3.7 Conversion intensity
6.3.7.1 n-6 fatty acid series
Demmelmair et al., (1999) have suggested that the transfer intensity can be 
expressed as the ratio of AUC of products, in this case DGLA or AA, with their 
precursor, LA. Such calculations require no definitions of the pathway, but it 
has to be assumed that the 13C-labelled LA from the measured phospholipid 
pool is the precursor of 13C-labelled DGLA and AA from the same 
phospholipid pools. The LA conversions expressed in this way are shown in 
Fig. 6.17 Conversion did not differ between diets for DGLA, 6.86 %  ±3.2 vs. 
8.75 %  ±2.2 (ns), but was marginally significantly lower for AA in the flaxseed- 
oil diet (5.92 %  ±3.4) compared with the high n-6 diet 9%  ±3.1 (p=0.09).
Within dietary group comparisons show that for both flaxseed-oil and high n-6 
diets, LA converted to DGLA and AA were similar at 6.9% ±3.2 vs. 5.9% ±3.4 
(DGLA vs. AA, flaxseed-oil ns), and 8.8%  ±2.2 vs. 9%  ±3.1 (DGLA vs. AA, 
high n-6 diet, ns).
6.3.7.2 n-3 fatty acid series
Fig 6.17 also shows that a-LNA conversion to EPA was high but did not differ 
between the diets at 44.9% ±27.8 vs. 35.9% ±22.5 (high n-6 vs. flaxseed-oil; 
ns). However rates of a-LNA conversion to DPA (n-3) were much lower at 
9.86% ±4.4 vs. 5.87% ±3.6 (high n-6 vs. flaxseed-oil; ns), even lower for DHA 
at 4.29% ±1.7 for the high n-6 diet and especially low for flaxseed-oil at 0.78% 
±0.5 on average (p=0.0002) with no detectable conversion in some subjects.
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Fig. 6.17 Long chain conversions (transfer intensity) of 13C-labelled LA and a- 
LNA to their n-6 and n-3 metabolites.
Values expressed as AUC of the products as a %  of AUC of the precursor. Transfer 
intensity of DHA is significantly higher in the high n-6 (n=4) than in the flaxseed-oil 
(n=6) group. See the abbreviation list.
Within dietary group comparisons show that for both control and flaxseed-oil 
diets there was a significant slowing of n-3 conversion after EPA (DPA 
formation was significantly slower than EPA formation; p=0.007, flaxseed-oil 
diet and p=0.04, high n-6 diet) and DHA formation was significantly slower 
than DPA (n-3) formation; p=0.006, flaxseed-oil diet and p=0.03, high n-6 diet.
6.3.8 Fish-oil diet
Although not part of the experimental design, one subject from the fish oil 
intervention group was studied. In this subject in line with the rest of this group 
discussed in chapter 2 plasma total EPA and DHA concentration were 
increased as a result of the EPA/DHA-supplemented diet compared to the 
flaxseed or high n-6 diets. Low levels of 13C enrichment of n-3 LC-PUFA were 
found on this diet. The concentrations of 13C n-3 LCFA metabolites were very 
low, suggesting that conversion of 13C-a-LNA may be lowered on a diet 
enriched with EPA & DHA. Fig.6.18 (A) and (B) shows data from one subject
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for percent conversion and the distribution of total label respectively, in 
relation to the flaxseed and high n-6 diets.
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Fig. 6.18 Influence of dietary fish oil (one subject) on 13C LA and a-LNA
conversion rates and distribution of label in comparison with the flaxseed 
and high n-6 diets.
(A) shows the %  conversion of the fish-diet in relation to the flaxseed and high n-6 
diet. (B) shows the distribution of total label of the fish-diet in relation to the flaxseed 
and high n-6 diet. See the abbreviation list.
6.3.9 13C -labeled n-3 and n-6 fatty acids in erythrocyte membrane
As discussed in the methods section a set of some but not all samples of red 
blood cell phospholipids (flaxseed oil; n=2 and high n-6; n=3) were analysed. 
This set was incomplete because for some subjects there was not sufficient 
red blood cell sample remaining to enable the analysis. Thus these studies 
are presented as a guide to the long chain conversion of LA and a-LNA as 
observed in the red cell phosphatidylcholine phospholipid compartment. 
Given the small numbers no statistics can be applied to the data.
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6.3.9.1 Enrichments (Atom percent excess: APE)
APE n-3 scries (A)
2.5
—  a-LNA flaxseed 
-»—  EPA flaxseed
—  DPA flaxseed 
-*—  DHA flaxseed
a-LNA high n-6 
..... epa high n-6 
■a- • DPA high n-6 
DHA high n-6
APE n-6 series (B)
0.8
—♦—  LA flaxseed 
—»—  DGLA flaxseed 
—e— AA flaxseed 
- LA high n-6 
DGLA high n-6 
-A---AA high n-6
Time (hours)
Fig. 6.19 Atom percent excess (APE) for the n-3 (A) and the n-6 fatty acids (B) 
in erythrocyte phosphatidylcholine (PC).
Data shown for the flaxseed-oil (n=2) and high n-6 (n=3) diets. Data shown as means 
± SD. See the abbreviation list.
The patterns of atom percent excess (APE) in erythrocyte phosphatidylcholine 
(PC) are presented in Fig. 6.19 (A) for the n-3 and (B) n-6 fatty acids series. 
For the n-3 fatty acid series the 13C enrichment of both a-LNA and EPA were 
considerably higher (3-4 fold) in the high n-6 compared with the flaxseed 
group, although less difference was identified in DPA (n-3). For DHA no
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enrichment was observed for the flaxseed oil subjects (n=2 ) but enrichment 
albeit at very low levels, was observed after 10 days for each of the high n-6 
subjects (n=3).
For n-6 fatty acid series dietary influences on 13C enrichment were small if 
present at all.
6.3.9.2 Analysis of area under the red blood cell 13C fatty acid labelling curves
The isotopic labelling expressed as AUC of the total 13C versus time plots for 
a-LNA and LA and their conversion products in erythrocyte PC in individual 
subjects on both diets is shown in Table 6.6 and graphically in Fig 6.20 and 
6.21. For the n-3 series, these results show that compared with the large 
dietary differences in a-LNA and EPA enrichment shown above (Fig 6.19), the 
AUC for total 13C labelling of a-LNA and n-3 metabolites were less different 
between the diets although values were still slightly higher for the high n-6 
compared with flaxseed oil, with no labelling at all observed in DHA in the 
flaxseed subjects (see Fig.6.20).
For the n-6 series, these results show that the AUC for total 13C labelling of LA 
and n-6 metabolites were very similar in each dietary group (see Fig.6.20).
Table 6.6 Concentration (pg/ ml) of 13C a-LNA, 13C-LA and their fatty acid
metabolites in erythrocyte PCa.
Subject aLNA EPA DPA DHA Sum n-3 
metab.5
LA DGLA AA Sum n-6 
metab.5
Flaxseed-oil
F5 0.092 0.032 0.010 0.000 0.043 0.849 0.013 0.021 0.035
F6 0.034 0.024 0.006 0.000 0.030 0.454 0.007 0.010 0.018
A v g . 0.063 0.028 0.008 0.000 0.036 0.652 0.010 0.016 0.026
Sd . 0.041 0.006 0.003 0.000 0.009 0.279 0.004 0.008 0.012
High n-6
C2 0.129 0.071 0.019 0.003 0.093 0.931 0.015 0.047 0.062
C3 0.109 0.043 0.019 0.001 0.063 0.870 0.009 0.015 0.024
C4 0.048 0.002 0.003 0.002 0.007 0.390 0.004 0.007 0.011
A vg . 0.095 0.039 0.014 0.002 0.054 0.730 0.009 0.023 0.032
S d . 0.042 0.035 0.009 0.001 0.043 0.296 0.005 0.021 0.026
All Subjects 
A v g . 0.083 0.035 0.012 0.001 0.047 0.699 0.010 0.020 0.030
Sd . 0.040 0.025 0.007 0.001 0.033 0.255 0.004 0.016 0.020
a Concentration (pg/ml) for the label fatty acids and their metabolites calculated by 
integrating the areas under the time course curves. 
b Sum n-3 (EPA, DPA, DHA) or n-6 (DGLA, AA) fatty acid metabolites.
See the abbreviation list.
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High n-6 Flaxseed-oil
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n-3 Fatty acids n-6 Fatty acids
Fig. 6.20 Concentrations of 13C-labeled individual fatty acids in erythrocyte PC. 
n-3 (A) and n-6 (B) series for flaxseed-oil (n=2) and high n-6 (n=3) diets. Data 
plotted are for the total areas under the time-course curves per ml of red blood cells. 
See the abbreviation list.
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Fig. 6.21 Concentrations of 13C-labeled a-LNA & LA and total n-3 and n-6 
metabolites in erythrocyte PC.
(A) a-LNA vs. LA of flaxseed-oil (n=2) and high n-6 (n=3) diets. (B) n-3 and n-6 fatty 
acid metabolites. Data plotted are for the total areas under the time-course curves 
per ml of red blood cells. a-LNA; a-linolenic acid, LA; linoleic acid.
Between n-6 and n-3 series comparisons are shown in Fig 6.21. Initial 
labelling of LA was much higher than that of a-LNA for both diets. However 
differences between the n-3 and n-6 metabolites were much less marked on 
either diet.
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6.3.9.3 Desaturation and elongation as indicated by distribution of isotope
The distribution of the label in both n-3 and n-6 fatty acid series are shown in 
Table 6.7. For the n-3 fatty acid series, the distribution of the label was on 
average 66%, 25%, 9%  and 1% for a-LNA, EPA, DPA and DHA, i.e. a total of 
34% in metabolites with no marked dietary differences except for the lack of 
DHA labelling in the flaxseed group.
For the n-6 fatty acid series, the distribution of the label was on average 96% 
1% and 3%  for LA, DGLA and AA, i.e. a total of 4%  in metabolites with no 
marked dietary differences (See Fig.6.22 for the distribution of total label in n- 
3 and n-6 fatty acids).
Table 6.7 Distribution of 13C labelling from ingested 13C labelled LA and a- 
LNA between n-6 and n-3 fatty acid series in erythrocyte PC. Values show 
each fatty acid in a series expressed as a percent of the total observed 
labelling in the series.
Sub. a - E P A D P A D H A Sum  n-3 L A D G L A A A Sum  n-(
ID L N A m etab.b m etab b
F la x se e d -o il
F5 68 .4 2 4 .0 7 .7 0.00 31 .6 96.1 1.51 2 .4 3.91
F6 53.1 37.3 9 .7 0.00 4 6 .9 96.3 1.57 2 .1 6 3 .7 4
A v g . 6 0 .7 3 0 .6 8 .7 0.00 39.3 96 .2 1.54 2 .28 3.83
S d . 10.8 9 .4 1.4 0.00 10.8 0.13 0 .04 0 .1 7 0 .13
High n-6
C 2 58 .0 32.1 8.5 1.34 4 2 .0 93 .8 1.50 4 .7 2 6 .22
C3 6 3 .4 2 5 .0 10.9 0 .69 3 6 .6 9 7 .4 0 .98 1.66 2 .6 4
C4 86 .7 4 .2 6.1 2 .9 6 13.3 97.1 1.07 1.78 2 .8 6
A v g . 6 9 .4 2 0 .4 8.5 1.66 3 0 .6 96.1 1.19 2 .7 2 3.91
Sd . 15.3 14.5 2 .4 1.17 15.3 2 .0 0 .28 1.73 2.01
All Subjects
A v g . 65 .9 2 4 .5 8.6 1.00 34.1 96.1 1.33 2 .55 3 .87
S d . 13.0 12.6 1.8 1.23 13.0 1.4 0 .28 1.25 1.42
b Sum n-3 (EPA, DPA, DHA) or n-6 (DGLA, AA) fatty acid metabolites. 
See the abbreviation list.
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Distribution of total label
120i □ Flaxseed-oil 
■  High n-6
Fig. 6.22 Distribution of total label appearing in n-3 and n-6 fatty acids in 
erythrocyte PC.
Percentage data are calculated from total-area-under-the-time-course curve 
concentration data. See the abbreviation list.
6.3.9.4 Conversion intensity
The conversion intensity or transfer intensity, expressed as the ratio of total 
13C AUC of products, with their precursors either LA or a-LNA, are shown in 
Fig 6.23. As observed in the plasma phospholipids, conversion of the n-3 
series was much higher than for the n-6 series.
For the n-3 series conversions of a-LNA were on average 40%, 14% and 1% 
for EPA, DPA and DHA (no conversion for the flaxseed subjects).
For the n-6 series conversions of LA were on average 1.5% and 2.6% for 
DGLA and AA.
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Conversion rates
Flaxseed-oil 
High n-6
DCLA EPA DPA DHA
Fig. 6.23 Long chain conversions (transfer intensity) of 13C-labelled LA and 
a-LNA to their n-6 and n-3 metabolites.
Values expressed as AUC of the products as a %  of AUC of the precursor. See the 
abbreviation list.
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CHAPTER 7 DISCUSSION OF STABLE ISOTOPE STUDIES
This study was designed to determine the extent of the long chain conversion 
of 13C a-LNA to EPA, DPA (n-3) and DHA and especially the influence of a 
low n-6 high a-LNA diet as opposed to a high n-6 diet on the conversion.
7.1 Shortcomings in the isotopic analysis
Two sets of analysis were performed. Analysis 1 was based on stable 
isotope measurements of PC fatty acid fractions of plasma and red cells 
membranes prepared by the investigator and analysed under contract by the 
University of Southampton because of the late arrival of the GC-Combustuion 
mass spectrometer at Surrey. These measurements were unsatisfactory, 
mainly because of the lack of an internal standard in the initial preparation of 
the samples sent for analysis, which precluded accurate quantitation of the 
total 13C labelling of the fatty acids. This error was rectified in analysis 2 
which was based on the total plasma lipid pool and with stable isotope 
measurements made by the investigator in the instrument in the Nutrition 
laboratory at Surrey, after it had been installed.
In one respect both analyses reached the same conclusion of a) considerable 
conversion of a-LNA to EPA, with much less conversion to DPA and very little 
conversion to DHA, b) little or no dietary effect of the background dietary a- 
LNA:LA ratio on a-LNA conversion to EPA. However there were two important 
differences between the two analyses.
Firstly there were no observed dietary influences on DHA formation in 
analysis 1 while in analysis 2, DHA formation was lower in the subjects fed the 
flaxseed oil diet. However a likely explanation of this difference is that in both 
sets of analysis 13C labeling of DHA was very low indeed and in analysis 2, 
there was more opportunity to examine baseline enrichments and instrument 
variability. As a result a more stringent analysis of the DHA enrichment was 
made.
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Secondly there was a difference between the two analyses in the extent of 
initial conversion of a-LNA conversion to EPA. Thus whilst both showed that 
there was substantial conversion of a-LNA to EPA, analysis 1 indicated a very 
high proportion of label in EPA compared with a-LNA, suggesting >100% 
conversion, while analysis 2 showed what might be considered to be a more 
reasonable value of 30-50% conversion. There is no completely satisfying 
explanation of this difference. However there is considerable uncertainty 
about the quantitation of tracer in analysis 1 because of the lack of the internal 
standard and use of “guestimates” of concentrations based on separate 
measurements of fatty acid profiles in the subjects. The potential also exists 
for tracer compartmentation problems between the phospholipid subtractions 
measured in analysis 1 which would not be so marked in the total plasma pool 
measured in analysis 2 , although the actual relationship between each fatty 
acids measured in plasma and the intracellular pool where desaturation and 
elongation occurs is unknown. For these reasons the rest of this discussion 
will focus on analysis 2 .
7.2 Shortcomings in the experimental design
The experimental design deployed in these studies was primarily established 
to identify the extent of any conversion of a-LNA to both EPA and DHA, with 
DHA predicted to be slow turning over and therefore requiring sampling over 
an extended time period. Because of this and the need to ensure subject 
compliance as far as repeated blood sampling over a 2 week period, a more 
invasive protocol involving continuous C 0 2 collection and more frequent blood 
sampling over the initial few days was not deployed. (In any case given that 
both n-6 and n-3 tracers were given measurement of C 0 2 oxidation would not 
have discriminated between the two tracers). The problem with such a design 
is that if the peak enrichment of a-LNA was achieved earlier than 24 hrs then 
there will be an underestimation of the a-LNA 13C AUC and if this is more 
marked for a-LNA than for EPA then there will be an overestimation of the a- 
LNA conversion rate. However measurements were made in one subject with 
blood sampling within the first 24 hrs enabling an estimate of the likely error to
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be calculated. This data is shown in Fig 7.1 with the AUC values and derived 
conversion rates (AUC product/AUC precursor %) shown in Table 7.1.
APE n-6 series-RBC
Time (hr)
APE n-3 series-RBC
a-LNA
Time (hr)
Fig. 7.1 Time course of labeling measured during the first 24 hrs and 
subsequently in one subject (C5).
Table 7.1 Error associated with calculation of the AUC (APE values) values 
with 24 hr time point as first measurement.
Fatty acids AUC total3 conversion AUC 0-24b conversion overestimate0
%
n-6 series
LA 18.1 17.0
DGLA 6.8 37.9 6.9 40.3 6.5
AA 1.5 8.1 1.4 8.1 0.2
n-3 series
ALA 79.0 70.8
EPA 19.9 25.1 20.0 28.3 12.5
DPA 11.9 15.1 11.4 16.1 7.0
DHA 0.8 1.1 0.8 1.1 0.8
a AUC calculated for the curves shown in Fig 7.1.
b AUC calculated for the curves shown in Fig 7.1 assuming that the first measured 
time point is at 24hrs.
c Extent that the conversion value calculated from the AUC 0-24 overerestimates the 
true AUC.
See the abbreviation list.
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The AUC values and derived conversion rates are calculated for both the 
complete time course values or assuming that the first measured value was at 
the 24 hr time point. The extent of the overestimation of the true conversion 
rate is shown as a %. The errors were overestimates of 6.5% and 0.2% for 
the n-6 series conversions and 12.5%, 7% and 0.8% for the n-3 series. 
However other fractions would probably be more highly labeled than the red 
blood cell membrane so that these may be underestimates of the errors. 
Vermunt et al., (2000) reported that after a single dose of 13C a-LNA peak 
labeling in total plasma lipids was 5-7 times that at 24 hrs, similar to results 
reported by Burdge et al., (2002) for 13C a-LNA peak labeling in the TAG 
fraction at 4 hrs. This would mean that true a-LNA conversion to EPA will be 
less than the value of 25% shown in Table 7.1, so that the underestimate 
error will be larger than the 12.5% shown. Thus although the results in Table
7.1 might be an underestimate of the error, the extent of any underestimate 
cannot be predicted for the present results with any certainty. In any event 
these errors are unlikely to influence the conclusions of this study in terms of 
the relative conversion of 13C a-LNA to EPA and DPA (n-3) compared with 
DHA.
7.3 Power of the study
The numbers of subjects studied here were very small, i.e. an initial plan of 6 
subjects per group. This was of necessity given the high cost of the isotope at 
$4000 per subject. Also the CV of the measured values a-LNA or LA 
conversion was not known in advance. In fact the CV of the 13C a-LNA-> EPA 
conversion was (Fig 6.17) 60%. This means that to detect a 50% difference 
with a & (3 errors set at 0.05, (a error =probability of type 1 error: finding a 
difference when there isn’t one; p error= probability of type 2 error: not finding 
a difference when there is one), sample size must be 39 subjects or 24 if the 
Beta error is set at 0.2. Thus for an n=6 this would allow a difference of 140% 
to be detected. Whilst the difference between the a-LNA—► EPA conversions 
was much less than this (44.9% ±27.8 vs. 35.9% ±22.5 (high n-6 vs. flaxseed- 
oil) and not significant, the difference between the DHA synthesis rates, i.e. a-
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LNA—> DHA, at 4.29% ±1.7 and 0.78% ±0.5 (high n-6 vs. flaxseed-oil), was 
greater than this which did allow detection of the difference as significant.
7.4 Calculations of conversion rates
As far as the estimation of the extent of the long chain conversion of 13C a- 
LNA and LA to very long chain products is concerned, several approaches to 
this were made.
Firstly the areas under the 13C labelling curves were computed and 
comparisons made between the two diets for each of the conversion products 
which were detected in sufficient quantities to allow measurement, i.e. for the 
n-6 series DGLA and AA, and for the n-3 series EPA, DPA and DHA. Whilst 
this is a reasonably valid estimate of the relative amounts of the labelled fatty 
acids formed from the administered tracer, it is influenced by the initial 
metabolic fate of the tracer as far as any “first pass” effect. This involves 
uptake of the administered tracer by the splanchnic bed after ingestion, and its 
disposal through oxidation before it appears in the measured plasma pool. 
Thus dietary differences in any first pass effect could influence the relative 
AUC of the administered fatty acid and consequently, the AUC values of 
conversion products independently of variation in the conversion rate.
In fact it is known that a-LNA is normally used for energy and as a carbon 
source to a greater extent than for direct biosynthesis. In adult humans, about 
24% of ingested a-LNA was oxidized completely to C 0 2 within the first 10-24 
h in two studies (Delany et al., 2000; Bretillon et al., 2001). One of these 
studies reported that the diet consisted of 40% energy as fat with an LA/a- 
LNA ratio of 11:1 and a-LNA content of 0.7% energy, which is a typical of a 
western diet (Delany et al., 2000). A  study of normal and x-linked retinitis 
pigmentosa adult males reported that cumulative C 0 2 collected to a plateau at 
7 days was about 60% of the ingested dose (Hoffman et al., 2001). This is 
consistent with recent data appearing in abstract form, which also details 
collected breath for 7 days and shows that oxidation of a-LNA totalled 
69±29% (McCloy & Cunnane, 1999). The effects of dietary a-LNA on a-LNA 
oxidation in humans has been studied by Vermunt et al., (2000) who found
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that the mean proportion of labeled a-LNA recovered as 13C 0 2 in breath after 
12 h was slightly, although not significantly, higher in the a-LNA group 
compared to the oleic acid group, suggesting that the oxidation of a-LNA may 
not be inhibited by dietary a-LNA. Burdge et al., (2002) reported that 33% of 
administered 13C a-LNA was recovered as 13C 0 2 on breath over the first 24h, 
when studying young men consuming their habitual diet. However, in another 
study conducted in young women subjects, Burdge & Wootton (2002) 
reported a lower fractional oxidation of 13C a-LNA than in men, the 
investigator further suggested a selective sparing of a-LNA from p-oxidation in 
women, in addition, women tend to use carbohydrate as the preferred 
metabolic fuel in both the fasted (Toth et al., 1998) and post-prandial state 
(Jones et al., 1998). Both processes would potentially increase availability of 
n-3 fatty acids to peripheral tissues. Vermunt et al., (1999) found that the 
mean proportion of labeled a-LNA oxidized after 12 hr was about 18%, and 
was slightly higher in an EPA/DHA supplemented group compared to an oleic 
acid supplemented group.
Acetate resulting from partial oxidation of a-LNA and recycled as a carbon 
source is best known for de-novo lipid synthesis of saturated and 
monounsaturated fatty acids and cholesterol. The relative amount of recycled 
labelled a-LNA appearing in saturates and monounsaturates has been 
measured as high as 30-fold in the liver and brain of neonatal rodents and 
three-fold in neonatal primates (Sheaff et al., 1996; Cunnane et al., 1999) 
compared with the amount of labelled a-LNA appearing in n-3 LCP.
The metabolic pathways for long-chain fatty acids normally include oxidation 
to C 0 2 and H20 , secretion by the liver via VLDL or bile (especially in 
phosphatidylcholine), and incorporation in membrane phospholipids (Adam et 
al., 1986). Lands et al., (1982) reported on a preferential handling of 
polyunsaturated fatty acids by 1-acyl-sn-glycerol-3-phosphocholine 
acyltransferase, but found no differences among the polyunsaturated fatty 
acids of the n-6 and n-3 series. Absorption studies showed a 100% resorption 
of dietary n-3 fatty acids when the feces were monitored for fatty acid loss 
(Adam et al., 1986). However, when uptake was measured in rat chylomicrons, 
a lower concentration of a-LNA was observed, compared to LA (Vahouny,
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1984). An incorporation of a-LNA into liver phospholipids 5 hr postprandially 
was studied, proven by liver biopsy after an acute 100-ml linseed oil load. At 
no time in this experiment (1-26 hr) did a-LNA incorporation into liver lipids of 
man exceed 12 % of the 18:3 n-3 dose, while in plasma free fatty acids a 
higher percentage of a-LNA was observed. Monitoring 14C 0 2 production in 
these experiments revealed a higher oxidation rate for a-LNA than for LA. 
Taken together, these observations indicate that low a-LNA concentrations in 
plasma are due to a deposition of a-LNA in certain tissues (e.g., intestinal 
mucosa triglycerides) and/or by preferential oxidation of a-LNA (Adam et al., 
1986).
The second method of expressing conversion was calculation of the 
distribution of the label (expressed as percentages of total 13C for that series) 
between each of the fatty acids in the series and comparisons made between 
the two diets. This in effect compensates for any “first pass” differences 
examining in effect the relative metabolic fate of the ingested fatty acids after 
it has appeared in the plasma.
The third method of expressing the conversion of LA and a-LNA to their 
respective products was to calculate the AUC product/AUC LA or a-LNA 
(precursor). This is similar to calculating distribution of label but only takes into 
account the ingested fatty acid and one specific product.
The relative excursions of labelled fatty acids in plasma have been used 
previously to estimate fractional conversion of a-LNA to longer-chain 
metabolites (Emken et al., 1994, 1998, 1999; Burdge et al., 2002; Burdge & 
Wooton, 2002). The limitation of this approach is that it probably reflects an 
underestimate of hepatic conversion due to partitioning of metabolites into 
storage pools and towards b-oxidation, and differential incorporation into and 
turnover within plasma lipids. However, in the absence of techniques for 
measuring hepatic a-LNA conversion directly the results of such calculations 
are useful for comparative purposes within and between studies. In addition, it 
must be emphasized that absolute values cannot be obtained for precursor 
and product because the measured plasma enrichment do not reflect
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enrichment in liver ceils because of dilution of newly synthesized lipids by 
lipids already present in plasma. This effect would be minimised by the 
analysis of isolated very low-density lipoproteins (VLDL) secreted by the liver 
(Demmelmair e ta l., 1999).
Vermunt et al., (2000) have argued against use of AUC comparisons to 
estimate conversion rates as adopted by Emken et al. (1994, 1998,1999) and 
Burdge et al., (2002) and Burdge & Wooton, (2002) in the studies quoted 
above. They argue that after a single dose lack of a steady state and the 
overlapping characteristics of the tracer labelling curves precludes such 
calculations as suggested by Demmelmair et al., (1999). However in the 
detailed kinetic analysis of bolus versus repeated administration of tracer 
reported by Demmelmair et al., (1999), there were in fact reasonable 
correlations between conversion rates from AUC comparisons and 
compartmental analysis calculations of fractional turnover rates. For these 
reasons in the current work it has been assumed that any error in the use of 
the AUC values will not influence our findings.
7.5 Main findings of the study
The fractional excursions of labelled fatty acids in total plasma lipids for all 
subjects studied (n=10) over 336 hrs was a-LNA 69%, EPA 25%, DPA (n-3) 
5%, and DHA 1.4%, indicating conversion rates of 36%, 7% and 2% for a- 
LNA to EPA, DPA (n-3) and DHA. For the n-6 series fractional excursions 
over 336 hrs were 87%, 6.5%and 6.1% for LA, DGLA & AA indicating 
conversion rates of 7.8% and 7.5%.
7.5.1 n-3 compared with n-6 conversion
In the present study, differences in the amounts of labelled LA and a-LNA 
converted to their respective long-chain length polyunsaturated fatty acid 
metabolites were observed: i.e. a much higher absolute and proportional 
amount of 13C tracer in n-3 LC-FA metabolites than in n-6 LC-FA metabolites.
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This occurred even though the initial labelling as indicated by the 
concentration of the precursor 13C l_A was 1.7-fold higher than the 
concentration of the precursor 13C a-LNA. Although it might be thought that 
because enzyme reactions are generally pseudo first order reactions, a higher 
amount of n-6 LC-FA metabolites would be expected, a more likely 
explanation is that the high initial turnover of the LA which results in a higher 
initial incorporation of tracer, is associated with loss of LA to a pool involving 
either oxidation or storage rather than elongation and desaturation. 
Furthermore there was no significant difference between the flaxseed and 
high n-6 diet in the percentage of LA converted to DGLA or AA.
These data did not show a precursor-product relationship between DGLA and 
AA. This does not necessarily mean that intracellular DGLA is not desaturated 
to AA, but if dilution in plasma were different for the two fatty acids, e.g. 
because of different exogenous supply, such a relationship might be 
undetectable in our data. This is in contrast to the results obtained with the n-3 
fatty acids series. This did show a precursor-product relationship between 
EPA, DPA (n-3), and DHA, the AUC values of which were all significantly 
different from each other within each dietary group.
In fact this low distribution of total label for n-6 metabolites is consistent with 
both in vivo and in vitro results from other human studies (Cunnane et al., 
1984; Emken et al., 1989) and with animal data that show 18:2 n-6 competes 
with itself and 18:3 n-3 (Hwang et al., 1988; Ackman & Cunnane, 1991; 
Diboune et al., 1992)
Emken et al., (1994) studied healthy young subjects fed diets enriched with 
either n-6 polyunsaturated fats (PUFA diet, 30 g/d LA) or saturated fats (SAT 
diet, 15 g/d LA) for 12 days. Data re-calculated from his paper shows no 
significant difference for the percentage of LA converted to DGLA, and the 
percentage of LA converted to AA (PUFA vs. SAT).
With a different objective and using a compartmental modelling, (Demmelmair 
et al., 1999) compared a bolus vs. fractionated oral application of 13C -LA in 
humans subjects who were consuming omnivorous diets, finding that
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fractional conversion of LA to DGLA was very low in each case (1.5% vs. 
2.1%: bolus vs. fraction, p<0.05), with fractional conversion of LA to AA at 
0.3% vs. 0.6% (bolus vs. fraction, NS).
Nevertheless the differences between n-6 and n-3 conversion observed here 
are not easily explained. If one accepts that A6-desaturase is the common 
rate-limiting step in the conversion pathway for both LA and a-LNA (Ackman & 
Cunnane, 1991), then the concentrations and the distribution of label n-6 and 
n-3 LC-FA should be similar or at least proportional to the concentrations in 
plasma lipid (Emken et al., 1994). A  difference in the selectivity of A6- 
desaturase for LA and a-LNA is a plausible explanation for the difference in 
conversion observed in this study. These in vivo data for labeled n-6 and n-3 
LC-FA metabolites indicate that A6-desaturase is about 1.9 times more 
selective for a-LNA than LA. This selectivity is reasonably consistent with the 
1.5-3.0-fold difference in A6-desaturase conversion rates for LA and a-LNA 
reported for in vitro studies with rat liver microsomes (Sprecher, 1989, 1992).
Another possible explanation for the observed difference in the conversion 
data for labeled LA and a-LNA is that a second pathway exists for the 
conversion of a-LNA to n-3 fatty acid metabolites and that this pathway does 
not involve 6-desaturation as a rate limiting step (Cook et al., 1991). Evidence 
has been reported for conversion of a-LNA to DHA in 5 lines of cultured cells 
(rat glioma, mouse neuroblastoma, human fibroblast, HTB-10 and HTB-11 
human neuroblastoma) by a non-classical pathway that involves A8- 
desaturase (Cook et al., 1993). It is not clear whether one or a combination of 
these proposed explanations is the reason more a-LNA than LA is converted 
to their respective LC-FA metabolites as has been observed in this study.
In vitro, LA and a-LNA is observed to compete for A6-desaturation, the first 
step in the biosynthesis of LC-PUFA (Brenner & Peluffo, 1969; Garg et al., 
1988). By simple analogy, the increased tissue LA concentration in the high n- 
6 group would have been expected to slow the rate of a-LNA conversion. In 
vivo tissue compositional studies of dietary LA and a-LNA is consistent with 
this idea. For instance, early work showed that increasing dietary LA levels
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inhibited accretion of a-LNA derived LC-PUFA (Rahm & Holman, 1964), while 
increasing a-LNA levels inhibited accretion of LA derived LC-PUFA 
(Mohrhauer & Holman, 1963). In a study of adult young men conducted by 
Emken et al., (1994), based on area-under-the curve (AUC) calculations of 
tracer data, results showed that high intake of LA inhibited its own conversion 
as well as that of a-LNA to long-chain metabolites, possibly via saturation of 
enzymes. They reported that an intake of 30 g/day LA resulted in a 40 to 54 
percent lower conversion of stable-isotopically labeled linoleic and a-LNA to 
their metabolites compared to an intake of 15 g/day.
7.5.2 a-LNA conversion
In the subjects of this study, middle aged males, there was extensive (a-LNA 
conversion to EPA but much less to DPA (n-3) and especially DHA, with no 
obvious dietary effect on a-LNA conversion apart from lower conversion to 
DHA in subjects fed the flaxseed-oil diet compared with the high n-6 diet.
7.5.3 Conversion to EPA
As indicated above for all subjects studied conversion rates were 36%, 7% 
and 2% for a-LNA—► EPA, a-LNA—> DPA and a-LNA-> DHA. In contrast 
Emken et al., (1994) gave deuterium-labelled a-LNA and LA acids to young 
adult males for 48 hrs (n=7) and reported lower values for EPA formation i.e. 
values of 85%, 6%, 3.5%, and 3.8% indicating conversion rates of 7%, 4% 
and 4% for EPA, DPA (n-3) and DHA. Part of the difference probably relates 
to the shorter time period since after 48 hrs, whilst a-LNA labelling is falling, 
EPA labelling was still increasing, so the relative AUC values for EPA 
compared with a-LNA would increase with time. The ideal experimental 
design would involve measurements until labelling of all products has fallen to 
baseline. However studies in young men in total plasma lipids by Burdge et 
a!., (2002) which did extend over 21 days, also reported lower values for EPA 
formation, i.e. isotope distribution of a-LNA 84%, EPA 7.9%, DPA (n-3) 8.1%, 
and DHA 0%, equivalent to conversion rates of 9.4 and 10% for EPA and DPA
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(n-3). This was in contrast to their measurements of the conversion of a-LNA 
in young women (Burdge & Wooton, 2002), i.e. values of EPA 21%, DPA (n-3) 
6%, and DHA 9%.
Taken together these data show that whilst a-LNA conversion to DPA (n-3) in 
the present study (5%) was similar to or slightly lower than that reported 
previously (e.g. 6.0%, Emken et al. 1994, 10% Burdge et al., (2002), a-LNA 
conversion to EPA (36%) was about four-fold that reported by these authors in 
men in fact similar to the values for women reported by Burdge & Wooton,
(2002).
7.5.4 Conversion to DHA
These results suggest that in the subjects studied here, on both diets, 
although there was marked a-LNA conversion to EPA subsequent conversion 
of EPA to DPA (n-3) and especially DHA was inhibited to a considerable 
extent.
7.5.5 Diet and relative Iona chain conversions of LA and a-LNA
In the present study, there were markedly different dietary n-3:n-6 ratios: i.e. 
n-6;n-3 ratio = 0.4 through 18g/day a-LNA + 8g LA, compared with n-6:n-3 
ratio = 30 with 1 g/day a-LNA+ 25g LA. Yet in each case substantial initial a- 
LNA conversion occurred, with much lower LA conversion with no detectable 
dietary influences. Only at the level of DHA formation were dietary effects 
observed with the low level of conversion observed on the high n-6:n-3 ratio. 
There is little published work on the effects of high and low n-6:n-3 ratios on 
LA conversion. Emken et al., (1998) reported that a diet rich in AA has no 
significant effect on the low conversion of deuterated LA into AA, and in 
discussing this suggested that the reduced conversion of deuterated LA is 
caused by LA from the diet. Clearly the present results are contrary to this 
since no effect of altered LA intake was observed on LA conversion to either 
DGLA or AA. It may be of course that the high LA content of body fat stores 
negated the low dietary intake. Thus as shown in chapter 3 after the
157
intervention with a-LNA, and a low LA diet whilst LA levels in RBC 
phospholipids were lowered compared with the high LA diet, they were still 
very high compared with concentrations of a-LNA.
These findings of little dietary effects on a-LNA conversion are in contrast to 
those of Vermunt et al., (1999, 2000), who have also reported human in vivo 
studies of the effects of diets rich in a-LNA or MUFA (oleic acid) on 13C a- 
LNA conversion to LC-PUFA in both healthy elderly subjects (age > 60yr), or 
younger subjects. They showed a lowered conversion of a-LNA to EPA 
(p=0.01) and lower mean vales for DPA & DHA with the n-3 rich diets.
One difficulty of making these dietary comparisons is the large variation 
between individuals and the small sample size of the studies. Clearly as 
shown in Fig 7.2 there is very marked between subjects variation which is 
much greater than would be expected from the experimental error likely to 
occur in these studies as detailed in chapter 6. Such very marked variation 
was also reported by Burdge et al. (2002 b).
Variability in 13C labelling of a-LNA conversion products
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Fig. 7.2 Variability in 13C labelling of a-LNA conversion products.
Individuals values for the 13C fatty acid concentrations (AUC of 13C fatty acid 
concentration time courses over the study) for the two dietary groups.
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Fig. 7.3 Variability in 13C labelling of a-LNA conversion products.
Redrawn from Vermunt et al. (2000). Individuals values for the maximum 13C fatty 
acid concentrations after a dose of 13C a-LNA in subjects fed either a high a-LNA or 
high MUFA diet.
The extent of the variability in the study reported by Vermunt et al., (2000) is 
shown in Fig 7.3. Similar variability is seen as in the present studies. 
Furthermore whilst they report significant differences between EPA formation 
(p=0.01) it is clear that 2 out of the 5 control (high MUFA) subjects responded 
exactly as the mean of the high a-LNA group. This emphasises the difficulty of 
drawing firm conclusions about the presence or absence of dietary effects.
Because of this and the high cost of these studies which limits the subject 
numbers which can be studied dietary differences are unlikely to be identified 
in human studies unless they are very marked.
Animal studies confirm our finding of substantial a-LNA conversion in the 
presence of a high n-6 LA diet. Thus Lin et al., (1991) showed in a chick 
embryo model that LC-PUFA n-3 fatty acids are efficiently incorporated from
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yolk to chick in embryos of safflower oil-fed hens (high LA, low a-LNA) i.e. a 
high LA levels did not inhibit overall LC-PUFA n-3 accretion from available a- 
LNA. Furthermore a lower efficiency was observed in embryos with a more 
plentiful source of a-LNA as we showed for DHA. Indeed rat studies by 
Brenna and his co-worker (Sheaff et al., 1995) have shown that high dietary 
levels of LA increase conversion of labeled a-LNA to DHA in liver compared 
with of low dietary levels of LA suggesting that whilst high levels of tissue n-6 
fatty acids compete at the level of isotope incorporation, they do not appear to 
inhibit conversion.
7.5.6 DHA synthesis
The results of this study are in broad agreement with previous reports in adult 
humans which show some conversion of a-LNA to EPA but very marginal if 
any DHA synthesis (Emken et al., 1994; Salem et al., 1999; Vermunt et al., 
1999, 2000; Pawlosky et al., 2001, Burdge et al., 2002). The present studies 
have shown that at least as far as red cell membrane DHA concentrations are 
concerned, dietary a-LNA is ineffective in increasing DHA compared with a 
preformed source of DHA, (see Chapter 3).
The erythrocyte fatty acid pool has been used in a number of studies as an 
indicator of uptake of dietary fatty acids although differences might be 
expected between the erythrocyte PC and total plasma lipids because of 
compartmentation. Burdge et al., (2002) found no significant 13C enrichment 
of erythrocyte PC DHA whereas, our results demonstrated, some conversion 
especially in the absence of n-3 fatty acids, as we observed in total plasma 
lipids (Chapter 7).
Several reports examining neural concentrations of DHA indicate that a-LNA 
is a much lesser dietary source than a preformed source of DHA (Woods et al., 
1996; Abedin et al., 1999; Su et al., 1999; Bowen & Clandinin, 2000). 
Nevertheless any significant conversion is important and this question has 
been especially examined in infancy. The important issue of the perinatal
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conversion efficiency of a-LNA and formation of DHA has been investigated 
with clear evidence of DHA synthesis. Administration of labeled a-LNA to 
baboon fetuses demonstrates that the conversion is actively performed in 
primates in vivo (Su et al., 1999), with the brain accumulating about 4.6% of 
the dose as DHA.
Stable isotope tracer studies have established qualitatively that premature 
infants can perform the conversion from a-LNA to DHA, as well as LA to AA 
(Carnielli et al., 1996; Salem et al., 1996; Sauerwald et al., 1997). For 
practical and ethical reasons, these studies analyse only limited amounts of 
plasma, which cannot be used to infer absolute conversion efficiencies. 
Integrated area-under-the-curve (AUC) estimates for a-LNA —> DHA 
conversion of plasma fatty acids were greatest for preterm infants and lowest 
for term and intrauterine growth retarded infants (Uauy et al., 2000). 
Importantly as with the present studies, the conversion efficiency among 
infants is highly variable, with standard deviations approximately equal to the 
mean values. Because of this Brenna, (2002) has suggested that some 
infants at the low end of the conversion range may be vulnerable to poor LC- 
PUFA supply.
Several stable isotope tracer studies have shown healthy adults to synthesize 
DHA from a-LNA (Emken et al., 1990; Salem et al., 1999; Vermunt et al., 
2000). Absolute AUC estimates were made for adult males with retinitis 
pigmentosa or normal controls. Variability of peak labelled a-LNA and DHA 
over a factor of five was observed. AUC estimates over a 604 h (21-day) 
period for transformation of a-LNA-±DHA were 5%, (Hoffman et al., 2001). In 
a 3-day study in adults on low DHA diets, with isotopically-labelled a-LNA, 
Emken et al., (1999) reported that labelled EPA and DHA AUCs were 34 and 
20% respectively, of the total n-3 LC-PUFA AUC. Conversion to DHA was 
lower when 6 g of DHA was included in the diet.
As already mentioned, AUC estimates, though routine, do not account for 
turnover within pools and therefore provide rough estimates of relative 
abundances (Demmelmair et al., 1999; Brenna, 2002). Turnover was taken
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into account in a recent comprehensive approach to study a-LNA long chain 
conversion using high sensitivity mass spectrometric analysis of penta- 
deuterated tracers (Pawlosky et al., 2001). Eight healthy adults consumed a 
controlled low n-3 LC-PUFA diet (olive oil, beef and butter). Using a 
compartmental model, overall conversion efficiency for a -LN A -* DHA was 
0.047 %, although in that study conversion of EPA was high, once it had been 
formed, i.e. EPA->DPA (n-3) =63%, and DPA (n-3)-»DHA = 37%, indicating 
that EPA —> DHA was 23%. This indicated that the limiting step in the 
conversion, as observed from plasma measurements, was between a-LNA 
and EPA. However this result is at variance with the present studies and 
several other studies in the literature, and the actual calculations are not 
entirely clear in the report of the study. However most recently Pawlosky et al.,
(2003) have confirmed their findings of restriction of the rate of long-chain 
PUFA biosynthesis at the a-LNA-^EPA step in terms of further physiological 
compartmental analysis of a-LNA metabolism from the plasma concentration­
time curves for penta-deuterated tracers of a-LNA, EPA, DPA (n-3) and DHA 
in ten healthy subjects. In this model they found a shorter half-life (t%), i.e. a 
more rapid removal of a-LNA from plasma, consistent with a high flow of a- 
LNA exiting the biosynthetic pathway. Certainly a high rate of oxidation of a- 
LNA in humans and a substantial transfer to the skin in rodents was reported 
by other investigators, which accounts for loss of isotope from the system 
(Menard et al., 1998; Fu & Sinclair, 2000; Vermunt et al, 2000).
Alternatively it has been suggested that the (3-oxidation step in DHA synthesis 
may represent a point of metabolic control (Sprecher, 2000). Thus in subjects 
who were essentially well nourished in terms of the DHA status in both dietary 
groups (as judged by the DHA content of phospholipids, none of whom 
exhibited low values), and with relatively low metabolic demands for DHA 
which is not thought to be a substrate for eicosanoid synthesis, it is possible 
that their demands for DHA were met adequately by their diet even in the 
absence of noticeable oily fish intake, and thus there was no physiological 
drive for marked DHA synthesis from EPA and DPA (n-3). However this does
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not explain the differences between our findings and those of Emken et al.,
(1994), and Burdge et al., (2002).
7.5.7 Summary for DHA synthesis
The fact that there was extensive tracer conversion of the a-LNA to EPA but 
little conversion to DHA is consistant with the results presented in chapter 3, 
and reported by others, that an a-LNA enriched diet was associated with 
increased EPA and DPA (n-3) concentrations with no significant change in 
DHA concentration in plasma and/or membrane phospholipids (Chen et al., 
1993; Freese et al., 1994; Allman et al., 1995; Cunnane et al., 1995 b; Li et al., 
1999). Together these data are consistent with the view that in adults DHA 
synthesis from a-LNA is either severely constrained (Gerster, 1998) or simply 
very slow. The few studies which report increased DHA levels following a- 
LNA supplementation (Beitz et al. 1981; Valsta et al. 1996; Ezaki et al. 1999), 
suggest that there may be as yet unexplained differences between groups of 
individuals in the extent to which a-LNA is converted to DHA.
7.5.8 Dietary fish-oil effect
One subject was studied after the 12 week fish oil supplementation with 
clearly increased plasma EPA and DHA concentrations. In this case, whilst LA 
conversion rates did not differ from those on the other diets, a-LNA 
conversion was markedly reduced, with a-LNA—► EPA conversion halved, and 
even lower rates of DPA (n-3) and DHA conversion.
Vermunt et al., (2000), also reported a study of the effect of an EPA/DHA rich 
diet on a-LNA conversion. This increased plasma total EPA and DHA 
concentrations, but they reported little if any a-LNA, conversion as judged by 
13C enrichment of n-3 LC-PUFA, concluding, in line with a previous study, 
(Vermunt et al., 1999), that a-LNA conversion is inhibited by dietary EPA plus 
DHA. This is consistent with work by Emken et al., (1999) who found 
decreased accumulation of deuterated n-3 LC-PUFA in a diet enriched in DHA. 
In a recent report to the UK food standard agency about a-LNA, Wootton &
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Burdge presented results from studies designed to characterise a-LNA 
conversion in men after increasing dietary consumption of a-LNA or EPA and 
DHA, they found that increased dietary a-LNA (substrate) did not drive an 
increase in a-LNA conversion, but increasing dietary EPA+DHA (product) 
exerted a significant product inhibition on EPA and DPA (n-3) synthesis from 
a-LNA. DHA synthesis was unaffected, suggesting that hepatic DHA 
synthesis may be regulated independently from EPA and DPA (n-3) 
(Sanderson et al., 2002).
In contrast to this recently, Salem and his co-worker reported, with studies 
comparing a fish-based diet with a beef-based diet, in which plasma EPA and 
DHA were increased by the fish diet, that the effect of the fish-based diet on 
the kinetics of n-3 fatty acid metabolism appear to be centered on processes 
that inhibit the synthesis of DHA from DPA (n-3). They argued for a feedback 
control mechanism responsive to the plasma concentration of DHA may affect 
processes that regulate its own synthesis, thereby maintaining DHA 
homeostasis during dietary changes (Pawlosky et al., 2003).
7.6 Nutritional implication
In this study, the control diet, whilst designed as a high n-6 diet, is not 
untypical of the intake of many within the UK. The overall mean conversion of 
the a-LNA which had appeared in the plasma lipid pool was about 40%, i.e. 
35% for 13C distribution in all n-3 metabolites and 45% as % conversion to 
EPA. This is therefore a reasonable estimation of the conversion of a-LNA 
appearing in the plasma (a minimum value given the additional conversion 
products in tissues), which would be expected for the population studied 
(middle age males) consuming normal UK diets. The amount of a-LNA and LA 
appearing in the plasma as a proportion of dietary intake is probably best 
calculated from the peak 13C concentration and plasma volume. However 
given that peak labelleing of a-LNA occurred before our first sample at 24 hrs 
this calculation cannot be made from the current results. However Vermunt et 
al., (2000) reported that 6-10% of a dose of a-LNA appeared in the plasma
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on the basis of their peak concentration observed at 5 hrs after the dose in 
subjects fed either a MUFA rich diet (giving 10% of the dose) or a high a-LNA 
diet (giving 6% of the dose). Assuming the value of 6% for our high n-6 and 
high a-LNA diets, and with 40% a-LNA conversion to long chain products, this 
gives an overall conversion of 2.4%. Thus with an estimated 1.6 g of a-LNA in 
a typical diet (Gregory et al., 1990), the amount of long-chain n-3 fatty acids 
synthesized through conversion would be about 38 mg i.e. about 6% of the 
650 mg/day of long-chain length n-3 fatty acids that has been estimated to be 
needed by adults (Simipolous et al., 1999). However the simple dietary and 
food composition change from high n-6 corn oil or sunflower seed oils to 
rapeseed oil containing up to 10% a-LNA could markedly increase current 
intakes of a-LNA.
Whilst these values for a-LNA conversion seem low, they can be compared 
with the conversion efficiency values derived from the main intervention study. 
Thus the changes in red blood cell EPA content induced by the flaxseed oil 
diet can be compared with the fish oil-induced increases to calculate an 
approximate equivalence assuming a linear relationship between a-LNA or 
preformed EPA intake and red cell phospholipid concentration. The intakes of 
1.7g of preformed EPA and 18g of a-LNA induced increases in the red cell 
EPA content by 3.1 and 2.3 (% total fatty acids) respectively. This implies 1.85 
and 0.13 per g of dietary EPA or a-LNA giving an a-LNA: EPA equivalence of 
0.07, i.e. a-LNA has 7% of the efficacy of preformed EPA, in the same 
approximate range of the 2.4% for the a-LNA —► EPA conversion discussed 
above as estimated from the tracer study.
7.7 Conclusions
It is clear that dietary a-LNA can act as a source of EPA on diets with either 
high or low n-6: n-3 ratios, although the conversion rates of dietary a-LNA are 
low, only about 2-3% to EPA. It is also clear that dietary a-LNA appears to be 
a very poor source of DHA if at all in our subjects (only about 5% of the rate of 
EPA formation). However some DHA synthesis does occur especially in 
subjects fed diets more typical of the current UK diets, and failure to elevate
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DHA blood-compartment concentrations by a-LNA supplementation does not 
necessarily mean that DHA concentrations do not increase in tissues. 
Conversion and of a-LNA may be efficient in our subjects in very active 
tissues such as retina which actively recycles DHA, and in developing neural 
tissue which would be important in population groups such as the developing 
fetus and the preterm infant. Our results and previous work indicate that long 
chain conversion is a minor quantitative fate of a-LNA. Total oxidation and 
partial oxidation with carbon recycling appear to be predominant mechanisms 
and may be important processes per se. Conversion of a-LNA to n-3 LC- 
PUFA is progressively less efficient in the order consistent with the sequence 
of n-3 PUFA formation in the currently accepted biosynthetic pathway leading 
to DHA, so that DHA is the least efficiently formed n-3 LC-PUFA in humans. 
Conversion efficiency also appears to decrease as infants mature, and may 
be even less efficient in omnivorous adults where our estimates put it at about 
0.4% and 0.02% or less for EPA and DHA formation respectively on the 
relatively high dietary n-6/n-3 ratio characteristic of modern diets. Thus it 
would appear that consumption of preformed n-3 LC-PUFA is a far more 
efficient way to improve n-3 LC-PUFA status, of particular importance in 
relation to neural development and progression of chronic disease. 
Nevertheless the intriguing issue remains as to the origins of DHA found in 
tissues in subjects who do not appear to consume the preformed fatty acid. It 
may well be that given a low metabolic demand for DHA, dietary a-LNA 
conversion may be sufficient even at a very low rate.
7.8 Summary of the studies
The results from the dietary intervention study, clearly establish the 
effectiveness dietary of a-LNA fed as flaxseed oil providing about 18g/d of a- 
LNA to middle aged men for 12 weeks, as a method of increasing the 
concentration of EPA but not DHA, and increasing the n-3:n-6 and EPA:AA 
ratio in membrane phospholipids, with dietary a-LNA having 7% of the efficacy 
of preformed EPA. Although not studied here this is likely to reduce the overall 
inflammatory environment with beneficial effects for long-term health. This
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indicates an important potential for the use of flaxseed oil and other a-LNA 
rich oils in foods, salad dressings, cooking oils and spreads, replacing those 
oils that are high in n-6 fatty acids. However consumption of fish oil, i.e. of 
dietary EPA and DHA, bypasses the conversion step and is a more efficient 
way of increasing cellular EPA and especially DHA.
The stable isotope study provided additional information to the dietary 
intervention study on the extent of a-LNA conversion, namely the rate of 
conversion of both a-LNA and LA to their long chain metabolites, especially 
whether any DHA conversion occurs, and the dietary influences on these 
rates of a high a-LNA compared with a high LA intake. Conversion rates were 
expressed in several ways but rates calculated from the relative AUC of the 
13C fatty acid time courses over the 14 day time period studied indicated 
values for the two diets (high n-6 vs. flaxseed-oil) of 45% vs. 36% (ns), for a- 
LNA -> EPA; about 10% vs. 6% (ns) for a-LNA —> DPA (n-3) and about 4% 
vs. <1% (no detectable conversion in some subjects p=<0.01) for a-LNA -> 
DHA. Thus there was DHA synthesis albeit at a very low rate and with no 
detectable conversion in some subjects fed the high a-LNA diet. Combining 
these values with the proportion of the a-LNA dose appearing in the plasma 
(6%) indicates the conversion rates shown in Fig 7.4.
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4% plasma a-LNA 
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Fig. 7.4 Fate of ingested 13C a-LNA.
Losses are shown which are implied by the low recovery of the dose in the 
plasma (from Vermunt et al., 2000) which can be assumed to include both 
oxidation and carbon recycling. Subsequent long chain conversion is shown in 
terms of the measured isotope conversion rates and the implications of these 
values for overall conversion of the ingested dose
Thus the conversion rates of dietary a-LNA of about 2-3% to EPA is in the 
same range as the apparent value indicated by the relative increases in 
phospholipid EPA after dietary a-LNA and EPA, and if correct likely to provide 
about 6%. of one current estimate of the adult requirement for long-chain n-3 
fatty acids.
Conversions of the n-6 precursor LA indicated values for the two diets (high n- 
6 vs. flaxseed-oil) of 7 % vs. 9% (ns), for LA-» DGLA, and 6% vs. 9% (p=0.09) 
for LA—> AA.
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7.9 Recommendation for future research
If a-LNA is to act as a substitute for EPA and DHA its beneficial health effects 
should be equivalent to those of its metabolites. Several studies investigating 
the clinical effect of a-LNA rich vegetable oils have not observed this 
equivalence to marine oils. Harris, (1997) reviewed the available double-blind 
studies investigating the effect of n-3 fatty acids contained in plant or fish oil 
on human serum lipids and came to the conclusion that the plant-derived n-3 
fatty acids are not equivalent to marine-based fatty acids in terms of 
triglyceride reduction. The effect of flaxseed oil on various hemostatic factors 
was comparable to that of marine oil supplied together with LA (Freese & 
Mutanen, 1997). When a-LNA and LA were given at a ratio of 1:1, Ferretti and 
Flanagan, (1996) observed a significant modulation of thromboxane and 
prostacyclin biosynthesis suggesting an anti-thrombotic activity of n-3 
vegetable oil. It is evident that n-3 vegetable oils may have a certain beneficial 
effect on cardiovascular risk factors which is however not equivalent to the 
effect of equal amounts of marine oil. Further studies are needed to establish 
the biological effects of a-LNA in comparison with those of EPA+DHA.
The n-6/n-3 PUFA ratio is increasingly considered important and although in 
the present study the impact of a reduced n-6/n-3 ratio on a-LNA conversion 
was small and if anything detrimental in terms of DHA synthesis, there is 
obviously more work needed on the regulation of the long chain conversion of 
n-3 and n-6 PUFAs. One interesting area involves a potential dietary protein 
influence. In a rat study, the amount and composition of dietary protein had a 
significant influence on the activity of A-6 desaturase and thus on the amount 
of AA and DHA formed from the precursors LA and a-LNA (Ratnayake et ai., 
1997). If this proves important then it will mean even more uncertainty about 
defining valid conversion factors.
The potential influence of sex hormones on the regulation of a-LNA 
conversion, recently suggested by Burdge & Wooton, (2002), following his 
observation of a higher DHA formation from a-LNA in women compared with 
men is another important area for investigtion, since his reported fractional
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distribution of labelled n-3 fatty acids at about 9% DHA is the highest value 
reported to date. The differences in DHA status between women both in the 
non-pregnant state and in pregnancy require further investigation.
It should not be expected that everyone will have the same requirements, as 
humans are a biochemically diverse species with considerable genetic 
diversity. There may be groups of people who require higher levels of dietary 
n-3 because of a predisposition to a particular disease. Others, such as non­
insulin-dependent diabetics or aspirin-intolerant asthmatics, may have 
adverse reactions to diets rich in n-3 fatty acids. Recommendations based on 
individual bases will be much more appropriate than the current universal 
recommendations. For example it has been recently reported that the effect of 
dietary PUFA intake on HDL-cholesterol concentrations is modulated by a 
common genetic polymorphism in the promoter region of APOA1 gene. Thus, 
subjects carrying the A  allele at the -75 G/A polymorphism show an increase 
on HDL-C concentrations with increased intakes of PUFA; whereas those 
homozygotes for the more common G allele have the expected lowering on 
HDL-C levels as the intake of PUFA goes up (Ordovas, 2002).
It is recommended for future research that studies in a group of genetically 
characterised subjects should be conducted. The importance of genotype 
should be considered when planning for future studies. It has become clear 
that not only can genetics play a role in determining an individual’s lipid profile, 
but it can also influence their response to a lipid-altering interventions.
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APPENDICIES
APPENDIX 1 FATTY ACIDS AS PRECURSORS OF 
EICOSANOIDS
N-6 and n-3 PUFAs such as dihomo-gamma-linolenic acid (DGLA), 
arachidonic acid (AA) and eicosapentaenoic (EPA) are precursors for 
eicosanoids biosynthesis (Quoc & Pascaud,1996; Fan & Chapkin,1998), 
which can exert a wide range of biological actions (Hwang, 1992). The term 
“eicosanoids” has come to be a generic term referring to biologically active 
compounds produced by cyclooxygenase or lipoxygenase enzymes from 20- 
carbon PUFAs. In (Fig.A1.1) the structures of some common 2- or 3-series 
prostaglandins are shown, and (Fig.A1.2) depicts the structures of 
leukotrienes, lipoxins, and hydroxyl fatty acids. A “2-series” prostaglandin is 
one that contains two double bonds; the “4” in leukotriene C4 (LTC4) indicates 
that four double bonds are present. The 3-series prostaglandins and the 5- 
series leukotrienes are formed from EPA (Salem, 1989).
Cyclooxygenase-derived eicosanoids
The cyclooxygenase-catalyzed addition of two molecules of oxygen results in 
the synthesis of prostaglandins. The cyclooxygenase enzyme converts AA 
into cyclic endoperoxide, a key precursor molecule in the syntheses of 
prostacyclin (PGI2) a potent vasodilator, thromboxane (TXA2) a potent 
vasoconstrictor, and other prostaglandins (PGE2a , PGF2 and PGD2 ). These 
aforementioned eicosanoids are synthesized from PGH2 an initial product of 
the action of cyclooxygenase on free arachidonic acid (AA) (Schror, 1993).
Lipoxygenase -derived eicosanoids
The lipoxygenases are di-oxygenases that incorporate molecular oxygen into 
specific positions within PUFAs, and based on the site of insertion of the 
oxygen, are classified as 5-, 12-, or 15- lipoxygenases (Shimizu & Wolfe, 
1990).
Lipoxygenases catalyze the addition of a single molecule of oxygen 
converting AA to oxygenated products (leukotrienes) which possess potent
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biological properties. Lipoxygenases activity has been detected in platelets, 
leukocytes, lungs, skin, ocular tissue, and blood vessels (Mayatepek & 
Hoffman, 1995). In brain, 12- lipoxygenase has been found to be most 
prominent, expressed in cortical neurons, oligoendrocytes, and astrocytes 
(Bendani et al., 1995).
Eicosapentaenoic (EPA) has an inhibitory effect on the cyclo-oxygenase 
enzyme that converts AA to thromboxane A2 thus leading to a lessened 
thrombogenic state (Holub, 2002).
Indeed, n-3 dietary supplementation leads to:
1) decreased production of prostaglandin E2 metabolites;
2) decreased concentrations of thromboxane A2, a potent platelet 
aggregator and vasoconstrictor;
3) decreased formation of leukotriene B4 , an inducer of inflammation and 
a powerful inducer of leukocyte chemotaxis and adherence;
4) increased concentrations of thromoboxane A3, a weak platelet 
aggregator and vasoconstrictor;
5) increased concentration of prostacyclin by increasing PGI3, leading to 
an overall increase in total prostacyclin by increasing PGI3 without decreasing 
PGI2 (both PGI2 and PGI3 are active vasodilators and inhibitors of platelet 
aggregation);
6) increased concentrations of leukotriene B5, a weak inducer of 
inflammation and chemotactic agent (Weber et al., 1986).
It is well known that 5-, 12-, 15-hydroxy-eicosatetraenoic acid (HETE) as well 
as other positional isomers are formed by the action of various lipoxygenases 
(Fig.A1.2). In platelet, 12-lipoxygenase catalyzes the formation of 12-hydroxy- 
EHA (12-HEPE) after EPA incorporation (Lagarde et al., 1985). Lipoxins A4 
and B4 (Fig. A1.2) are another group of biologically active eicosanoids whose 
structures and biological activities have been elucidated by (Serhan et al., 
1984). Pace-Asciak (1986) has discovered that EPA can be converted to 
hydroxyl-epoxy compounds as can AA, and he has termed these “hepoxilins”. 
Hepoxilin A4 and B4 possess insulin secretagogue activity as do their AA- 
derived homologues (Pace-Asciak & Martin, 1984).
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Fig A1.1 Cyclooxygenase products of arachidonic (AA) and eicosapentaenoic 
acids (EPA) (Salem, 1989).
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Fig. A1.2 Lipoxygenase products of arachidonic (AA), eicosapentaenoic 
(EPA), and docosahexaenoic acids (DHA) (Salem, 1989).
Whilst EPA content of membranes is a source for eicosanoid synthesis, DHA 
content may also play a contributory role, both directly and indirectly. Although 
a relatively unexplored field, DHA can function as a source for EPA through a
retroconversion reaction, which in turn will be oxygenated to the various 
eicosanoid metabolites (Conquer & Holub, 1997). Croset et al., (1988) 
demonstrated that 14-hydroxy-22:6n-3 antagonizes the thromboxane A2- 
induced vasoconstriction of rabbit aorta and is more potent than 12-HETE in 
this regard.
Direct oxygenated products of DHA, resulting from peroxidative damage have 
also been identified and are commonly referred to as docosanoids (Bazan, 
1989; Sawazaki et al., 1994; Reinboth et al., 1996). These DHA derivatives 
resemble eicosanoids and may provide a source of unique mediators of 
phsiological processes in the central nervous system, such as that reported in 
the rat pineal body (Sawazaki et al., 1994), but in particular the retina 
(Reinboth et al., 1996).
Because of the increased amounts of n-6 fatty acids in the western diet, the 
eicosanoid metabolic products from AA, specifically prostaglandins, 
thromboxanes, leukotrienes, hydroxy fatty acids, and lipoxins, are formed in 
larger quantities than those formed from n-3 fatty acids, specifically EPA. 
Enrichment of the diet with EPA is followed by a concomitant enhancement in 
the activity of 5-lipoxygenase enzyme, because this FA is a preferred 
substrate for 5-lipoxygenase as compared with AA (Ochi et al., 1983). This is 
an important physiological event since the metabolism of EPA favors the 
synthesis of leukotriene B5 (LT B5) instead of LT B4. Consequently, the less 
active LT B5 as compared with LT B4 in chemotactic and aggregation 
activities will potentiate a more confined inflamatory response during an 
inflammatory-mediated insult (Youdim et al., 2000).
The eicosanoids from AA are biologically active in small quantities and if they 
are formed in larger amounts, they contribute to the formation of thrombi and 
atheromas; the development of allergic and inflammatory disorders, 
particularly in susceptible people. Thus, a diet rich in n-6 fatty acids shifts the 
physiologic state to one that is prothrombotic and proaggregatory, with 
increases in blood viscosity, vasospasm, and vasoconstriction and decreases 
in bleeding time (Simopoulos, 1999).
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APPENDIX 2 FATTY ACIDS IN THE BRAIN
During human development, n-3 and n-6 fatty acids accrue in fetal tissues as 
an essential component of structural lipids and rapid synthesis of brain tissue 
occurs in the third trimester. This synthesis causes increases in cell size, cell 
type, and cell number (Clandinin et al,, 1980 b). Lipid levels increase rapidly, 
mostly because of the myelination that is taking place. Levels of LA and a- 
LNA are consistently low in the brain during the last trimester of pregnancy 
(Clandinin et al., 1980 b). Accretion of long-chain desaturation products AA 
and DHA occurs, and the absolute accretion rates of the omega-3 fatty acids, 
specifically DHA, are greater in the prenatal period compared to the postnatal 
period (Clandinin et al., 1980 a, b).
Lipid composition of brain is unique in its high concentration of 
polyunsaturated fatty acids, especially, AA and DHA. In contrast to circulating 
lipids and peripheral tissues, brain phospholipids contain little or no detectable 
a-LNA or EPA and only trace amounts of LA (Purvis et al., 1982). The in vivo 
pathway for long-chain fatty acid synthesis occurs by elongation rather than 
by de novo synthesis.
Cultured cerebrovascular endothelial cells were found to readily elongate and 
desaturate both linoleic and a-LNA. The major derivative of LA was AA. DPA 
(n-6) was not detected in incubations with LA, suggesting that delta-4 
desaturase activity was not present. A similar result was noted for incubations 
with a-LNA. The primary product of a-LNA elongation-desaturation was 
observed to be EPA with some labeled DPA (n-3) formed. DHA was not 
detected, suggesting a lack of delta-4 desaturase activity. Brain endothelial 
cells also take up preformed AA and EPA when they are available in the 
extracellular fluid. The ability of the cerebromicrovascular endothelial cells to 
produce and release AA, EPA, and DPA (n-3) (Moore et al., 1990) suggests 
that these cells play a central role in metabolism of long-chain essential fatty 
acids in brain. This role is further indicated by their strategic anatomical 
location, at the interface between the blood and brain parenchyma, where the 
endothelial cells have initial access to all incoming essential fatty acid
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precursors. Thus, it appears that the cerebromicrovascular endothelia may be 
a potentially important site for essential fatty acid processing and eicosanoid 
production in brain.
In terms of chain elongation of fatty acids in rat brain cell types, neurons, 
astrocytes and oligodendrocytes have been shown to contain the necessary 
enzymes (Cohen and Bernsohn, 1978). Studies by Moore et al., (1991) 
indicate that astrocytes and cerebral endothelium may be the cells primarily 
responsible. Moore, (1993) further suggested that cerebral endothelium is 
involved in uptake and transfer of preformed DHA into brain. Desaturation and 
elongation of fatty acids to AA and DHA within brain is evident. However, 
which cells are responsible for synthesis and metabolism of essential fatty 
acids remains to be unequivocally confirmed. The extent to which gut, liver, 
and/or brain contribute to the final fatty acid metabolites present in brain is still 
uncertain.
Of all body organs, the brain has been viewed as most resistant to structural 
change by both endogenous and exogenous factors (Mohrhauer and Holman, 
1963 a). Research in recent years has shown the brain to be more responsive 
to exogenous factors (Bourre et al., 1989 a). An alteration in the n-6 or n-3 
series in the diet can trigger dramatic alteration in brain lipid composition (Foot 
et al., 1982; Hargreaves and Clandinin, 1990) and greatly affect the pattern of 
tissue lipids. These alterations are sometimes associated with changes in 
membrane physical properties (Foot et al., 1982), alteration in activities of 
enzymes (Hargreaves and Clandinin, 1987 a, b), receptors and carrier- 
mediated transport (Stubbs and smith, 1984; Spector and Yorek, 1985), and 
alterations in cellular interactions (Scott et al., 1989). In studies by Hargreaves 
and Clandinin, (1988) and Enslen et al., (1991), it was shown that alterations 
in the fatty acid composition of brain cells and subceliular fractions (myelin, 
microsomal, and synaptosomal plasma membranes) could be induced 
through alterations in dietary fat. These alterations may ultimately contribute 
to brain neuronal processes (Yehuda, 1987). With evidence showing that the 
brain is responsive to alterations in exogenous factors, it becomes
217
exceedingly important to optimize diet-induced alterations during brain 
development.
In a retrospective analysis of published body composition data to estimate the 
actual accumulation of DHA in the human infant brain, liver, adipose tissue, 
remaining lean tissue, and whole body. Cunnane et al., (2000) reported that 
the brain of formula-fed infants not consuming DHA accumulates half the DHA 
of the brain of breast-fed infants while the rest of the body actually loses DHA 
over the first six month of life. It can be concluded that DHA stores and 
synthesis alone appear inadequate to meet the rate of DHA accumulation of 
breast-fed term infants. Therefore, a need for dietary DHA in infant formula 
seems to exist if the rate of DHA accumulation in breast-fed infants is to be 
achieved.
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APPENDIX 3 FATTY ACIDS COMPONENTS OF THE RETINA
As cellular differentiation and active synaptogenesis occur, photoreceptor 
biosynthesis is also taking place. In photoreceptor outer segments (rod outer 
segments), the level of DHA can account for up to 50% of all fatty acids, 
depending on the phospholipid class (Fleisler and Anderson, 1983). Since the 
highest level of DHA is found in the retina as well as in the cerebral cortex, 
accretion or lack of this fatty acid, could markedly affect retinal development 
and visual acuity. Feeding diets unbalanced in n-6 and n-3 fatty acid (Martinez, 
1989) or deficient in essential fatty acids (Neuringer and Connor, 1987) alters 
the fatty acid composition of the retina. This results in impaired visual cell 
renewal (Anderson et al., 1974) and abnormal visual function (Neuringer and 
Connor, 1987). In the photoreceptor membrane, very long-chain fatty acids of 
C24-C34 have been associated with rhodopsin function (Aveldano, 1988). 
Suh et al., (1994) demonstrated that these fatty acids are not of dietary origin, 
but are synthesized from shorter chain precursors which respond to the 
dietary n-6/n-3 ratio fed.
Birch et al., (1992) and Carlson et al., (1993) examined visual acuity in 
preterm and very-low-birthweight infants and the effect of diets containing 
long-chain n-3 fatty acids. Visual acuity was improved when preformed long- 
chain n-3 fatty acids were fed compared to commercially available formulas. 
Thus, for preterm and low birthweight infants, the incorporation of long-chain 
n-3 fatty acids may be important for proper membrane development in the 
visual apparatus and for development of visual acuity, suggesting that the 
biological effect of a-linolenic indicated above was through its conversion to 
long chain products.
Connor et al., (1985) and Neuringer et al., (1985) examined the reversibility of 
the biochemical and functional changes, as measured by an electroretinogram 
associated with n-3 fatty acid deficiency in primates. Although brain fatty acid 
composition could be altered and docosahexaenoate levels restored to normal, 
the electroretinogram recordings showed no improvement in either peak 
latencies or recovery times at 3, 6, and 9 months after supplementation. 
These observations suggest that the availability of dietary n-3 fatty acids 
during early development may be critical for later visual function.
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APPENDIX 4 MEMBRANE STRUCTURE AND FUNCTION: 
RELATION TO FATTY ACIDS PROFILE
In spite of the diversity in the types of cell membranes, they all 
compartmentalize the cell and provide domains in which very active enzymes, 
ions and transporters can be found. In general the lipid bilayer tends to exist 
at an optimum transition point between gel and liquid crystal, and the 
maintenance of this state, often loosely referred to as fluidity, is of paramount 
importance. The term “membrane fluidity” refers to the physical state of the 
fatty acyl chains comprising the membrane bilayer structure, as well as a 
measure of the different rates of motion of molecule elements within the 
membrane. The fatty acyl chains, which elicit the most influence, such as AA, 
EPA and DHA, contain double bonds, which are exclusively in the cis 
conformation. The replacement of even a single double bond in these PUFAs 
is sufficient to exert a profound effect on the physical properties of the 
membrane (Cohen & Zubenko, 1985; Mason et al., 1997).
Membrane fatty acids composition, which can be modulated through dietary 
sources, provides the general framework that coordinates the fluidity of the 
membrane and consequently the efficiency of membrane systems. One 
particular membrane transporter whose activity is often assessed, is that of 
the Na+, K+-ATPase. Viani et al. (1991) reported that age-related declines in 
PUFAs resulted in a decrease of Na+, K+ATPase activity in brain 
synaptosomes.
Polyunsaturated fatty acids have also been shown to regulate neuronal 
excitability. Vreugdenhil et al., (1996), showed that extracellular application of 
DHA or EPA to freshly isolated hippocampal CA1 neurons produced a 
concentration-dependant shift of the voltage dependence of inactivation of 
Na+ and Ca2+ currents to more hyperpolarized potentials. This consequently 
accelerated the inactivation and retarded the recovery from inactivation, which 
may have potential anticonvulsive effects in vivo. With respect to enzymes 
important in cellular function, an important relationship between DHA and 
PLA2 has been reported (Shikano et al., 1993; Martin, 1998). Shikano et al.
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(1993), found that following DHA supplementation into culture of human 
eosinophilic leukemia cells (Eo1-1), platelet activating factor (PAF) production 
was reduced, whilst supplementation with EPA had no effect. It appeared that 
DHA attenuated PLA2 activity, though the exact mechanism was not known, 
consequently reducing the levels of AA liberated, a rate limiting step in the 
synthesis of biologically active eicosanoids. Martin, (1998), also found a 
correlation between DHA and PI_A2 activity, a rate limiting enzyme involved in 
the hydrolysis of AA from membranes for metabolism into eicosanoids. He 
showed that supplementation of PC12 cell media with DHA increased levels 
of this PUFA in ethanoiamine glycerolipids of the neurite and nerve growth 
cone (NGC) fraction, which was accompanied by a concomitant decline in 
PLA2 activity, which may have important implications, when considering the 
role PLA2 plays in ischemia.
The potential role of PUFAs in signal transduction, was also reported by Slater 
et al., (1996), who found using a model bilayer system, that alterations in the 
unsaturation of phosphatidyl choline (PC) phospholipids, elevated the activity 
of protein kinase C (PKC) alpha, possibly through changes in membrane 
surface curvature stress (i.e. the stress that nonbilayer preferring lipids create 
in plannar biological membranes has been termed curvature stress or 
curvature strain (Epand, 1998). By contrast, increasing the unsaturation of 
phosphatidyl serine (PS), decreased PKC alpha activity. The effects of PS 
unsaturation may be due to specific iipid-protein interactions. This result 
indicates that changes in phospholipid unsaturation may have profound 
effects on signal transduction pathways in which PKC plays a contributory role.
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APPENDIX 5 ADEQUATE INTAKES FOR OMEGA-3 AND 
OMEGA-6 FATTY ACIDS
A National Institutes of Health workshop held in 1999 resulted in the 
recommendation of a combined average EPA and DHA intake of 650 mg/day 
for healthy adults (Simopoulos et al., 1999). The newly released American 
Heart Association guidelines (Krauss et al., 2000) included the following 
recommendations with respect to omega-3 fatty acid supplementation: 
“ Consumption of 1 fatty fish meal per day (or alternatively, a fish oil 
supplement) could result in an omega-3 fatty acid intake (ie, EPA and DHA) of 
~ 900mg/d, an amount shown to beneficially affect coronary heart disease 
mortality rates in patients with coronary disease”. Recently, the Dietary 
Reference Intakes (DRIs) for Macronutrients (2002) has been published with 
recommendations for Adequate Intakes of linoleic and a-LNA (men, women, 
pregnancy and lactation). These are shown in (Table A5.1).
Table A5.1 Adequate intakes (Al)* for adults.
Linoleic acid A l Summary, Adults 19 years and older
17 g/day o f  linoleic acid 
14 g/day o f  linoleic acid
12 g/day o f  linoleic acid
11 g/day o f  linoleic acid
Al for Pregnant and Lactating Women
14-18 years
19-30 years 13 g/day o f  linoleic acid
31-50 years
a-Linoleic acid A l Summary, Adults 19 years and older 
Al for Men
19-30 year’s
31 -5 0 years 1 5  g/day o f  a-LNA
51-70 years 
> 7 0  years
Al for Men
19-30 years 
31-50 years 
51-70 years
> 70 years
Al for Women
19-30 years 
31-50 years
51-70 years
> 70 years
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Al for Women
19-30 years
31-50 years 1.1 g/day o f  a-LNA
51-70 years
> 70 years
Al for Pregnancy
14-18 years
19-30 years 1.4 g/day o f  a-LNA
31-50 years
Al for Lactation
14-18 years
19-30 years 1.3 g/day o f  a-LNA acid
31-50 years
*AI-Adequate Intake. If sufficient scientific evidence is not available to calculate an 
Estimated Average Requirement, a reference intake called an Adequate Intake is 
used instead of a Recommended Dietary Allowance. The Al is a value based on 
experimentally derived intake levels or approximations of observed mean nutrient 
intakes by a group (or groups) of healthy people. The Al for children and adults is 
expected to meet or exceed the amount needed to maintain a defined nutritional 
state or criterion of adequacy in essentially ail members of a specific healthy 
population (Simopoulos et al., 1999).
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APPENDIX 6: STABLE ISOTOPE ANALYSIS OF FATTY ACIDS 
BY GAS CHROMATOGRAPHY-ISOTOPE RATIO MASS 
SPECTROMETRY
Introduction
During the 14 years that followed the first publications reporting the coupling 
of gas chromatography (GC) to on-line combustion of GC separated 
compounds to yield C02 and N2 for isotope ratio analysis by a single collector 
mass spectrometer (Sano et al., 1976), hardly any work was published that 
made use of this new technique. In 1984, a dual collector mass spectrometer 
was coupled to a GC via an on-line combustion interface, thus permitting 
continuous recording of (m+1)/m isotope ratios by detecting two successive 
masses at the same time. Their instrument was the first genuine GC- 
combustion interfaced-isotope ratio mass spectrometry (GC-C-IRMS) system 
and produced isotope ratios that were an order of magnitude more precise 
than obtained from an optimised single collector instrument.
However, it was not until 1990 that GC-C-IRMS instruments became 
commercially available. IRMS is a very sensitive detector, able to yield highly 
precise measurements of isotope ratios with a standard deviation in the range 
of four to six significant figures. When coupled to a GC system, it enables the 
analyst to conduct highly precise compound-specific isotope analysis (CSIA), 
especially at natural isotopic abundance level. High-precision CSIA at natural 
abundance level can provide information on biogenetic relation and origin of a 
given organic compound (Meier-Augenstein, 1999).
There is also an increasing interest in the application of high-precision CSIA in 
tracer studies. One area of application is concerned with quantitative studies 
of biochemical processes such as assimilation/ incorporation of nutrients, 
turnover rates of biologically important molecules, and quantitation of protein 
synthesis. The other area aims to improve detection limits of bio-organic 
molecules by using labelled precursor compounds at high enrichment levels.
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In either case, high-resolution capillary gas chromatography (HRcGC) is a 
prerequisite for high-precision CSIA by on-line IRMS. Peak overlap and peak 
distortion have a detrimental effect on both accuracy and precision of isotope 
ratio measurements.
Principles of IRMS and GC-C-IRMS 
IRMS
In contrast to organic mass spectrometers (MS) that yield structural 
information by scanning a mass range for characteristic fragment ions, IRMS 
instruments achieve highly precise measurement of isotopic abundance at the 
expense of the flexibility of scanning MS.
For isotope ratio measurement, the analyte must be converted into a simple 
gas, isotopically representative of the original sample, before entering the ion 
source of an IRMS. Continuous flow isotope ratio measurements of 2H/1H, 
15N/14N, 13C/12C, 180 /160  and 34S/32S are performed on gases of H2, N2, C02, 
CO and S02, respectively, with 13C abundance measurements accounting for 
almost 70 % of aii gas isotope ratio analyses made. IRMS measurements 
yield the information of isotopic abundance of the analyte gas relative to the 
measured isotope ratio of a standard or reference gas. This is done to 
compensate for mass discriminating effects that may fluctuate with time and 
from instrument to instrument.
In the case of C02, the data comprise three ion traces for the different 
isotopomers 12C 160 2, 13C 160 2 and 12C 1sO 160 with their corresponding 
masses at m/z 44, 45 and 46, respectively. The three ion beams are 
registered simultaneously by a multiple Faraday cup (FC) arrangement with a 
dedicated FC for each isotopmer.
Due to simultaneous measurement of two or three isotopomeric ions, GC-C- 
IRMS can measure isotopic composition at low enrichment and natural 
abundance level with a high degree of accuracy and precision. This means 
that minute variations in very small amounts of the heavier isotope are 
detected in the presence of large amounts of the lighter isotope. The
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abundance As of the heavier isotope n2 in a sample s, given in at. % is defined 
as:
As = Rs/(1+Rs)x  100 (at. %) (1)
where Rs is the ratio n2/ni of the two isotopes for the sample. The enrichment 
of an isotope in a sample as compared to a standared value (Astd) is given in 
at. % excess (APE):
Since the small variations of the heavier isotope habitually measured by IRMS 
are of the order of 0.001-0.05 at. %, the 5-notation in units of per mil (%o) has 
been adopted to report changes in isotopic abundance as a per mil deviation 
compared to a designated isotopic standard:
where Rs is the measured isotope ratio for the sample and Rstd is the 
measured isotope ratio for the standard.
GC-C-IRMS
From the above it is obvious that a GC cannot be directly coupled to an IRMS. 
The need for sample conversion into simple gases has prompted the design 
of a combustion interface where the GC effluent is fed into a combustion 
reactor (Fig.A6.1). This reactor, either a quartz glass or ceramic tube, is filled 
with CuO/ Pt or CuO/ NiO/ Pt and maintained at a temperature of 
approximately 820 or 940°C, respectively (Merritt et al., 1995). To remove 
water vapour generated during combustion, a water trap is required. Most 
instrument manufacturers employ a Nafion tube for this purpose. Nafion is a 
fluorinated polymer that acts as a semi-permeable membrane through which 
water passes freely while all the other combustion products are retained in the 
carrier gas stream. Quantitative water removal prior to admitting the 
combustion gases into the ion source is essential because any water residue
APE = Ag — Astd (2)
5s = (Rs/ R st d - 1 ) x  1000 (%o) ( 3 )
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would lead to protonation of C02 to produce HCO+2, which interferes with 
analysis of 13C02 (isobaric interference) (Leckrone & Hayes, 1998).
Isotopic calibration during GC-C-IRMS analysis
Owing to its unique design, it is not possible in GC-C-IRMS to calibrate target 
compound against a standard of known isotopic composition, introducing the 
standard in exactly the same way as the analyte. There are only three feasible 
means of introducing a standard: (a) addition of reference compounds to the 
sample; (b) introduction of reference gas pulses into the carrier gas stream; or 
(c) introduction of reference gas pulses directly into the ion source (Merritt & 
Hayes 1994).
13C isotope analysis of fatty acids at natural abundance level
High-precision compound-specific isotope analysis (CSIA) of 13C isotopic 
abundance at both natural abundance (NA) and low enrichment level can 
yield measurements of 5 13C values with a precision of 0.3 %o on average. 
Even small changes in 13C isotopic abundance of 1 %o can be reliably 
detected.
In contrast to the generally held opinion, the natural abundance of stable 
isotopes is not a fixed constant but displays a considerable, yet subtle, degree 
of variation. The variation on the natural abundance of 13C can be as high as 
0.1 %. This wide range reflects the varying degree of mass discrimination 
associated with the different pathways of carbon assimilation and fixation. To 
give an example, glucose derived from C3 plants has a 5 13C value of about - 
25 %o, whereas glucose derived from C4 plants exhibits a more positive 5 13C 
value about -11 %o indicating a mass discrimination bias towards 13C02 of the 
Hatch-Slack cycle. Although the vast majority of plants belong the C3 group 
(>300 000) with bulk 6 13C values of < -24 %o, differences in the rate of 
photosynthesis (mainly caused by differences in climate and geographical 
location) and in enzyme kinetics of biochemical pathways result in subtle 
variation of 13C/12C ratios that can be detected by GC-C-IRMS, and can be
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used to determine origin of an organic compound and, thus, the authenticity of 
a sample (Meier-Augenstein, 1999).
Detector
Gas chromatograph
Combustion 
(800 £C)
Fig. A6.1. Set-up of an isotope ratio mass spectrometer coupled to a gas 
chromatograph via a combustion interface to measure 1X /12C (carbon 
mode) or 5N/14N ratios (nitrogen mode).
This schematic shows the reference gas set-up used for automated internal isotopic 
calibration (Meier-Augenstein, 1999).
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ALNA 0 L j*nave explored Tne 
the influence of a low n6:n3 diet providing generous ALNA from
U,3C ALNA conversion to EPA, DPA and DHA was measured in men after 
diets enriched with either flaxseed-oil (high ALNA n=6) or sunflower oil 
(high n-6 diet n=5) as 13C enrichment in phospholipids at 1, 2, 3,7 ,10 and 
14 days. Subjects were a subgroup of a larger trial of responses of lipid- 
related CVD risk factors (see Griffin et a! accompanying poster)
mcTnoas
•  Subjects: Normal, healthy, free-living male volunteers aged 35-60 
years, expressing an atherogenic lipoprotein phenotype (ALP)
•  Intervention: 12 week parallel dietary trial with a fat exchange of 
approximately 45g of dietary fat to achieve target dietary intake levels 
of 15g/day ALNA, (n-6:n-3 ratio of <1) or 20g n-6 linoleic acid, LA, (n- 
6:n-3 ratio of >20).
•  Diets: Either flaxseed oil (56% ALNA) or sunflower oil (52% LA), 
provided as laminated foil sachets (17g each oil/sachet) as well as 
cooking oils-rape seed oil for high ALNA or sunflower oil for high n-6, 
and spreads- a modified ‘ Mono' with a higher rapeseed content (137o) 
for the high ALNA diet or rapeseed based 'Mono', (St Ivel) for high n-6 
diet.
•  Isotope administration: subjects were given an oral dose of 400mg 
of uniformly [13C]-labelled a-LA in a milk shake at breakfast after 12 
weeks on the diets. Blood was sampled at 1, 2, 3, 7, 10 and 14days, 
phosphatidylcholine fractions were isolated from plasma (PPC) and 
erythrocytes (EPC), fatty acid profiles were measured by GC and 13C 
enrichments measured by GC-combustion-IRMS in ALNA, EPA, DPA and 
DHA. 13C labeling was expressed as 13C atoms% excess (APE) or total 13C 
as APE x % total membrane fatty acids.
Calculation of ALNA conversion
1. Relative distribution of isotope (AUC total 13C enrichment) between 
ALNA, EPA, DPA and DHA over 14 days- as % of the sum of all AUCs
2. Standardized values- i.e. total 13C enrichment adjusted to same 
precursor enrichment to take account of the lower APE of the high 
ALNA group because of the higher ALNA pool size:
i.e. standardized 13C enrichment 
= observed individual l3C enrichment X mean precursor 13C APE (AUC)
observed individual 13C APE (AUC) 
with ALNA, EPA and DPA assumed as precursors for EPA, DPA and DHA
0 1 2 3 r  10 14
Figure 2. DHA 13C enrichments in PPC and EPC PC fractions.
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Table 1 14 day 13C distribution through plasma and RBC PC pools (X total AUC)
Plasma PC
RBC PC
ALNA 
moan sd 
High N6 32 9
Flax 22 3
High N6 24 17
Flax 37 21
EPA 
moan sd
53 3
55 7
54 60
47 27
DPA 
can sd
12 7
16 6 
20 7
14 14
DHA 
moan sd 
4 4
7 5
3 3
2 2
grand moan 28 13 52 24 16 8 4 3
Table 2 Standardised estimates of ALNA conversion on the two diets
AUC APE l,C AUC (standardized) total l,C
ALNA 
mean sd
EPA 
mean sd
DPA 
mean sd
DHA 
mean sdDiet PL fraction
Flax oil diet RBC PC 86 43 277 211 55 29 4 5
High n-6 diet RBC PC 285 25 141 167 27 12 7 5
P <0.01 ns ns ns
Flax oil diet Plasma PC 17 2 454 79 54 15 12 5
High n-6 diet Plasma PC 270 77 133 28 28 9 6 1
P <0.01 <0.01 <0.05 <0.05
Conclusions
Discussion
9 Fig 1: substantial conversion of ALNA into EPA with 
some but much less further conversion to DPA or DHA 
9 Fig 2: significant enrichment in plasma DHA at 24 hrs 
on both diets and in RBC DHA a fte r 7 days in all subjects. 
9 Table 1: 14 day 13C distribution between ALNA, EPA, 
DPA and DHA, was 28%, 52%, 16% and 4% respectively 
with no dietary effects.
9 Table 2: ALNA conversion was increased on flax 
diet: i.e. higher standardized 13C AUC for EPA and DPA 
which was significant in plasma PC (>3x for EPA and >2x 
for DPA).
ALNA can serve as a s ign ifican t source o f EPA and DPA, especially in sub jects  where the  conversion is 
optim ised by a low n6:n3 ra tio , as shown by these data and by increased phospholipid EPA (160%) and DPA (27%) 
concentrations and a reduced arachidonic acid: EPA ra tio  (from  15 to  5), in th e  sub jec ts  fed  the  fla x  seed oil 
d ie t (data not shown). Thus increased d ie ta ry  ALNA from  fla x  seed oil can reduce the  in flam m atory 
environment, which may be im portant in re la tion  to  cardiovascular disease risk  reduction.
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